<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE MedlineCitationSet PUBLIC "-//NLM//DTD Medline Citation, 1st January, 2014//EN" "http://www.nlm.nih.gov/databases/dtd/nlmmedlinecitationset_140101.dtd">
<MedlineCitationSet>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10540283</PMID>
<DateCreated>
<Year>1999</Year>
<Month>12</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>12</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0950-382X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>34</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1999</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular microbiology</Title>
<ISOAbbreviation>Mol. Microbiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Transcription regulation of the nir gene cluster encoding nitrite reductase of Paracoccus denitrificans involves NNR and NirI, a novel type of membrane protein.</ArticleTitle>
<Pagination>
<MedlinePgn>24-36</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The nirIX gene cluster of Paracoccus denitrificans is located between the nir and nor gene clusters encoding nitrite and nitric oxide reductases respectively. The NirI sequence corresponds to that of a membrane-bound protein with six transmembrane helices, a large periplasmic domain and cysteine-rich cytoplasmic domains that resemble the binding sites of [4Fe-4S] clusters in many ferredoxin-like proteins. NirX is soluble and apparently located in the periplasm, as judged by the predicted signal sequence. NirI and NirX are homologues of NosR and NosX, proteins involved in regulation of the expression of the nos gene cluster encoding nitrous oxide reductase in Pseudomonas stutzeri and Sinorhizobium meliloti. Analysis of a NirI-deficient mutant strain revealed that NirI is involved in transcription activation of the nir gene cluster in response to oxygen limitation and the presence of N-oxides. The NirX-deficient mutant transiently accumulated nitrite in the growth medium, but it had a final growth yield similar to that of the wild type. Transcription of the nirIX gene cluster itself was controlled by NNR, a member of the family of FNR-like transcriptional activators. An NNR binding sequence is located in the middle of the intergenic region between the nirI and nirS genes with its centre located at position -41.5 relative to the transcription start sites of both genes. Attempts to complement the NirI mutation via cloning of the nirIX gene cluster on a broad-host-range vector were unsuccessful, the ability to express nitrite reductase being restored only when the nirIX gene cluster was reintegrated into the chromosome of the NirI-deficient mutant via homologous recombination in such a way that the wild-type nirI gene was present directly upstream of the nir operon.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Saunders</LastName>
<ForeName>N F</ForeName>
<Initials>NF</Initials>
<Affiliation>Department of Molecular Cell Physiology, Faculty of Biology, BioCentrum Amsterdam, Vrije Universiteit, De Boelelaan 1087, NL-1081 HV Amsterdam, The Netherlands.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Houben</LastName>
<ForeName>E N</ForeName>
<Initials>EN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koefoed</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Weert</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reijnders</LastName>
<ForeName>W N</ForeName>
<Initials>WN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Westerhoff</LastName>
<ForeName>H V</ForeName>
<Initials>HV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Boer</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Spanning</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>AF005358</AccessionNumber>
<AccessionNumber>U47133</AccessionNumber>
<AccessionNumber>U94899</AccessionNumber>
</AccessionNumberList>
</DataBank>
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>P33943</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Mol Microbiol</MedlineTA>
<NlmUniqueID>8712028</NlmUniqueID>
<ISSNLinking>0950-382X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Bacterial Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>NNR protein, Paracoccus denitrificans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>NirI protein, Paracoccus denitrificans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>NirX protein, Paracoccus denitrificans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.7.-</RegistryNumber>
<NameOfSubstance>Nitrite Reductases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Bacterial Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Bacterial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genetic Complementation Test</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Multigene Family</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nitrite Reductases</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Paracoccus denitrificans</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Structure, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10612833</PMID>
<DateCreated>
<Year>2000</Year>
<Month>01</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>01</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>07</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1098-1004</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>15</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2000</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Human mutation</Title>
<ISOAbbreviation>Hum. Mutat.</ISOAbbreviation>
</Journal>
<ArticleTitle>Erratum: analysis of DNA elements that modulate myosin VIIa expression in humans.</ArticleTitle>
<Pagination>
<MedlinePgn>114-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Usher syndromeIb (USH1B), an autosomal recessive disorder caused by mutations in myosin VIIa (MYO7A), is characterized by congenital profound hearing loss, vestibular abnormalities and retinitis pigmentosa. Promoter elements in the 5 kb upstream of the translation start were identified using adult retinal pigment epithelium cells (ARPE-19) as a model system. A 160 bp minimal promoter within the first intron was active in ARPE-19 cells, but not in HeLa cells that do not express MYO7A. A 100 bp sequence, 5' of the first exon, and repeated with 90% homology within the first intron, appeared to modulate expression in both cell lines. Segments containing these elements were screened by heteroduplex analysis. No heteroduplexes were detected in the minimal promoter, suggesting that this sequence is conserved. A -2568 A&gt;T transversion in the 5' 100 bp repeat, eliminating a CCAAT element, was found only in USH1B patients. However, in all 5 families, -2568 A&gt;T was in cis with the same missense mutation in the myosin VIIa tail (Arg1240Gln), and 4 of the 5 families were Dutch. These observations suggest either 1) linkage disequilibrium or 2)that a combination of a promoter mutation with a less active myosin VIIa protein results in USH1B.</AbstractText>
<CopyrightInformation>Copyright 2000 Wiley-Liss, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Orten</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
<Affiliation>Center for Hereditary Communication Disorders, Boys Town National Research Hospital Omaha, NE, USA. ortend@boystown.org</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Weston</LastName>
<ForeName>M D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kelley</LastName>
<ForeName>P M</ForeName>
<Initials>PM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cremers</LastName>
<ForeName>C W</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagenaar</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jacobson</LastName>
<ForeName>S G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kimberling</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="N">
<Grant>
<GrantID>DC00677</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DC00982</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DC03351</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Corrected and Republished Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Hum Mutat</MedlineTA>
<NlmUniqueID>9215429</NlmUniqueID>
<ISSNLinking>1059-7794</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 3.6.4.1</RegistryNumber>
<NameOfSubstance>Myosins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.1</RegistryNumber>
<NameOfSubstance>myosin VIIa</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.2</RegistryNumber>
<NameOfSubstance>Dyneins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="RepublishedFrom">
<RefSource>Hum Mutat. 1999 Oct;14(4):354</RefSource>
<PMID Version="1">10502787</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dyneins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hearing Loss, Sensorineural</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Linkage Disequilibrium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myosins</DescriptorName>
<QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pedigree</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pigment Epithelium of Eye</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Polymorphism, Restriction Fragment Length</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Retinitis Pigmentosa</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Syndrome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vestibular Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10737756</PMID>
<DateCreated>
<Year>2000</Year>
<Month>04</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>04</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-2623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>43</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2000</Year>
<Month>Mar</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Journal of medicinal chemistry</Title>
<ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.</ArticleTitle>
<Pagination>
<MedlinePgn>1234-41</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The regioselective dibenzylphosphorylation of 2 followed by catalytic reduction in the presence of N-methyl-D-glucamine afforded 2-(S)-(1-(R)-(3, 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(5-(2- phosphoryl-3-oxo-4H,-1,2,4-triazolo)methylmorpholine, bis(N-methyl-D-glucamine) salt, 11. Incubation of 11 in rat, dog, and human plasma and in human hepatic subcellular fractions in vitro indicated that conversion to 2 would be expected to occur in vivo most readily in humans during hepatic circulation. Conversion of 11 to 2 occurred rapidly in vivo in the rat and dog with the levels of 11 being undetectable within 5 min after 1 and 8 mg/kg doses iv in the rat and within 15 min after 0.5, 2, and 32 mg/kg doses iv in the dog. Compound 11 has a 10-fold lower affinity for the human NK-1 receptor as compared to 2, but it is functionally equivalent to 2 in preclinical models of NK-1-mediated inflammation in the guinea pig and cisplatin-induced emesis in the ferret, indicating that 11 acts as a prodrug of 2. Based in part on these data, 11 was identified as a novel, water-soluble prodrug of the clinical candidate 2 suitable for intravenous administration in humans.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hale</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
<Affiliation>Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, and Merck, Sharp &amp; Dohme, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, U.K. jeffrey_hale@merck.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Mills</LastName>
<ForeName>S G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacCoss</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dorn</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Finke</LastName>
<ForeName>P E</ForeName>
<Initials>PE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Budhu</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reamer</LastName>
<ForeName>R A</ForeName>
<Initials>RA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huskey</LastName>
<ForeName>S E</ForeName>
<Initials>SE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luffer-Atlas</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dean</LastName>
<ForeName>B J</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McGowan</LastName>
<ForeName>E M</ForeName>
<Initials>EM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Feeney</LastName>
<ForeName>W P</ForeName>
<Initials>WP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chiu</LastName>
<ForeName>S H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cascieri</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chicchi</LastName>
<ForeName>G G</ForeName>
<Initials>GG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kurtz</LastName>
<ForeName>M M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sadowski</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ber</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tattersall</LastName>
<ForeName>F D</ForeName>
<Initials>FD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rupniak</LastName>
<ForeName>N M</ForeName>
<Initials>NM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rycroft</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hargreaves</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Metzger</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacIntyre</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>J Med Chem</MedlineTA>
<NlmUniqueID>9716531</NlmUniqueID>
<ISSNLinking>0022-2623</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluoro)phenyl-4-(5-(2-phosphoryl-3-oxo-4H,-1,2,4-triazolo))methylmorpholine, bis(N-methylglucamine) salt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Acetals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antiemetics</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>L 754030</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Morpholines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Prodrugs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Neurokinin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>15663-27-1</RegistryNumber>
<NameOfSubstance>Cisplatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7732-18-5</RegistryNumber>
<NameOfSubstance>Water</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acetals</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antiemetics</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cisplatin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Guinea Pigs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Morpholines</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prodrugs</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Neurokinin-1</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stereoisomerism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vomiting</DescriptorName>
<QualifierName MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Water</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10854512</PMID>
<DateCreated>
<Year>2000</Year>
<Month>06</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>06</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-2218</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2000</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Surgical endoscopy</Title>
<ISOAbbreviation>Surg Endosc</ISOAbbreviation>
</Journal>
<ArticleTitle>Inflammatory fibroid polyp of the duodenum.</ArticleTitle>
<Pagination>
<MedlinePgn>86</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Duodenal inflammatory fibroid polyps (IFP) are extemely rare lesions indistinguishable from submucosal tumors by endoscopic inspection alone. Like gastric inflammatory fibroid polyps, they can be managed by endoscopic polypectomy or mucosectomy. However, preoperative diagnosis of this benign lesion is difficult. Here we present a case of duodenal IFP causing gastrointestinal bleeding that was evaluated by endoscopic ultrasound before surgical removal. On endosonography, the duodenal IFP appeared as a coarsely heterogeneous isoechoic and hypoechoic mass circumscribed by a distinct margin and arising from the third layer of the duodenal wall. The endosonographic appearance of this lesion was in marked contrast to that previously reported for gastric IFPs, which have tended to appear as hypoechoic homogeneous lesions with indistinct margins. Endosonographic evaluation of suspected IFPs before endoscopic or surgical treatment is useful. However, the endosonographic appearances of duodenal and gastric IFPs may be significantly different, possibly because of differences in the makeup of the duodenal and gastric walls.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Soon</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
<Affiliation>Division of Gastroenterology, ChangHua Christian Medical Center, ChangHua, Taiwan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>O S</ForeName>
<Initials>OS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>1999</Year>
<Month>11</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Surg Endosc</MedlineTA>
<NlmUniqueID>8806653</NlmUniqueID>
<ISSNLinking>0930-2794</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Duodenal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Duodenitis</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Endosonography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroma</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastric Mucosa</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intestinal Polyps</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10972993</PMID>
<DateCreated>
<Year>2000</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0899-1987</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>28</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2000</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.</ArticleTitle>
<Pagination>
<MedlinePgn>236-46</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Germline mutations of BRCA1 and BRCA2 predispose to hereditary breast, ovarian, and possibly prostate cancer, yet structural mutations in these genes are infrequent in sporadic cancer cases. To better define the involvement of these genes in sporadic cancers, we characterized expression levels of BRCA1 and BRCA2 transcripts in cancer cell lines derived from neoplasms of the ovary, prostate, and breast and compared them with those expressed in primary cultures of normal epithelial cells established from these organs. We observed upregulation of BRCA1 and/or BRCA2 expression in six of seven ovarian cancer cell lines (OVCA420, OVCA429, OVCA432, ALST, DOV13, and SKOV3) when compared with levels found in normal ovary surface epithelial cells. Furthermore, five cancerous or immortalized prostatic epithelial cell lines (BPH-1, TSU-Pr1, LNCaP, PC-3, and DU145) also expressed higher levels of BRCA1 and/or BRCA2 mRNA than did primary cultures of normal prostatic epithelial cells. In contrast, only the estrogen receptor-positive MCF-7 cell line overexpressed these messages, whereas the estrogen receptor-negative breast cancer cell lines Hs578T, MDA-MB-231, and MDA-MB-468 showed no change in expression levels when compared with normal breast epithelial cells. In addition, expanding on our recent identification of a novel BRCA2 transcript variant carrying an in-frame exon 12 deletion (BRCA2 delta 12), we report increased expression of this variant in several ovarian, prostate, and mammary cancer cell lines (OVCA420, OVCA433, ALST, DOV13, SKOV3, TSU-Pr1, DU145, and MDA-MB-468). Most notably, high levels of BRCA2 delta 12 mRNA were detected in an estrogen receptor-positive breast cancer cell line, MCF-7, and in an androgen-independent prostate cancer cell line, DU-145. Interestingly, the wild-type BRCA2 transcript was barely detectable in DU145, which could be used as a model system for future investigations on BRCA2 delta 12 function. Taken together, our data suggest disruption of BRCA1 and/or BRCA2 gene expression in certain epithelial cancer cell lines of the ovary, prostate, and breast. Because wild-type BRCA1 and BRCA2 gene products increase during cell-cycle progression and are believed to exert growth-inhibitory action, enhanced expression of these genes in cancer cells may represent a negative feedback mechanism for curbing proliferation in fast-growing cells. At present, the functionality of BRCA2 delta 12 remains elusive.</AbstractText>
<CopyrightInformation>Copyright 2000 Wiley-Liss, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rauh-Adelmann</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<Affiliation>Department of Biology, Tufts University, Medford, Massachusetts, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lau</LastName>
<ForeName>K M</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sabeti</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Long</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mok</LastName>
<ForeName>S C</ForeName>
<Initials>SC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ho</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="N">
<Grant>
<GrantID>C69453</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA15576</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA62269</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>BRCA1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>BRCA2 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">BRCA1 Protein</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">BRCA2 Protein</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Breast</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Exons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Genes, BRCA1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genetic Variation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11025314</PMID>
<DateCreated>
<Year>2001</Year>
<Month>01</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>01</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0108-2701</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>56 ( Pt 10)</Volume>
<PubDate>
<Year>2000</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Acta crystallographica. Section C, Crystal structure communications</Title>
<ISOAbbreviation>Acta Crystallogr C</ISOAbbreviation>
</Journal>
<ArticleTitle>Multicentre hydrogen bonds in a 2:1 arylsulfonylimidazolone hydrochloride salt.</ArticleTitle>
<Pagination>
<MedlinePgn>1247-50</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The title compound, (S)-(+)-4-[5-(2-oxo-4, 5-dihydroimidazol-1-ylsulfonyl)indolin-1 -ylcarbonyl ]anilinium chloride (S)-(+)-1-[1-(4-aminobenzoyl)indoline-5- sulfonyl]-4-phenyl-4, 5-dihydroimidazol-2-one, C(24)H(23)N(4)O(4)S(+).Cl(-). C(24)H(22)N(4)O(4)S, crystallizes in space group C2 from a CH(3)OH/CH(2)Cl(2) solution. In the crystal structure, there are two different conformers with their terminal C(6) aromatic rings mutually oriented at angles of 67.69 (14) and 61.16 (15) degrees. The distances of the terminal N atoms (of the two conformers) from the chloride ion are 3.110 (4) and 3.502 (4) A. There are eight distinct hydrogen bonds, i.e. four N-H...Cl, three N-H...O and one N-H...N, with one N-H group involved in a bifurcated hydrogen bond with two acceptors sharing the H atom. C-H...O contacts assist in the overall hydrogen-bonding process.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>K L</ForeName>
<Initials>KL</Initials>
<Affiliation>College of Pharmacy, Chungnam National University, Taejeon 305-764, Korea. parki@cnu.ac.kr.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Moon</LastName>
<ForeName>B G</ForeName>
<Initials>BG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>S H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>J G</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Suh</LastName>
<ForeName>I H</ForeName>
<Initials>IH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>DENMARK</Country>
<MedlineTA>Acta Crystallogr C</MedlineTA>
<NlmUniqueID>8305826</NlmUniqueID>
<ISSNLinking>0108-2701</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>1-(1-(4-aminobenzoyl)indoline-5-sulfonyl)-4-phenyl-4,5-dihydroimidazol-2-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Sulfones</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Crystallography, X-Ray</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hydrogen Bonding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stereoisomerism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sulfones</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Process">
<PMID Version="1">11056631</PMID>
<DateCreated>
<Year>2000</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-9007</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>85</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2000</Year>
<Month>Nov</Month>
<Day>6</Day>
</PubDate>
</JournalIssue>
<Title>Physical review letters</Title>
<ISOAbbreviation>Phys. Rev. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dislocated epitaxial islands.</ArticleTitle>
<Pagination>
<MedlinePgn>4088-91</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Dislocation networks observed in CoSi (2) islands grown epitaxially on Si are compared with the results of dislocation-dynamics calculations. The calculations make use of the fact that image forces play a relatively minor role compared to line tension forces and dislocation-dislocation interactions. Remarkable agreement is achieved, demonstrating that this approach can be applied more generally to study dislocations in other mesostructures.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>X H</ForeName>
<Initials>XH</Initials>
<Affiliation>IBM Watson Research Center, P.O. Box 218, Yorktown Heights, New York 10598, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ross</LastName>
<ForeName>F M</ForeName>
<Initials>FM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schwarz</LastName>
<ForeName>K W</ForeName>
<Initials>KW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Phys Rev Lett</MedlineTA>
<NlmUniqueID>0401141</NlmUniqueID>
<ISSNLinking>0031-9007</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11034741</PMID>
<DateCreated>
<Year>2001</Year>
<Month>01</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>08</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>06</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1469-493X</ISSN>
<JournalIssue CitedMedium="Internet">
<Issue>4</Issue>
<PubDate>
<Year>2000</Year>
</PubDate>
</JournalIssue>
<Title>The Cochrane database of systematic reviews</Title>
<ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Parent-training programmes for improving maternal psychosocial health.</ArticleTitle>
<Pagination>
<MedlinePgn>CD002020</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prevalence of mental health problems in women is 1:3 and such problems tend to be persistent. There is evidence from a range of studies to suggest that a number of factors relating to maternal psychosocial health can have a significant effect on the mother-infant relationship, and that this can have consequences for the psychological health of the child. It is now thought that parenting programmes may have an important role to play in the improvement of maternal psychosocial health.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objective of this review is to address whether group-based parenting programmes are effective in improving maternal psychosocial health including anxiety, depression and self-esteem.</AbstractText>
<AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">A range of biomedical, social science, educational and general reference electronic databases were searched including MEDLINE, EMBASE CINAHL, PsychLIT, ERIC, ASSIA, Sociofile and the Social Science Citation Index. Other sources of information included the Cochrane Library (SPECTR, CENTRAL), and the National Research Register (NRR).</AbstractText>
<AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Only randomised controlled trials were included in which participants had been randomly allocated to an experimental and a control group, the latter being either a waiting-list, no-treatment or a placebo control group. Studies had to include at least one group-based parenting programme, and one standardised instrument measuring maternal psychosocial health.</AbstractText>
<AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">A systematic critical appraisal of all included studies was undertaken using the Journal of the American Medical Association (JAMA) published criteria. The data were summarised using effect sizes but were not combined in a meta-analysis due to the small number of studies within each group and the presence of significant heterogeneity.</AbstractText>
<AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">A total of 22 studies were included in the review but only 17 provided sufficient data to calculate effect sizes. These 17 studies reported on a total of 59 outcomes including depression, anxiety, stress, self-esteem, social competence, social support, guilt, mood, automatic thoughts, dyadic adjustment, psychiatric morbidity, irrationality, anger and aggression, mood, attitude, personality, and beliefs. Approximately 22% of the outcomes measured suggested significant differences favouring the intervention group. A further 40% showed differences favouring the intervention group but which failed to achieve conventional levels of statistical significance, in some cases due to the small numbers that were used. Approximately 38% of outcomes suggested no evidence of effectiveness.</AbstractText>
<AbstractText Label="REVIEWER'S CONCLUSIONS" NlmCategory="CONCLUSIONS">It is suggested that parenting programmes can make a significant contribution to the improvement of psychosocial health in mothers. While the critical appraisal suggests some variability in the quality of the included studies, it is concluded that there is sufficient evidence to support their use with diverse groups of parents. However, it is also suggested that some caution should be exercised before the results are generalised to parents irrespective of the level of pathology present, and that further research is still required.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barlow</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<Affiliation>Health Services Research Unit, University of Oxford, Institute of Health Sciences, Old Road, Oxford, UK, OX3 7LF. esther.coren@dphpc.ox.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Coren</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cochrane Database Syst Rev</MedlineTA>
<NlmUniqueID>100909747</NlmUniqueID>
<ISSNLinking>1361-6137</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="UpdateIn">
<RefSource>Cochrane Database Syst Rev. 2001;(2):CD002020</RefSource>
<PMID Version="1">11406024</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anxiety</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Depression</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Maternal Behavior</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mother-Child Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Parenting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Self Concept</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>99</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11237011</PMID>
<DateCreated>
<Year>2001</Year>
<Month>03</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0028-0836</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>409</Volume>
<Issue>6822</Issue>
<PubDate>
<Year>2001</Year>
<Month>Feb</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Initial sequencing and analysis of the human genome.</ArticleTitle>
<Pagination>
<MedlinePgn>860-921</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The human genome holds an extraordinary trove of information about human development, physiology, medicine and evolution. Here we report the results of an international collaboration to produce and make freely available a draft sequence of the human genome. We also present an initial analysis of the data, describing some of the insights that can be gleaned from the sequence.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lander</LastName>
<ForeName>E S</ForeName>
<Initials>ES</Initials>
<Affiliation>Whitehead Institute for Biomedical Research, Center for Genome Research, Cambridge, Massachusetts 02142, USA. lander@genome.wi.mit.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Linton</LastName>
<ForeName>L M</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Birren</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nusbaum</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zody</LastName>
<ForeName>M C</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baldwin</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Devon</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dewar</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doyle</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>FitzHugh</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Funke</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gage</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harris</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heaford</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Howland</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kann</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lehoczky</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>LeVine</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McEwan</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McKernan</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meldrim</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mesirov</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miranda</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morris</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Naylor</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raymond</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rosetti</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santos</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sheridan</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sougnez</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stange-Thomann</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stojanovic</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Subramanian</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wyman</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rogers</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sulston</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ainscough</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beck</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bentley</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Burton</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clee</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carter</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Coulson</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deadman</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deloukas</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dunham</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dunham</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Durbin</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>French</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grafham</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gregory</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hubbard</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Humphray</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hunt</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lloyd</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McMurray</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matthews</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mercer</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Milne</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mullikin</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mungall</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Plumb</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ross</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shownkeen</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sims</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Waterston</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>R K</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hillier</LastName>
<ForeName>L W</ForeName>
<Initials>LW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McPherson</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marra</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mardis</LastName>
<ForeName>E R</ForeName>
<Initials>ER</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fulton</LastName>
<ForeName>L A</ForeName>
<Initials>LA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chinwalla</LastName>
<ForeName>A T</ForeName>
<Initials>AT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pepin</LastName>
<ForeName>K H</ForeName>
<Initials>KH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gish</LastName>
<ForeName>W R</ForeName>
<Initials>WR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chissoe</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wendl</LastName>
<ForeName>M C</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Delehaunty</LastName>
<ForeName>K D</ForeName>
<Initials>KD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miner</LastName>
<ForeName>T L</ForeName>
<Initials>TL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Delehaunty</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kramer</LastName>
<ForeName>J B</ForeName>
<Initials>JB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cook</LastName>
<ForeName>L L</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fulton</LastName>
<ForeName>R S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>D L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Minx</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clifton</LastName>
<ForeName>S W</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hawkins</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Branscomb</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Predki</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Richardson</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wenning</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Slezak</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doggett</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>J F</ForeName>
<Initials>JF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olsen</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lucas</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elkin</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uberbacher</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frazier</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gibbs</LastName>
<ForeName>R A</ForeName>
<Initials>RA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Muzny</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scherer</LastName>
<ForeName>S E</ForeName>
<Initials>SE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bouck</LastName>
<ForeName>J B</ForeName>
<Initials>JB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sodergren</LastName>
<ForeName>E J</ForeName>
<Initials>EJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Worley</LastName>
<ForeName>K C</ForeName>
<Initials>KC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rives</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gorrell</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Metzker</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Naylor</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kucherlapati</LastName>
<ForeName>R S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nelson</LastName>
<ForeName>D L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weinstock</LastName>
<ForeName>G M</ForeName>
<Initials>GM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sakaki</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fujiyama</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hattori</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yada</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Toyoda</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Itoh</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawagoe</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watanabe</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Totoki</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taylor</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weissenbach</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heilig</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saurin</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Artiguenave</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brottier</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bruls</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pelletier</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robert</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wincker</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>D R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doucette-Stamm</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rubenfield</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weinstock</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>H M</ForeName>
<Initials>HM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dubois</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rosenthal</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Platzer</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nyakatura</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taudien</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rump</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gu</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hood</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rowen</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Madan</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Davis</LastName>
<ForeName>R W</ForeName>
<Initials>RW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Federspiel</LastName>
<ForeName>N A</ForeName>
<Initials>NA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abola</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Proctor</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Myers</LastName>
<ForeName>R M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schmutz</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dickson</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grimwood</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cox</LastName>
<ForeName>D R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olson</LastName>
<ForeName>M V</ForeName>
<Initials>MV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaul</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raymond</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shimizu</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawasaki</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Minoshima</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>G A</ForeName>
<Initials>GA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Athanasiou</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schultz</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roe</LastName>
<ForeName>B A</ForeName>
<Initials>BA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ramser</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lehrach</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reinhardt</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McCombie</LastName>
<ForeName>W R</ForeName>
<Initials>WR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de la Bastide</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dedhia</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blcker</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hornischer</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nordsiek</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Agarwala</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aravind</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bailey</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bateman</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Batzoglou</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Birney</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bork</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>D G</ForeName>
<Initials>DG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Burge</LastName>
<ForeName>C B</ForeName>
<Initials>CB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cerutti</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>H C</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Church</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clamp</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Copley</LastName>
<ForeName>R R</ForeName>
<Initials>RR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doerks</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eddy</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eichler</LastName>
<ForeName>E E</ForeName>
<Initials>EE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Furey</LastName>
<ForeName>T S</ForeName>
<Initials>TS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Galagan</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gilbert</LastName>
<ForeName>J G</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harmon</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hayashizaki</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haussler</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hermjakob</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hokamp</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jang</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>L S</ForeName>
<Initials>LS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>T A</ForeName>
<Initials>TA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kasif</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaspryzk</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kennedy</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kent</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kitts</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koonin</LastName>
<ForeName>E V</ForeName>
<Initials>EV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Korf</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kulp</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lancet</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lowe</LastName>
<ForeName>T M</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McLysaght</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mikkelsen</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moran</LastName>
<ForeName>J V</ForeName>
<Initials>JV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mulder</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pollara</LastName>
<ForeName>V J</ForeName>
<Initials>VJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ponting</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schuler</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schultz</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Slater</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smit</LastName>
<ForeName>A F</ForeName>
<Initials>AF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stupka</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Szustakowski</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thierry-Mieg</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thierry-Mieg</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wallis</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wheeler</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wolf</LastName>
<ForeName>Y I</ForeName>
<Initials>YI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wolfe</LastName>
<ForeName>K H</ForeName>
<Initials>KH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>S P</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yeh</LastName>
<ForeName>R F</ForeName>
<Initials>RF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Collins</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guyer</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peterson</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Felsenfeld</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wetterstrand</LastName>
<ForeName>K A</ForeName>
<Initials>KA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Patrinos</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morgan</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Jong</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Catanese</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Osoegawa</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shizuya</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Y J</ForeName>
<Initials>YJ</Initials>
</Author>
<Author ValidYN="N">
<LastName>Szustakowki</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>International Human Genome Sequencing Consortium</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA Transposable Elements</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Proteome</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance>RNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nature. 2001 Oct 18;413(6857):660</RefSource>
<PMID Version="1">11606985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nature. 2001 Feb 15;409(6822):822-3</RefSource>
<PMID Version="1">11236997</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nature. 2001 Feb 15;409(6822):818-20</RefSource>
<PMID Version="1">11236994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nature. 2001 Feb 15;409(6822):820-1</RefSource>
<PMID Version="1">11236995</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nature. 2001 Feb 15;409(6822):814-6</RefSource>
<PMID Version="1">11236992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Nature 2001 Jun 7;411(6838):720</RefSource>
<Note>Szustakowki, J [corrected to Szustakowski, J]</Note>
</CommentsCorrections>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Nature 2001 Aug 2;412(6846):565</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromosome Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Conserved Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">CpG Islands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Transposable Elements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Databases, Factual</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Industry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Evolution, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Forecasting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">GC Rich Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Duplication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genetic Diseases, Inborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genetics, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Genome, Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Human Genome Project</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Private Sector</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proteome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Public Sector</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Repetitive Sequences, Nucleic Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Sequence Analysis, DNA</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Species Specificity</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11243089</PMID>
<DateCreated>
<Year>2001</Year>
<Month>03</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>05</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0019-557X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>43</Volume>
<Issue>1</Issue>
<PubDate>
<MedlineDate>1999 Jan-Mar</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Indian journal of public health</Title>
<ISOAbbreviation>Indian J Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Nutritional status of pavement dweller children of Calcutta City.</ArticleTitle>
<Pagination>
<MedlinePgn>49-54</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Pavement dwelling is likely to aggravate malnutrition among its residents due to extreme poverty, lack of dwelling and access to food and their exposure to polluted environment. Paucity of information about nutritional status of street children compared to that among urban slum dwellers, squatters or rural/tribal population is quite evident. The present study revealed the magnitude of Protein Energy Malnutrition (PEM) and few associated factors among a sample of 435 underfives belonging to pavement dweller families and selected randomly from clusters of such families, from each of the five geographical sectors of Calcutta city. Overall prevalence of PEM was found almost similar (about 70%) to that among other 'urban poor' children viz. slum dwellers etc., but about 16% of them were found severely undernourished (Grade III &amp; V of IAP classification of PEM). About 35% and 70% of street dweller children had wasting and stunting respectively. Severe PEM (Grade III &amp; IV) was more prevalent among 12-23 months old, girl child, those belonged to illiterate parents and housewife mothers rather than wage earners. It also did increase with increase of birth rate of decrease of birth interval.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ray</LastName>
<ForeName>S K</ForeName>
<Initials>SK</Initials>
<Affiliation>Department of Community Medicine, Medical College, Calcutta.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Mishra</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Biswas</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Halder</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chatterjee</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian J Public Health</MedlineTA>
<NlmUniqueID>0400673</NlmUniqueID>
<ISSNLinking>0019-557X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CitationSubset>J</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Educational Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">India</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nutritional Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Poverty</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prejudice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein-Energy Malnutrition</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="PIP">143717</OtherID>
<OtherID Source="POP">00288124</OtherID>
<OtherAbstract Type="PIP" Language="eng">
<AbstractText>This document presents a cross-sectional survey concerning the magnitude of protein energy  malnutrition (PEM) and its associated factors among 435 under-5 pavement-dwelling children in  Calcutta.  Results revealed that 69.43% were undernourished and that 16% of them were  suffering from severe malnutrition (grade III and IV of the Indian Academy of Pediatrics criteria  for PEM).  The 24-35 month age group had the highest prevalence of malnutrition (82.93%)  followed by the 36-47 and 12-23 month age groups with prevalences of 76.19% and 74.03%,  respectively.  Prevalence of severe grade malnutrition was noted to be three times higher in  females (24.76%) than males (8.45%), and among families it increased in direct proportion to  birth rate and inverse proportion to birth interval.  Moreover, children of illiterate parents and  nonworking mothers had a higher incidence of severe PEM.  Simple measures such as exclusive  breast-feeding and timely complementary feeding as well as measures directed toward birth  spacing and limiting family size should be implemented to solve the problem of malnutrition.</AbstractText>
</OtherAbstract>
<KeywordList Owner="PIP">
<Keyword MajorTopicYN="N">Age Factors</Keyword>
<Keyword MajorTopicYN="N">Asia</Keyword>
<Keyword MajorTopicYN="Y">Child</Keyword>
<Keyword MajorTopicYN="Y">Child Nutrition</Keyword>
<Keyword MajorTopicYN="N">Demographic Factors</Keyword>
<Keyword MajorTopicYN="N">Developing Countries</Keyword>
<Keyword MajorTopicYN="N">Diseases</Keyword>
<Keyword MajorTopicYN="N">Geographic Factors</Keyword>
<Keyword MajorTopicYN="N">Health</Keyword>
<Keyword MajorTopicYN="Y">Homeless Persons</Keyword>
<Keyword MajorTopicYN="N">India</Keyword>
<Keyword MajorTopicYN="Y">Malnutrition</Keyword>
<Keyword MajorTopicYN="N">Nutrition</Keyword>
<Keyword MajorTopicYN="N">Nutrition Disorders</Keyword>
<Keyword MajorTopicYN="N">Population</Keyword>
<Keyword MajorTopicYN="N">Population Characteristics</Keyword>
<Keyword MajorTopicYN="N">Research Methodology</Keyword>
<Keyword MajorTopicYN="Y">Research Report</Keyword>
<Keyword MajorTopicYN="N">Residence Characteristics</Keyword>
<Keyword MajorTopicYN="N">Sampling Studies</Keyword>
<Keyword MajorTopicYN="N">Southern Asia</Keyword>
<Keyword MajorTopicYN="N">Spatial Distribution</Keyword>
<Keyword MajorTopicYN="N">Studies</Keyword>
<Keyword MajorTopicYN="Y">Surveys</Keyword>
<Keyword MajorTopicYN="Y">Urban Population</Keyword>
<Keyword MajorTopicYN="N">Youth</Keyword>
</KeywordList>
<GeneralNote Owner="PIP">TJ: INDIAN JOURNAL OF PUBLIC HEALTH.</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11238657</PMID>
<DateCreated>
<Year>2001</Year>
<Month>03</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>05</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-1767</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>166</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2001</Year>
<Month>Mar</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.</ArticleTitle>
<Pagination>
<MedlinePgn>4083-91</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Increasing evidence suggests that a continuous release of histamine from mast cells occurs in the airways of asthmatic patients and that histamine may modulate functions of other inflammatory cells such as macrophages. In the present study histamine (10(-9)-10(-6) M) increased in a concentration-dependent fashion the basal release of beta-glucuronidase (EC(50) = 8.2 +/- 3.5 x 10(-9) M) and IL-6 (EC(50) = 9.3 +/- 2.9 x 10(-8) M) from human lung macrophages. Enhancement of beta-glucuronidase release induced by histamine was evident after 30 min and peaked at 90 min, whereas that of IL-6 required 2-6 h of incubation. These effects were reproduced by the H(1) agonist (6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)heptane carboxamide but not by the H(2) agonist dimaprit. Furthermore, histamine induced a concentration-dependent increase of intracellular Ca(2+) concentrations ([Ca(2+)](i)) that followed three types of response, one characterized by a rapid increase, a second in which [Ca(2+)](i) displays a slow but progressive increase, and a third characterized by an oscillatory pattern. Histamine-induced beta-glucuronidase and IL-6 release and [Ca(2+)](i) elevation were inhibited by the selective H(1) antagonist fexofenadine (10(-7)-10(-4) M), but not by the H(2) antagonist ranitidine. Inhibition of histamine-induced beta-glucuronidase and IL-6 release by fexofenadine was concentration dependent and displayed the characteristics of a competitive antagonism (K(d) = 89 nM). These data demonstrate that histamine induces exocytosis and IL-6 production from human macrophages by activating H(1) receptor and by increasing [Ca(2+)](i) and they suggest that histamine may play a relevant role in the long-term sustainment of allergic inflammation in the airways.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Triggiani</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Division of Clinical Immunology and Allergy, University of Naples Federico II, Naples, Italy. triggian@unina.it</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Gentile</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Secondo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Granata</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oriente</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taglialatela</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Annunziato</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marone</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Histamine Agonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Histamine H1 Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Histamine H2 Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Histamine H1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Toluidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>103827-15-2</RegistryNumber>
<NameOfSubstance>6-((2-(4-imidazolyl)ethyl)amino)heptanoic acid 4-toluidide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-45-6</RegistryNumber>
<NameOfSubstance>Histamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>65119-89-3</RegistryNumber>
<NameOfSubstance>Dimaprit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.2.1.31</RegistryNumber>
<NameOfSubstance>Glucuronidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cytosol</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dimaprit</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Exocytosis</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Glucuronidase</DescriptorName>
<QualifierName MajorTopicYN="N">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Histamine</DescriptorName>
<QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Histamine Agonists</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Histamine H1 Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Histamine H2 Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lung</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Histamine H1</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Toluidines</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11279676</PMID>
<DateCreated>
<Year>2001</Year>
<Month>03</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>12</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>06</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1469-493X</ISSN>
<JournalIssue CitedMedium="Internet">
<Issue>1</Issue>
<PubDate>
<Year>2001</Year>
</PubDate>
</JournalIssue>
<Title>The Cochrane database of systematic reviews</Title>
<ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Elective versus selective caesarean section for delivery of the small baby.</ArticleTitle>
<Pagination>
<MedlinePgn>CD000078</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elective caesarean delivery for women in preterm labour might reduce the chances of fetal or neonatal death, but it might also increase the risk of maternal morbidity.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effects of a policy of elective caesarean delivery versus selective caesarean delivery for women in preterm labour.</AbstractText>
<AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">The Cochrane Pregnancy and Childbirth Group trials register was searched. Date of last search: September 2000.</AbstractText>
<AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised trials comparing a policy of elective caesarean delivery versus expectant management with recourse to caesarean section.</AbstractText>
<AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">One reviewer assessed eligibility and trial quality, and both contributed to the update.</AbstractText>
<AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Six studies involving 122 women were included. All trials reported recruiting difficulties. No significant differences between elective and selective policies for caesarean delivery were found for fetal, neonatal or maternal outcomes.</AbstractText>
<AbstractText Label="REVIEWER'S CONCLUSIONS" NlmCategory="CONCLUSIONS">There is not enough evidence to evaluate the use of a policy for elective caesarean delivery for small babies. Randomised trials in this area are likely to continue to experience recruitment problems. However, it still may be possible to investigate elective caesarean delivery in preterm babies with cephalic presentations.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Grant</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Affiliation>Health Services Research Unit, The Polwarth Building, Foresterhill, Aberdeen, UK, AB9 2ZD. a.grant@abdn.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Glazener</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cochrane Database Syst Rev</MedlineTA>
<NlmUniqueID>100909747</NlmUniqueID>
<ISSNLinking>1361-6137</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="UpdateIn">
<RefSource>Cochrane Database Syst Rev. 2001;(2):CD000078</RefSource>
<PMID Version="1">11405950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="UpdateOf">
<RefSource>Cochrane Database Syst Rev. 2000;(2):CD000078</RefSource>
<PMID Version="1">10796117</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cesarean Section</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant, Premature</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Obstetric Labor, Premature</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Surgical Procedures, Elective</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>21</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11406024</PMID>
<DateCreated>
<Year>2001</Year>
<Month>06</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>02</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>06</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1469-493X</ISSN>
<JournalIssue CitedMedium="Internet">
<Issue>2</Issue>
<PubDate>
<Year>2001</Year>
</PubDate>
</JournalIssue>
<Title>The Cochrane database of systematic reviews</Title>
<ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Parent-training programmes for improving maternal psychosocial health.</ArticleTitle>
<Pagination>
<MedlinePgn>CD002020</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mental health problems are common, and there is evidence from a range of studies to suggest that a number of factors relating to maternal psychosocial health can have a significant effect on the mother-infant relationship, and that this can have consequences for both the short and long-term psychological health of the child. The use of parenting programmes is increasing in the UK and evidence of their effectiveness in improving outcomes for mothers is now required.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objective of this review is to address whether group-based parenting programmes are effective in improving maternal psychosocial health including anxiety, depression, and self-esteem.</AbstractText>
<AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">A range of biomedical, social science, educational and general reference electronic databases were searched including MEDLINE, EMBASE CINAHL, PsychLIT, ERIC, ASSIA, Sociofile and the Social Science Citation Index. Other sources of information included the Cochrane Library (SPECTR, CENTRAL), and the National Research Register (NRR).</AbstractText>
<AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Only randomised controlled trials were included in which participants had been randomly allocated to an experimental and a control group, the latter being either a waiting-list, no-treatment or a placebo control group. Studies had to include at least one group-based parenting programme, and one standardised instrument measuring maternal psychosocial health.</AbstractText>
<AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">A systematic critical appraisal of all included studies was undertaken using a modified version of the Journal of the American Medical Association (JAMA) published criteria. The treatment effect for each outcome in each study was standardised by dividing the mean difference in post-intervention scores for the intervention and treatment group, by the pooled standard deviation, to produce an effect size. Where appropriate the results were then combined in a meta-analysis using a fixed-effect model, and 95% confidence intervals were used to assess the significance of the findings.</AbstractText>
<AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">A total of 23 studies were included in the review but only 17 provided sufficient data to calculate effect sizes. The 17 studies provided a total of 59 assessments of outcome on a range of aspects of psychosocial functioning including depression, anxiety, stress, self-esteem, social competence, social support, guilt, mood, automatic thoughts, dyadic adjustment, psychiatric morbidity, irrationality, anger and aggression, mood, attitude, personality, and beliefs. There was only sufficient data, however, on five outcomes (depression; anxiety/stress; self-esteem; social support; and relationship with spouse/marital adjustment) to combine the results in a meta-analysis. The meta-analyses show statistically significant results favouring the intervention group as regards depression; anxiety/stress; self-esteem; and relationship with spouse/marital adjustment. The meta-analysis of the social support data, however, showed no evidence of effectiveness. These results suggest that parenting programmes, irrespective of the type (or content) of programme, can be effective in improving important aspects of maternal psycho-social functioning. Of the data summarising the effectiveness of the different types of parenting programmes, which it was not possible to combine in a meta-analysis, approximately 22% of the outcomes measured, showed significant differences between the intervention group and the control group. A further 40% showed medium to large non-significant differences favouring the intervention group. Approximately one-third of outcomes showed small non-significant differences or no evidence of effectiveness. A meta-analysis of the follow-up data on three outcomes was also conducted - depression, self-esteem and relationship with spouse/marital adjustment. The results show that there was a continued improvement in self-esteem, depression and marital adjustment at follow-up, although the latter two findings were not statistically significant.</AbstractText>
<AbstractText Label="REVIEWER'S CONCLUSIONS" NlmCategory="CONCLUSIONS">It is suggested that parenting programmes can make a significant contribution to short-term psychosocial health in mothers, and that the limited follow-up data available suggest that these are maintained over time. However, the overall paucity of long-term follow-up data points to the need for further evidence concerning the long-term effectiveness of parenting programmes on maternal mental health. Furthermore, it is suggested that some caution should be exercised before the results are generalised to parents irrespective of the level of pathology present, and that further research is still required.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barlow</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<Affiliation>Health Services Research Unit, University of Oxford, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. esther.coren@public-health.oxford.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Coren</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cochrane Database Syst Rev</MedlineTA>
<NlmUniqueID>100909747</NlmUniqueID>
<ISSNLinking>1361-6137</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="UpdateIn">
<RefSource>Cochrane Database Syst Rev. 2004;(1):CD002020</RefSource>
<PMID Version="1">14973981</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="UpdateOf">
<RefSource>Cochrane Database Syst Rev. 2000;(4):CD002020</RefSource>
<PMID Version="1">11034741</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anxiety</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Depression</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Maternal Behavior</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Maternal Welfare</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mother-Child Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Parenting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Self Concept</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>100</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11428848</PMID>
<DateCreated>
<Year>2001</Year>
<Month>06</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>09</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0195-668X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>22</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2001</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>European heart journal</Title>
<ISOAbbreviation>Eur. Heart J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology.</ArticleTitle>
<Pagination>
<MedlinePgn>1074-81</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hauer </LastName>
<ForeName>R N</ForeName>
<Initials>RN</Initials>
<Affiliation>Heart Lung Center Utrecht, University Medical Center, The Netherlands.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Aliot</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Block</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Capucci</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lderitz</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santini</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vardas</LastName>
<ForeName>P E</ForeName>
<Initials>PE</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>European Society of Cardiology. Working Group on Arrhythmias and Working Group on Cardiac Pacing</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Guideline</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Practice Guideline</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Eur Heart J</MedlineTA>
<NlmUniqueID>8006263</NlmUniqueID>
<ISSNLinking>0195-668X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Arrhythmogenic Right Ventricular Dysplasia</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiomyopathy, Dilated</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiomyopathy, Hypertrophic</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Coronary Disease</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Death, Sudden, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Defibrillators, Implantable</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Valve Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Long QT Syndrome</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ventricular Fibrillation</DescriptorName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11441930</PMID>
<DateCreated>
<Year>2001</Year>
<Month>07</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>07</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>05</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0284-186X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>40</Volume>
<Issue>2-3</Issue>
<PubDate>
<Year>2001</Year>
</PubDate>
</JournalIssue>
<Title>Acta oncologica (Stockholm, Sweden)</Title>
<ISOAbbreviation>Acta Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Assessment of quality of life during chemotherapy.</ArticleTitle>
<Pagination>
<MedlinePgn>175-84</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Increasingly more aggressive chemotherapy together with expected small differences between treatments with respect to objective endpoints has heightened awareness about the importance of addressing how patients experience and value the impact that treatment has had on their overall life situation. Assessment of a patient's quality of life (QoL) is now conceptually viewed as an important complement to traditional objective evaluation measures. It was therefore considered important to review the basis for the assessment of this endpoint when The Swedish Council of Technology Assessment in Health Care (SBU) performed a systematic overview of chemotherapy effects in several tumour types. The group came to the following conclusions: QoL assessments, mostly by patient self-reporting in questionnaires, have come increasingly into use during the past decade. A number of general, cancer-specific and cancer diagnosis-specific instruments have been developed. There is at present little need for development of new cancer instruments, although specific treatment modalities and tumour types may need new additional modules. A predefined hypothesis should determine the instrument to be used. Since the selection of a QoL instrument in a specific study influences both the results and the conclusions, it is essential to carefully select the instrument or instruments that have the greatest likelihood of identifying relevant differences between treatment alternatives. Interpretation of QoL data is more difficult than interpretation of objective endpoints such as survival time, objective response rates or toxicity. Despite these difficulties, QoL analyses have provided new insights into the advantages and disadvantages of various treatments not provided by traditional end-points. Some palliative treatments seemingly increase patients' QoL despite side-effects or the lack of, or marginal, increases in survival. When using potentially curative chemotherapy, it is not a matter of when the treatment should be started, but rather when it should be concluded. When using less active chemotherapy, the expected small therapeutic gains must be weighed against the QoL costs of using the therapy: does the toxicity and/or the inconvenience of the proposed treatment justify the expected gain? When it is found that the strain on the patient is greater than the effects of the cancer, treatment must be discontinued. It is not possible to determine whether or not the advantages of palliative chemotherapy are worth their costs without knowledge about patients' personal values regarding the influence on factors of relevance for QoL. The mostly used QoL questionnaires do not consider individual preferences, which therefore need to be addressed in the dialogue with the patient. QoL assessment is clearly in need of further methodological improvement before this endpoint can be regarded as fully established with respect to ability to provide unequivocally useful data in clinical trials. The multitude of questionnaires, missing data, lack of pre-study hypotheses of relevant differences between treatments and data multiplicity giving a risk for chance findings are examples of serious methodological problems. Patient response-shifts over time further complicate the interpretation of the data. Thus, QoL data, also from seemingly well-performed clinical trials, have to be interpreted cautiously. The international development during recent years has aimed at creating increased standardization of QoL measures. This has created greater possibilities to compare results from different trials. Hopefully, this also implies that it will be possible to draw firmer conclusions from QoL measurements in recently completed or ongoing trials than has been the case previously. QoL assessments are resource demanding even when short standardized questionnaires are used. Since cancer patients also generally give priority to anticancer effects over toxicity and convenience, QoL assessments in clinical trials are motivated mainly in study settings comparing treatments without expected major differences of outcome in objective endpoints.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gunnars</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<Affiliation>Department of Oncology, University Hospital, Lund, Sweden.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Nygren</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Glimelius</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>SBU-group.  Swedish Council of Technology Assessment in Health Care</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Norway</Country>
<MedlineTA>Acta Oncol</MedlineTA>
<NlmUniqueID>8709065</NlmUniqueID>
<ISSNLinking>0284-186X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Endpoint Determination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Outcome Assessment (Health Care)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Patient Satisfaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>112</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11442735</PMID>
<DateCreated>
<Year>2001</Year>
<Month>07</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0303-6979</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>28</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2001</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical periodontology</Title>
<ISOAbbreviation>J. Clin. Periodontol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Utilisation of locally delivered doxycycline in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 treatment approaches.</ArticleTitle>
<Pagination>
<MedlinePgn>753-61</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">In the present 6-month multicentre trial, the outcome of 2 different approaches to non-surgical treatment of chronic periodontitis, both involving the use of a locally delivered controlled-release doxycycline, was evaluated.</AbstractText>
<AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">105 adult patients with moderately advanced chronic periodontitis from 3 centres participated in the trial. Each patient had to present with at least 8 periodontal sites in 2 jaw quadrants with a probing pocket depth (PPD) of &gt; or =5 mm and bleeding following pocket probing (BoP), out of which at least 2 sites had to be &gt; or =7 mm and a further 2 sites &gt; or =6 mm. Following a baseline examination, including assessments of plaque, PPD, clinical attachment level (CAL) and BoP, careful instruction in oral hygiene was given. The patients were then randomly assigned to one of two treatment groups: scaling/root planing (SRP) with local analgesia or debridement (supra- and subgingival ultrasonic instrumentation without analgesia). The "SRP" group received a single episode of full-mouth supra-/subgingival scaling and root planing under local analgesia. In addition, at a 3-month recall visit, a full-mouth supra-/subgingival debridement using ultrasonic instrumentation was provided. This was followed by subgingival application of an 8.5% w/w doxycycline polymer at sites with a remaining PPD of &gt; or =5 mm. The patients of the "debridement" group were initially subjected to a 45-minute full-mouth debridement with the use of an ultrasonic instrument and without administration of local analgesia, and followed by application of doxycycline in sites with a PPD of &gt; or =5 mm. At month 3, sites with a remaining PPD of &gt; or =5 mm were subjected to scaling and root planing. Clinical re-examinations were performed at 3 and 6 months.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">At 3 months, the proportion of sites showing PPD of &lt; or =4 mm was significantly higher in the "debridement" group than in the "SRP" group (58% versus 50%; p&lt;0.05). The CAL gain at 3 months amounted to 0.8 mm in the "debridement" group and 0.5 mm in the "SRP" group (p=0.064). The proportion of sites demonstrating a clinically significant CAL gain (&gt; or =2 mm) was higher in the "debridement" group than in the "SRP" group (38% versus 30%; p&lt;0.05). At the 6-month examination, no statistically significant differences in PPD or CAL were found between the two treatment groups. BoP was significantly lower for the "debridement" group than for the "SRP" group (p&lt;0.001) both at 3- and 6 months. The mean total treatment time (baseline and 3-month) for the "SRP" patients was 3:11 h, compared to 2:00 h for the patients in the "debridement" group (p&lt;0.001).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicate that simplified subgingival instrumentation combined with local application of doxycycline in deep periodontal sites can be considered as a justified approach for non-surgical treatment of chronic periodontitis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wennstrm</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
<Affiliation>Department of Periodontology, Institute of Odontology, Gteborg University, SE 405 30 Gteborg, Sweden. wennstrom@odontologi.gu.se</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Newman</LastName>
<ForeName>H N</ForeName>
<Initials>HN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacNeill</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Killoy</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Griffiths</LastName>
<ForeName>G S</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gillam</LastName>
<ForeName>D G</ForeName>
<Initials>DG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krok</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Needleman</LastName>
<ForeName>I G</ForeName>
<Initials>IG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weiss</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Garrett</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Multicenter Study</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Denmark</Country>
<MedlineTA>J Clin Periodontol</MedlineTA>
<NlmUniqueID>0425123</NlmUniqueID>
<ISSNLinking>0303-6979</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>564-25-0</RegistryNumber>
<NameOfSubstance>Doxycycline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>D</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Clinical Protocols</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Debridement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dental Scaling</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Doxycycline</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Compounding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gingival Hemorrhage</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Periodontal Pocket</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Periodontitis</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Root Planing</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Single-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11488864</PMID>
<DateCreated>
<Year>2001</Year>
<Month>08</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0905-7161</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2001</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Clinical oral implants research</Title>
<ISOAbbreviation>Clin Oral Implants Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Early endosseous integration enhanced by dual acid etching of titanium: a torque removal study in the rabbit.</ArticleTitle>
<Pagination>
<MedlinePgn>350-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Textured implant surfaces are thought to enhance endosseous integration. Torque removal forces have been used as a biomechanical measure of anchorage, or endosseous integration, in which the greater forces required to remove implants may be interpreted as an increase in the strength of bony integration. The purpose of this study was to compare the torque resistance to removal of screw-shaped titanium implants having a dual acid-etched surface (Osseotite) with implants having either a machined surface, or a titanium plasma spray surface that exhibited a significantly more complex surface topography. Three custom screw-shaped implant types - machined, dual acid-etched (DAE), and titanium plasma sprayed (TPS) - were used in this study. Each implant surface was characterized by scanning electron microscopy and optical profilometry. One DAE implant was placed into each distal femur of eighteen adult New Zealand White rabbits along with one of the other implant types. Thus, each rabbit received two DAE implants and one each of the machined, or TPS, implants. All implants measured 3.25 mm in diameter x 4.00 mm in length without holes, grooves or slots to resist rotation. Eighteen rabbits were used for reverse torque measurements. Groups of six rabbits were sacrificed following one, two and three month healing periods. Implants were removed by reverse torque rotation with a digital torque-measuring device. Three implants with the machined surface preparation failed to achieve endosseous integration. All other implants were anchored by bone. Mean torque values for machined, DAE and TPS implants at one, two and three months were 6.00+/-0.64 N-cm, 9.07+/-0.67 N-cm and 6.73+/-0.95 N-cm; 21.86+/-1.37 N-cm, 27.63+/-3.41 N-cm and 27.40+/-3.89 N-cm; and 27.48+/-1.61 N-cm, 44.28+/-4.53 N-cm and 59.23+/-3.88 N-cm, respectively. Clearly, at the earliest time point the stability of DAE implants was comparable to that of TPS implants, while that of the machined implants was an order of magnitude lower. The TPS implants increased resistance to reverse torque removal over the three-month period. The results of this study confirm our previous results that demonstrated enhanced bony anchorage to dual acid-etched implants as compared to machined implants. Furthermore, the present results indicate that dual acid etching of titanium enhances early endosseous integration to a level which is comparable to that achieved by the topographically more complex TPS surfaces.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Klokkevold</LastName>
<ForeName>P R</ForeName>
<Initials>PR</Initials>
<Affiliation>Division of Associated Specialties, Section of Periodontics, UCLA School of Dentistry, Los Angeles, CA 90095, USA. pklok@ucla.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dadgostari</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Caputo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Davies</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishimura</LastName>
<ForeName>R D</ForeName>
<Initials>RD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Denmark</Country>
<MedlineTA>Clin Oral Implants Res</MedlineTA>
<NlmUniqueID>9105713</NlmUniqueID>
<ISSNLinking>0905-7161</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Coated Materials, Biocompatible</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Dental Implants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Sulfuric Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-32-6</RegistryNumber>
<NameOfSubstance>Titanium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7647-01-0</RegistryNumber>
<NameOfSubstance>Hydrochloric Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>O40UQP6WCF</RegistryNumber>
<NameOfSubstance>sulfuric acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>D</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Coated Materials, Biocompatible</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dental Implantation, Endosseous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Dental Implants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dental Polishing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Dental Prosthesis Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Device Removal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Femur</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hydrochloric Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Implants, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Metallurgy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Osseointegration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rabbits</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sulfuric Acids</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surface Properties</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Titanium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Torque</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11488868</PMID>
<DateCreated>
<Year>2001</Year>
<Month>08</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0905-7161</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2001</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Clinical oral implants research</Title>
<ISOAbbreviation>Clin Oral Implants Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Histology of human alveolar bone regeneration with a porous tricalcium phosphate. A report of two cases.</ArticleTitle>
<Pagination>
<MedlinePgn>379-84</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Porous beta-phase tricalcium phosphate particles (pTCP) (Cerasorb) were used in two patients to restore or augment alveolar bone prior to the placement of dental implants. In one patient, pTCP was used to fill a large alveolar defect in the posterior mandible after the removal of a residual cyst, and in another patient to augment the sinus floor. Biopsies were taken at the time of implant placement, 9.5 and 8 months after grafting, respectively, and processed for hard tissue histology. Goldner-stained histological sections showed considerable replacement of the bone substitute by bone and bone marrow. In the 9.5 months biopsy of the mandible, 34% of the biopsy consisted of mineralised bone tissue and 29% of remaining pTCP, while the biopsy at 8 months after sinus floor augmentation consisted of 20% mineralised bone and 44% remaining pTCP. Bone and osteoid were lying in close contact with the remaining pTCP and were also seen within the micropores of the grafted particles. Tartrate resistant-acid phosphatase (TRAP) multinuclear cells, presumably osteoclasts, were found surrounding, within and in close contact with the pTCP particles, suggesting active resorption of the bone substitute. Remodelling of immature woven bone into mature lamellar bone was also found. No histological signs of inflammation were detected. The limited data presented from these two cases suggest that this graft material, possibly by virtue of its porosity and chemical nature, may be a suitable bone substitute that can biodegrade and be replaced by new mineralising bone tissue.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zerbo</LastName>
<ForeName>I R</ForeName>
<Initials>IR</Initials>
<Affiliation>Department of Oral Cell Biology, ACTA, Vrije Universiteit, Vander Boechorststraat 7, 1081 BT Amsterdam, Netherlands. IR.Zerbo.Ocb.ACTA@med.vu.nl</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bronckers</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Lange</LastName>
<ForeName>G L</ForeName>
<Initials>GL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>van Beek</LastName>
<ForeName>G J</ForeName>
<Initials>GJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Burger</LastName>
<ForeName>E H</ForeName>
<Initials>EH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Denmark</Country>
<MedlineTA>Clin Oral Implants Res</MedlineTA>
<NlmUniqueID>9105713</NlmUniqueID>
<ISSNLinking>0905-7161</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Bone Substitutes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Calcium Phosphates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>beta-tricalcium phosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K4C08XP666</RegistryNumber>
<NameOfSubstance>tricalcium phosphate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>D</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Absorbable Implants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Alveolar Ridge Augmentation</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone Regeneration</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone Substitutes</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium Phosphates</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mandible</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Maxillary Sinus</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Oral Surgical Procedures, Preprosthetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Porosity</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11520209</PMID>
<DateCreated>
<Year>2001</Year>
<Month>08</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>09</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-2623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>44</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2001</Year>
<Month>Aug</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Journal of medicinal chemistry</Title>
<ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.</ArticleTitle>
<Pagination>
<MedlinePgn>3001-13</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This paper describes the synthesis of a series of azo compounds able to deliver 5-aminosalicylic acid (5-ASA) and a potent platelet activating factor (PAF) antagonist in a colon-specific manner for the purpose of treating ulcerative colitis. We found it possible to add an amino group on the aromatic moiety of our reported 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives or on British Biotech compounds BB-882 and BB-823 maintaining a high level of activity as PAF antagonist. A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats. Through attachment of 49c to the 5-ASA via azo functionality we obtained UR-12746 (70). Pharmacokinetics experiments with [14C]-70 allow us to reach the following conclusions, critical in the design of these new prodrugs of 5-ASA. Neither the whole molecule 70 nor the carrier 49c were absorbed after oral administration of [14C]-70 in rat as was demonstrated by the absence of plasma levels of radioactivity and the high recovery of it in feces. Effective cleavage of azo bond (84%) by microflora in the colon is achieved. These facts ensure high topical concentrations of 5-ASA and 49c in the colon. Additionally, 70 exhibited a potent anticolitic effect in the trinitrobenzenesulfonic acid-induced colitis model in the rat. This profile suggests that UR-12746 (70) provides an attractive new approach to the treatment of ulcerative colitis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Carceller</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<Affiliation>Research Center, J. Uriach &amp; Ca.S.A., Deg Bah 59-67, 08026 Barcelona, Spain. chem-carceller@uriach.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Salas</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Merlos</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Giral</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferrando</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Escamilla</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ramis</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Garca-Rafanell</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Forn</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Med Chem</MedlineTA>
<NlmUniqueID>9716531</NlmUniqueID>
<ISSNLinking>0022-2623</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>1-((1-(3-(4-aminophenyl)-3-phenylpropenoyl)-4-piperidyl)methyl)-1H-2-methylimidazo(4,5-c)pyridine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Amines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Aminosalicylic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Aza Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Azo Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Platelet Activating Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Prodrugs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>UR 12746</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2508-19-2</RegistryNumber>
<NameOfSubstance>Trinitrobenzenesulfonic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>89-57-6</RegistryNumber>
<NameOfSubstance>Mesalamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amines</DescriptorName>
<QualifierName MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aminosalicylic Acids</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aza Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Azo Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
<QualifierName MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hypotension</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mesalamine</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Platelet Activating Factor</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Platelet Aggregation</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prodrugs</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stereoisomerism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Trinitrobenzenesulfonic Acid</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11525160</PMID>
<DateCreated>
<Year>2001</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>08</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0250-5525</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>124</Volume>
<PubDate>
<Year>2000</Year>
</PubDate>
</JournalIssue>
<Title>Schweizerische medizinische Wochenschrift. Supplementum</Title>
<ISOAbbreviation>Schweiz Med Wochenschr Suppl</ISOAbbreviation>
</Journal>
<ArticleTitle>32nd Annual meeting of the Swiss Society of Nephrology. Lausanne, 14-15 December 2000. Abstracts.</ArticleTitle>
<Pagination>
<MedlinePgn>1S-20S</MedlinePgn>
</Pagination>
<Language>eng</Language>
<Language>fre</Language>
<Language>ger</Language>
<PublicationTypeList>
<PublicationType>Congresses</PublicationType>
<PublicationType>Overall</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Schweiz Med Wochenschr Suppl</MedlineTA>
<NlmUniqueID>7708316</NlmUniqueID>
<ISSNLinking>0250-5525</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Kidney Diseases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nephrology</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11524736</PMID>
<DateCreated>
<Year>2001</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>12</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1098-1004</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>18</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2001</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Human mutation</Title>
<ISOAbbreviation>Hum. Mutat.</ISOAbbreviation>
</Journal>
<ArticleTitle>Detection of six novel FBN1 mutations in British patients affected by Marfan syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>251</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular matrix, is due to mutations in fibrillin-1 (FBN1) gene. Investigations carried out in the last decade, unveiled the unpredictability of the site of the mutation, which could be anywhere in the gene. FBN1 mutations have been reported in a spectrum of diseases related to MFS, with no clear evidence for a phenotype-genotype correlation. In this paper we analysed 10 British patients affected by MFS and we were able to characterise five novel missense mutations (C474W, C1402Y, G1987R, C2153Y, G2536R), one novel frameshift mutation (7926delC), one already described mutation (P1424A) and one FBN1 variant (P1148A) classified as a polymorphism in the Asian population. Four out of the five novel missense mutations involved either cysteines or an amino acid conserved in the domain structure. The mutation yield in this study is calculated at 80.0% (8/10), thus indicating that SSCA is a reliable and cost-effective technique for the screening of such a large gene. Our results suggest that this method is reliable to search for FBN1 mutations and that FBN1 screening could be a helpful tool to confirm and possibly anticipate the clinical diagnosis in familial cases. Hum Mutat 18:251, 2001.</AbstractText>
<CopyrightInformation>Copyright 2001 Wiley-Liss, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Comeglio</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<Affiliation>Department of Cardiological Sciences, St. George's Hospital Medical School, London, UK. p.comeglio@sghms.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brice</LastName>
<ForeName>G W</ForeName>
<Initials>GW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Child</LastName>
<ForeName>A H</ForeName>
<Initials>AH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Mutat</MedlineTA>
<NlmUniqueID>9215429</NlmUniqueID>
<ISSNLinking>1059-7794</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Microfilament Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>fibrillin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="RepublishedIn">
<RefSource>Hum Mutat. 2001 Dec;18(6):546-7</RefSource>
<PMID Version="1">11748851</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Frameshift Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Marfan Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Microfilament Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Deletion</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11543891</PMID>
<DateCreated>
<Year>2001</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>09</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0198-8859</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>62</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2001</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Human immunology</Title>
<ISOAbbreviation>Hum. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The origin of Palestinians and their genetic relatedness with other Mediterranean populations.</ArticleTitle>
<Pagination>
<MedlinePgn>889-900</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The genetic profile of Palestinians has, for the first time, been studied by using human leukocyte antigen (HLA) gene variability and haplotypes. The comparison with other Mediterranean populations by using neighbor-joining dendrograms and correspondence analyses reveal that Palestinians are genetically very close to Jews and other Middle East populations, including Turks (Anatolians), Lebanese, Egyptians, Armenians, and Iranians. Archaeologic and genetic data support that both Jews and Palestinians came from the ancient Canaanites, who extensively mixed with Egyptians, Mesopotamian, and Anatolian peoples in ancient times. Thus, Palestinian-Jewish rivalry is based in cultural and religious, but not in genetic, differences. The relatively close relatedness of both Jews and Palestinians to western Mediterranean populations reflects the continuous circum-Mediterranean cultural and gene flow that have occurred in prehistoric and historic times. This flow overtly contradicts the demic diffusion model of western Mediterranean populations substitution by agriculturalists coming from the Middle East in the Mesolithic-Neolithic transition.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Arnaiz-Villena</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Immunology and Molecular Biology, H. 12 de Octubre, Universidad Complutense, Madrid, Spain. aarnaiz@eucmax.sim.ucm.es</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Elaiwa</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Silvera</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rostom</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moscoso</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gmez-Casado</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Allende</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Varela</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martnez-Laso</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Retracted Publication</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Immunol</MedlineTA>
<NlmUniqueID>8010936</NlmUniqueID>
<ISSNLinking>0198-8859</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-A Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-B Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-DQ Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-DQ beta-Chains</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-DQB1 antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-DR Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA-DRB1 Chains</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Hum Immunol. 2001 Oct;62(10):1064</RefSource>
<PMID Version="1">11600211</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="RetractionIn">
<RefSource>Suciu-Foca N, Lewis R. Hum Immunol. 2001 Oct;62(10):1063</RefSource>
<PMID Version="1">11600210</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Alleles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Arabs</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Frequency</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Greece</DescriptorName>
<QualifierName MajorTopicYN="N">ethnology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA Antigens</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA-A Antigens</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA-B Antigens</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA-DQ Antigens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA-DQ beta-Chains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA-DR Antigens</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Haplotypes</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Islam</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Israel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Jews</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Linkage Disequilibrium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Mediterranean Region</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Middle East</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phylogeny</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11562649</PMID>
<DateCreated>
<Year>2001</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>02</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0891-5245</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2001 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates &amp; Practitioners</Title>
<ISOAbbreviation>J Pediatr Health Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Educating parents about normal stool pattern changes in infants.</ArticleTitle>
<Pagination>
<MedlinePgn>269-74</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Arias</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Affiliation>Pediatric Nurse Practitioner Program at Ohio State University College of Nursing, Columbus, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bennison</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Justus</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thurman</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pediatr Health Care</MedlineTA>
<NlmUniqueID>8709735</NlmUniqueID>
<ISSNLinking>0891-5245</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="SummaryForPatientsIn">
<RefSource>J Pediatr Health Care. 2001 Sep-Oct;15(5):270-1</RefSource>
<PMID Version="1">11858131</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Consumer Satisfaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Defecation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Feces</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Education</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Ohio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Parenting</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>13</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">11567133</PMID>
<DateCreated>
<Year>2001</Year>
<Month>09</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>03</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0036-8075</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>293</Volume>
<Issue>5538</Issue>
<PubDate>
<Year>2001</Year>
<Month>Sep</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Changes in seismic anisotropy after volcanic eruptions: evidence from Mount Ruapehu.</ArticleTitle>
<Pagination>
<MedlinePgn>2231-3</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The eruptions of andesite volcanoes are explosively catastrophic and notoriously difficult to predict. Yet changes in shear waveforms observed after an eruption of Mount Ruapehu, New Zealand, suggest that forces generated by such volcanoes are powerful and dynamic enough to locally overprint the regional stress regime, which suggests a new method of monitoring volcanoes for future eruptions. These results show a change in shear-wave polarization with time and are interpreted as being due to a localized stress regime caused by the volcano, with a release in pressure after the eruption.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<Affiliation>Institute of Geophysics, Victoria University of Wellington, Wellington, New Zealand.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Savage</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11473127</PMID>
<DateCreated>
<Year>2001</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0021-9258</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>276</Volume>
<Issue>39</Issue>
<PubDate>
<Year>2001</Year>
<Month>Sep</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evidence that ligand and metal ion binding to integrin alpha 4beta 1 are regulated through a coupled equilibrium.</ArticleTitle>
<Pagination>
<MedlinePgn>36520-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>We have used the highly selective alpha(4)beta(1) inhibitor 2S-[(1-benzenesulfonyl-pyrrolidine-2S-carbonyl)-amino]-4-[4-methyl-2S-(methyl-[2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl]-amino)-pentanoylamino]-butyric acid (BIO7662) as a model ligand to study alpha(4)beta(1) integrin-ligand interactions on Jurkat cells. Binding of [(35)S]BIO7662 to Jurkat cells was dependent on the presence of divalent cations and could be blocked by treatment with an excess of unlabeled inhibitor or with EDTA. K(D) values for the binding of BIO7662 to Mn(2+)-activated alpha(4)beta(1) and to the nonactivated state of the integrin that exists in 1 mm Mg(2+), 1 mm Ca(2+) were &lt;10 pm, indicating that it has a high affinity for both activated and nonactivated integrin. No binding was observed on alpha(4)beta(1) negative cells. Through an analysis of the metal ion dependences of ligand binding, several unexpected findings about alpha(4)beta(1) function were made. First, we observed that Ca(2+) binding to alpha(4)beta(1) was stimulated by the addition of BIO7662. From solution binding studies on purified alpha(4)beta(1), two types of Ca(2+)-binding sites were identified, one dependent upon and the other independent of BIO7662 binding. Second, we observed that the metal ion dependence of ligand binding was affected by the affinity of the ligand for alpha(4)beta(1). ED(50) values for the metal ion dependence of the binding of BIO7762 and the binding of a lower affinity ligand, BIO1211, differed by 2-fold for Mn(2+), 30-fold for Mg(2+), and &gt;1000-fold for Ca(2+). Low Ca(2+) (ED(50) = 5-10 microm) stimulated the binding of BIO7662 to alpha(4)beta(1). The effects of microm Ca(2+) closely resembled the effects of Mn(2+) on alpha(4)beta(1) function. Third, we observed that the rate of BIO7662 binding was dependent on the metal ion concentration and that the ED(50) for the metal ion dependence of BIO7662 binding was affected by the concentration of the BIO7662. These studies point to an even more complex interplay between metal ion and ligand binding than previously appreciated and provide evidence for a three-component coupled equilibrium model for metal ion-dependent binding of ligands to alpha(4)beta(1).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>L L</ForeName>
<Initials>LL</Initials>
<Affiliation>Biogen, Inc., Cambridge, Massachusetts 02142, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Whitty</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scott</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>W C</ForeName>
<Initials>WC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cornebise</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adams</LastName>
<ForeName>S P</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Petter</LastName>
<ForeName>R C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lobb</LastName>
<ForeName>R R</ForeName>
<Initials>RR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pepinsky</LastName>
<ForeName>R B</ForeName>
<Initials>RB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2001</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>2-((1-benzenesulfonylpyrrolidine-2-carbonyl)amino)-4-(4-methyl-2-(methyl-(2-(4-(3-o-tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Benzoates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cations</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Dipeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Integrin alpha4beta1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Integrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Ions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Lymphocyte Homing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>60-00-4</RegistryNumber>
<NameOfSubstance>Edetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7439-95-4</RegistryNumber>
<NameOfSubstance>Magnesium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7439-96-5</RegistryNumber>
<NameOfSubstance>Manganese</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Benzoates</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dipeptides</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Edetic Acid</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Integrin alpha4beta1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Integrins</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Jurkat Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Magnesium</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Manganese</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Chemical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Lymphocyte Homing</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">11583040</PMID>
<DateCreated>
<Year>2001</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0084-6597</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>28</Volume>
<PubDate>
<Year>2000</Year>
</PubDate>
</JournalIssue>
<Title>Annual review of earth and planetary sciences</Title>
<ISOAbbreviation>Annu Rev Earth Planet Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Understanding oblique impacts from experiments, observations, and modeling.</ArticleTitle>
<Pagination>
<MedlinePgn>141-67</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Natural impacts in which the projectile strikes the target vertically are virtually nonexistent. Nevertheless, our inherent drive to simplify nature often causes us to suppose most impacts are nearly vertical. Recent theoretical, observational, and experimental work is improving this situation, but even with the current wealth of studies on impact cratering, the effect of impact angle on the final crater is not well understood. Although craters' rims may appear circular down to low impact angles, the distribution of ejecta around the crater is more sensitive to the angle of impact and currently serves as the best guide to obliquity of impacts. Experimental studies established that crater dimensions depend only on the vertical component of the impact velocity. The shock wave generated by the impact weakens with decreasing impact angle. As a result, melting and vaporization depend on impact angle; however, these processes do not seem to depend on the vertical component of the velocity alone. Finally, obliquity influences the fate of the projectile: in particular, the amount and velocity of ricochet are a strong function of impact angle.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pierazzo</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<Affiliation>Lunar and Planetary Lab., University of Arizona, Tucson, 84721, USA. betty@lpl.arizona.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Melosh</LastName>
<ForeName>H J</ForeName>
<Initials>HJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Annu Rev Earth Planet Sci</MedlineTA>
<NlmUniqueID>100971465</NlmUniqueID>
<ISSNLinking>0084-6597</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Computer Simulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Evolution, Planetary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gravitation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Meteoroids</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Models, Theoretical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Moon</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Planets</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>96</NumberOfReferences>
<OtherID Source="NASA">00026602</OtherID>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Discipline Exobiology</Keyword>
<Keyword MajorTopicYN="N">Non-NASA Center</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Melosh</LastName>
<ForeName>H J</ForeName>
<Initials>HJ</Initials>
<Affiliation>U AZ, Tucson</Affiliation>
</Investigator>
</InvestigatorList>
<GeneralNote Owner="NASA">Grant numbers: NAGW-5159, NAGW-428.</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11580607</PMID>
<DateCreated>
<Year>2001</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0031-9007</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>87</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2001</Year>
<Month>Sep</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>Physical review letters</Title>
<ISOAbbreviation>Phys. Rev. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Maximal height scaling of kinetically growing surfaces.</ArticleTitle>
<Pagination>
<MedlinePgn>136101</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The scaling properties of the maximal height of a growing self-affine surface with a lateral extent L are considered. In the late-time regime its value measured relative to the evolving average height scales like the roughness: h*(L) approximately L alpha. For large values its distribution obeys logP(h*(L)) approximately (-)A(h*(L)/L(alpha))(a). In the early-time regime where the roughness grows as t(beta), we find h*(L) approximately t(beta)[lnL-(beta/alpha)lnt+C](1/b), where either b = a or b is the corresponding exponent of the velocity distribution. These properties are derived from scaling and extreme-value arguments. They are corroborated by numerical simulations and supported by exact results for surfaces in 1D with the asymptotic behavior of a Brownian path.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Raychaudhuri</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cranston</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Przybyla</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shapir</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2001</Year>
<Month>09</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Phys Rev Lett</MedlineTA>
<NlmUniqueID>0401141</NlmUniqueID>
<ISSNLinking>0031-9007</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacteria</DescriptorName>
<QualifierName MajorTopicYN="N">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Crystallization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Models, Theoretical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surface Properties</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11600210</PMID>
<DateCreated>
<Year>2001</Year>
<Month>10</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>25</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0198-8859</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>62</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2001</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Human immunology</Title>
<ISOAbbreviation>Hum. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Editorial. Anthropology and genetic markers.</ArticleTitle>
<Pagination>
<MedlinePgn>1063</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Suciu-Foca</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lewis</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Retraction of Publication</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Immunol</MedlineTA>
<NlmUniqueID>8010936</NlmUniqueID>
<ISSNLinking>0198-8859</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="RetractionOf">
<RefSource>Arnaiz-Villena A, Elaiwa N, Silvera C, Rostom A, Moscoso J, Gmez-Casado E, Allende L, Varela P, Martnez-Laso J. Hum Immunol. 2001 Sep;62(9):889-900</RefSource>
<PMID Version="1">11543891</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11600211</PMID>
<DateCreated>
<Year>2001</Year>
<Month>10</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>10</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0198-8859</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>62</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2001</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Human immunology</Title>
<ISOAbbreviation>Hum. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Letter from the ASHI president and council.</ArticleTitle>
<Pagination>
<MedlinePgn>1064</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tyan</LastName>
<ForeName>D B</ForeName>
<Initials>DB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Immunol</MedlineTA>
<NlmUniqueID>8010936</NlmUniqueID>
<ISSNLinking>0198-8859</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Hum Immunol. 2001 Sep;62(9):889-900</RefSource>
<PMID Version="1">11543891</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ethics, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Histocompatibility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Immunogenetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Publishing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Societies, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">11686176</PMID>
<DateCreated>
<Year>1982</Year>
<Month>01</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1982</Year>
<Month>01</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0094-6133</ISSN>
<JournalIssue CitedMedium="Print">
<PubDate>
<MedlineDate>1979 Jan-Feb</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Malpractice digest</Title>
<ISOAbbreviation>Malpract Dig</ISOAbbreviation>
</Journal>
<ArticleTitle>How physicians may minimize their chances of becoming involved in an informed consent claim.</ArticleTitle>
<Pagination>
<MedlinePgn>1-2</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bower</LastName>
<ForeName>John J</ForeName>
<Initials>JJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Malpract Dig</MedlineTA>
<NlmUniqueID>9879884</NlmUniqueID>
<ISSNLinking>0094-6133</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Consent Forms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Informed Consent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Jurisprudence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Malpractice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Records as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">12517</OtherID>
<GeneralNote Owner="KIE">KIE BoB Subject Heading: INFORMED CONSENT</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">11686167</PMID>
<DateCreated>
<Year>1990</Year>
<Month>10</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>1990</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">8756-2057</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>25-26</Volume>
<PubDate>
<MedlineDate>1990 Jan-Apr</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Reporter on human reproduction and the law</Title>
<ISOAbbreviation>Report Hum Reprod Law</ISOAbbreviation>
</Journal>
<ArticleTitle>The dilemma of the Webster decision: deconstitutionalizing the trimester system.</ArticleTitle>
<Pagination>
<MedlinePgn>276-92</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kindregan</LastName>
<ForeName>Charles P</ForeName>
<Initials>CP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Report Hum Reprod Law</MedlineTA>
<NlmUniqueID>100971950</NlmUniqueID>
<ISSNLinking>8756-2057</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Abortion, Eugenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Abortion, Induced</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Abortion, Therapeutic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Beginning of Human Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Civil Rights</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Embryonic and Fetal Development</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fetal Viability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fetus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Government Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Internationality</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Jurisprudence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Legislation as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pregnant Women</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Privacy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Religion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Social Control, Formal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">State Government</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Supreme Court Decisions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">31521</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Abortion Act 1967 (Great Britain)</Keyword>
<Keyword MajorTopicYN="N">Genetics and Reproduction</Keyword>
<Keyword MajorTopicYN="N">Legal Approach</Keyword>
<Keyword MajorTopicYN="Y">Roe v. Wade</Keyword>
<Keyword MajorTopicYN="Y">Webster v. Reproductive Health Services</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">63 fn.</GeneralNote>
<GeneralNote Owner="KIE">KIE BoB Subject Heading: abortion/legal aspects</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11694165</PMID>
<DateCreated>
<Year>2001</Year>
<Month>11</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>12</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0098-7484</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>286</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2001</Year>
<Month>Nov</Month>
<Day>7</Day>
</PubDate>
</JournalIssue>
<Title>JAMA : the journal of the American Medical Association</Title>
<ISOAbbreviation>JAMA</ISOAbbreviation>
</Journal>
<ArticleTitle>msJAMA: Breast reconstruction: one woman's choice.</ArticleTitle>
<Pagination>
<MedlinePgn>2163</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bily</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>JAMA</MedlineTA>
<NlmUniqueID>7501160</NlmUniqueID>
<ISSNLinking>0098-7484</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Body Image</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mammaplasty</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mastectomy</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11704686</PMID>
<DateCreated>
<Year>2001</Year>
<Month>11</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>12</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0028-4793</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>345</Volume>
<Issue>22</Issue>
<PubDate>
<Year>2001</Year>
<Month>Nov</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Recognition and management of anthrax--an update.</ArticleTitle>
<Pagination>
<MedlinePgn>1621-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Swartz</LastName>
<ForeName>M N</ForeName>
<Initials>MN</Initials>
<Affiliation>Department of Medicine, Massachusetts General Hospital, Boston 02114-2696, USA.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2001</Year>
<Month>11</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anthrax Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Penicillins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2002 Mar 21;346(12):943-5; discusson 943-5</RefSource>
<PMID Version="1">11911137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2002 Mar 21;346(12):943-5; author reply 943-5</RefSource>
<PMID Version="1">11907299</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2002 Mar 21;346(12):943-5; author reply 943-5</RefSource>
<PMID Version="1">11911138</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2002 Mar 21;346(12):943-5; author reply 943-5</RefSource>
<PMID Version="1">11911136</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="ErratumIn">
<RefSource>N Engl J Med 2002 Feb 21;346(8):634</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Anthrax</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anthrax Vaccines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacillus anthracis</DescriptorName>
<QualifierName MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bioterrorism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infection Control</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Meningitis, Bacterial</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Penicillins</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Respiratory Tract Infections</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Skin Diseases, Bacterial</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spores, Bacterial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Virulence</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>11</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11731716</PMID>
<DateCreated>
<Year>2001</Year>
<Month>12</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>02</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-7012</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>64</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2002</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Pharmacology</Title>
<ISOAbbreviation>Pharmacology</ISOAbbreviation>
</Journal>
<ArticleTitle>Progress in the search for ideal drugs.</ArticleTitle>
<Pagination>
<MedlinePgn>1-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The search for ideal drugs to improve patient care requires applications of modern scientific methods to both discovery and development. Using these modern methods, the pharmaceutical industry with strong academic and government collaboration has introduced in the last 25 years many new drugs that approach the ideal. After reviewing Bjrnsson's classification of drug action and the notion of contributory causality, this commentary defines an ideal drug from the perspectives of pharmacodynamics, pharmacokinetics, and therapeutics. Examples of new drugs for hypertension, heart disease, stroke, osteoporosis, asthma, ulcer, and migraine headaches are described. Finally, the profound implications of progress in developing ideal drugs not only for the patient but also for the academic, educational, and regulatory establishments are briefly reviewed.</AbstractText>
<CopyrightInformation>Copyright 2002 S. Karger AG, Basel</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Spector</LastName>
<ForeName>Reynold</ForeName>
<Initials>R</Initials>
<Affiliation>Department of Medicine, Robert Wood Johnson Medical School, Piscataway, NJ, USA.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Pharmacology</MedlineTA>
<NlmUniqueID>0152016</NlmUniqueID>
<ISSNLinking>0031-7012</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Pharmaceutical Preparations</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Industry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName>
<QualifierName MajorTopicYN="Y">classification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Pharmacokinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Pharmacology</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>25</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11748851</PMID>
<DateCreated>
<Year>2001</Year>
<Month>12</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1098-1004</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>18</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2001</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Human mutation</Title>
<ISOAbbreviation>Hum. Mutat.</ISOAbbreviation>
</Journal>
<ArticleTitle>Erratum: Detection of six novel FBN1 mutations in British patients affected by Marfan syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>546-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular matrix, is due to mutations in fibrillin-1 (FBN1) gene. Investigations carried out in the last decade, unveiled the unpredictability of the site of the mutation, which could be anywhere in the gene. FBN1 mutations have been reported in a spectrum of diseases related to MFS, with no clear evidence for a phenotype-genotype correlation. In this paper we analysed 10 British patients affected by MFS and we were able to characterise five novel missense mutations (C474W, C1402Y, G1987R, C2153Y, G2536R), one novel frameshift mutation (7926delC), one already described mutation (P1424A) and one FBN1 variant (P1148A) classified as a polymorphism in the Asian population. Four out of the five novel missense mutations involved either cysteines or an amino acid conserved in the domain structure. The mutation yield in this study is calculated at 80.0% (8/10), thus indicating that SSCA is a reliable and cost-effective technique for the screening of such a large gene. Our results suggest that this method is reliable to search for FBN1 mutations and that FBN1 screening could be a helpful tool to confirm and possibly anticipate the clinical diagnosis in familial cases.</AbstractText>
<CopyrightInformation>Copyright 2001 Wiley-Liss, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Comeglio</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<Affiliation>Department of Cardiological Sciences, St. George's Hospital Medical School, London, UK. p.comeglio@sghms.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brice</LastName>
<ForeName>G W</ForeName>
<Initials>GW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Child</LastName>
<ForeName>A H</ForeName>
<Initials>AH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Corrected and Republished Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Mutat</MedlineTA>
<NlmUniqueID>9215429</NlmUniqueID>
<ISSNLinking>1059-7794</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Microfilament Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>fibrillin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance>DNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="RepublishedFrom">
<RefSource>Hum Mutat. 2001 Sep;18(3):251</RefSource>
<PMID Version="1">11524736</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Frameshift Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Marfan Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Microfilament Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Polymorphism, Single-Stranded Conformational</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11748856</PMID>
<DateCreated>
<Year>2001</Year>
<Month>12</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1098-1004</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>18</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2001</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Human mutation</Title>
<ISOAbbreviation>Hum. Mutat.</ISOAbbreviation>
</Journal>
<ArticleTitle>Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer families from Spain.</ArticleTitle>
<Pagination>
<MedlinePgn>549</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Germline mutations in the MLH1 and MSH2 genes, account for the majority of HNPCC families. We have screened such families from Spain by using DGGE analysis and subsequent direct sequencing techniques. In eight families we identified six novel MLH1 and two novel MSH2 mutations comprising one frame shift mutation (c.1420 del C), two missense mutations (L622H and R687W), two splice site mutations (c.1990-1 G&gt;A and c.453+2 T&gt;C and one nonsense mutation (K329X) in the MLH1 gene as well as two frame shift mutations (c.1979-1980 del AT and c.1704-1705 del AG) in the MSH2 gene. Our analysis contributes to the further characterization of the mutational spectrum of MLH1 and MSH2 genes in HNPCC families.</AbstractText>
<CopyrightInformation>Copyright 2001 Wiley-Liss, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Godino</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<Affiliation>Laboratory of Molecular Oncology, San Carlos University Hospital, 28040 Madrid, Spain.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>de La Hoya</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Diaz-Rubio</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benito</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Calds</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>OMIM</DataBankName>
<AccessionNumberList>
<AccessionNumber>114500</AccessionNumber>
<AccessionNumber>120435</AccessionNumber>
<AccessionNumber>120436</AccessionNumber>
<AccessionNumber>600258</AccessionNumber>
<AccessionNumber>600259</AccessionNumber>
<AccessionNumber>600678</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Mutat</MedlineTA>
<NlmUniqueID>9215429</NlmUniqueID>
<ISSNLinking>1059-7794</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>MLH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance>DNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.3</RegistryNumber>
<NameOfSubstance>MSH2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.3</RegistryNumber>
<NameOfSubstance>MutS Homolog 2 Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Carrier Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Colorectal Neoplasms, Hereditary Nonpolyposis</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Family Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Germ-Line Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">MutS Homolog 2 Protein</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nuclear Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11885531</PMID>
<DateCreated>
<Year>2002</Year>
<Month>02</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>04</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0028-2200</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>99</Volume>
<Issue>7</Issue>
<PubDate>
<Year>1992</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Nederlands tijdschrift voor tandheelkunde</Title>
<ISOAbbreviation>Ned Tijdschr Tandheelkd</ISOAbbreviation>
</Journal>
<ArticleTitle>[Microbiological diagnostics in periodontal treatment].</ArticleTitle>
<Pagination>
<MedlinePgn>245-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Periodontal diseases are bacterial infections. The rationale for the use of microbiological diagnostics in periodontal treatment of severe periodontitis patients is discussed as well as the use of adjunct antimicrobial therapy for the elimination of specific bacterial species.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>de Graaff</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<Affiliation>Uit de vakgroep Orale Microbiologie van het Academisch Centrum Tandheelkunde Amsterdam (ACTA).</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>van Winkelhoff</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>dut</Language>
<PublicationTypeList>
<PublicationType>English Abstract</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Microbiologische diagnostiek in de paradontologie.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Ned Tijdschr Tandheelkd</MedlineTA>
<NlmUniqueID>0400771</NlmUniqueID>
<ISSNLinking>0028-2200</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>D</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Actinomycetales Infections</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hygiene</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Periodontal Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Periodontitis</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>6</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="PIP" Status="MEDLINE">
<PMID Version="1">12179763</PMID>
<DateCreated>
<Year>1991</Year>
<Month>12</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>1991</Year>
<Month>12</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2003</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1226-0282</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>10</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1990</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Pogn sahoe nonjip = Journal of population, health, and social welfare</Title>
<ISOAbbreviation>Bogeon sahoe nonjib</ISOAbbreviation>
</Journal>
<ArticleTitle>Recent changes in the population control policy and its future directions in Korea.</ArticleTitle>
<Pagination>
<MedlinePgn>152-73</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>N H</ForeName>
<Initials>NH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seo</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>B A</ForeName>
<Initials>BA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>KOREA, REPUBLIC OF</Country>
<MedlineTA>Bogeon sahoe nonjib</MedlineTA>
<NlmUniqueID>9422396</NlmUniqueID>
<ISSNLinking>1226-0282</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>J</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Asia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Birth Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Conservation of Natural Resources</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Contraception</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Delivery of Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Demography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Dependency (Psychology)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Developing Countries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Economics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Employment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Environment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Family Planning Services</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Far East</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fertility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Manpower</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Health Planning</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Services</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Korea</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Maternal-Child Health Centers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Organization and Administration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Population</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Population Characteristics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Population Density</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Population Dynamics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Population Growth</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Primary Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Public Policy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Public Sector</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Social Welfare</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Socioeconomic Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Sterilization, Reproductive</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="PIP">067656</OtherID>
<OtherID Source="POP">00204408</OtherID>
<OtherAbstract Type="PIP" Language="eng">
<AbstractText>The total fertility rate (TFR) in Korea decreased from 6.0 to 1.6 over the period 1960-87.  A national family planning program and socioeconomic development have played roles in this decline.  Should this most recent TFR prevail, the nation's population will increase to 50.2 million by 2020, shifting to negative growth thereafter.  Demographic aging and labor shortages will ensue.  Future population policy should consider Korea's socioeconomic conditions and its burgeoning population in relation to the available land area, and aim to maintain a minimum positive population growth rate.  In this context, this paper considers future population policy directions for Korea, acknowledging that its strategies and objectives must change.  Postponing reaching the goal of zero population growth rate is suggested to allow a moderate population infusion of economically active individuals.  These people will help facilitate greater economic development and work to improve the quality of life in Korea.  Strengthened family planning/maternal-child health programs which encourage and support temporary contraceptive methods instead of sterilization will help to achieve this goal.  Improving qualitative program aspects should be the center of attention in these programs.  The paper also calls upon the Korea Institute for Health and Social Affairs to strengthen its research and evaluation capabilities.</AbstractText>
</OtherAbstract>
<KeywordList Owner="PIP">
<Keyword MajorTopicYN="N">Adult</Keyword>
<Keyword MajorTopicYN="N">Age Factors</Keyword>
<Keyword MajorTopicYN="Y">Aged</Keyword>
<Keyword MajorTopicYN="N">Asia</Keyword>
<Keyword MajorTopicYN="N">Birth Rate</Keyword>
<Keyword MajorTopicYN="N">Carrying Capacity</Keyword>
<Keyword MajorTopicYN="N">Contraception</Keyword>
<Keyword MajorTopicYN="Y">Contraceptive Methods</Keyword>
<Keyword MajorTopicYN="N">Delivery Of Health Care</Keyword>
<Keyword MajorTopicYN="Y">Demographic Aging</Keyword>
<Keyword MajorTopicYN="N">Demographic Factors</Keyword>
<Keyword MajorTopicYN="Y">Demographic Transition</Keyword>
<Keyword MajorTopicYN="Y">Dependency Burden</Keyword>
<Keyword MajorTopicYN="N">Developing Countries</Keyword>
<Keyword MajorTopicYN="N">Eastern Asia</Keyword>
<Keyword MajorTopicYN="Y">Economic Development</Keyword>
<Keyword MajorTopicYN="N">Economic Factors</Keyword>
<Keyword MajorTopicYN="N">Environment</Keyword>
<Keyword MajorTopicYN="N">Family Planning</Keyword>
<Keyword MajorTopicYN="Y">Family Planning Programs</Keyword>
<Keyword MajorTopicYN="N">Fertility</Keyword>
<Keyword MajorTopicYN="N">Fertility Measurements</Keyword>
<Keyword MajorTopicYN="N">Fertility Rate</Keyword>
<Keyword MajorTopicYN="N">Health</Keyword>
<Keyword MajorTopicYN="N">Health Services</Keyword>
<Keyword MajorTopicYN="N">Human Resources</Keyword>
<Keyword MajorTopicYN="N">Korea</Keyword>
<Keyword MajorTopicYN="Y">Labor Force</Keyword>
<Keyword MajorTopicYN="N">Macroeconomic Factors</Keyword>
<Keyword MajorTopicYN="Y">Maternal-child Health Services</Keyword>
<Keyword MajorTopicYN="N">Microeconomic Factors</Keyword>
<Keyword MajorTopicYN="N">Natural Resources</Keyword>
<Keyword MajorTopicYN="N">Organization And Administration</Keyword>
<Keyword MajorTopicYN="N">Policy</Keyword>
<Keyword MajorTopicYN="N">Population</Keyword>
<Keyword MajorTopicYN="N">Population Characteristics</Keyword>
<Keyword MajorTopicYN="Y">Population Decrease</Keyword>
<Keyword MajorTopicYN="N">Population Dynamics</Keyword>
<Keyword MajorTopicYN="Y">Population Growth</Keyword>
<Keyword MajorTopicYN="Y">Population Policy</Keyword>
<Keyword MajorTopicYN="Y">Population Pressure</Keyword>
<Keyword MajorTopicYN="N">Population Size</Keyword>
<Keyword MajorTopicYN="N">Primary Health Care</Keyword>
<Keyword MajorTopicYN="Y">Program Evaluation</Keyword>
<Keyword MajorTopicYN="N">Programs</Keyword>
<Keyword MajorTopicYN="Y">Public Sector</Keyword>
<Keyword MajorTopicYN="Y">Research Methodology</Keyword>
<Keyword MajorTopicYN="N">Social Policy</Keyword>
<Keyword MajorTopicYN="Y">Social Welfare</Keyword>
<Keyword MajorTopicYN="Y">Socioeconomic Factors</Keyword>
<Keyword MajorTopicYN="Y">Sterilization, Sexual</Keyword>
<Keyword MajorTopicYN="Y">Total Fertility Rate--changes</Keyword>
<Keyword MajorTopicYN="Y">Zero Population Growth</Keyword>
</KeywordList>
<GeneralNote Owner="PIP">TJ: JOURNAL OF POPULATION, HEALTH AND SOCIAL WELFARE</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="PIP" Status="MEDLINE">
<PMID Version="1">12349809</PMID>
<DateCreated>
<Year>2000</Year>
<Month>12</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>12</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0251-7329</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>37</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2000</Year>
</PubDate>
</JournalIssue>
<Title>UN chronicle</Title>
<ISOAbbreviation>UN Chron</ISOAbbreviation>
</Journal>
<ArticleTitle>Gender and globalization. A century in retrospect.</ArticleTitle>
<Pagination>
<MedlinePgn>69-70</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chinkin</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>UN Chron</MedlineTA>
<NlmUniqueID>8305532</NlmUniqueID>
<ISSNLinking>0251-7329</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>J</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Economics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Evaluation Studies as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Interpersonal Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Social Change</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Socioeconomic Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Women's Rights</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="PIP">152034</OtherID>
<OtherID Source="POP">00297373</OtherID>
<OtherAbstract Type="PIP" Language="eng">
<AbstractText>In the past, power structures of the nation-State have been organized around patriarchal assumptions, granting men monopoly over power, authority, and wealth.  A number of structures have been erected to achieve this imbalance, which have disguised its inequity by making it appear as natural and universal.  However, with globalization, this centralization of power within the Sovereign State has been fragmented.  Although globalization opens up new spaces by weakening the nation-State, subsequently making possible the undermining of traditional gender hierarchies and devising new bases for gender relations, the reality that the State is no longer the sole institution that can define identity and belonging within it has denied women the space to assert their own claims to gendered self-determination.  In this regard, globalization has impacted upon gender relations in complex and contradictory ways.  This paper discusses such impacts of globalization on gender relations.  Overall, it has become apparent that forms of inequality still exist regardless of a State's prevailing political ideology.  Their manifestations may differ, but the reality of women's subordination remains constant.</AbstractText>
</OtherAbstract>
<KeywordList Owner="PIP">
<Keyword MajorTopicYN="Y">Critique</Keyword>
<Keyword MajorTopicYN="N">Economic Factors</Keyword>
<Keyword MajorTopicYN="N">Gender Issues</Keyword>
<Keyword MajorTopicYN="Y">Gender Relations</Keyword>
<Keyword MajorTopicYN="Y">Social Change</Keyword>
<Keyword MajorTopicYN="N">Socioeconomic Factors</Keyword>
<Keyword MajorTopicYN="Y">Women's Status</Keyword>
<Keyword MajorTopicYN="Y">World</Keyword>
</KeywordList>
<GeneralNote Owner="PIP">TJ: UN CHRONICLE</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11831940</PMID>
<DateCreated>
<Year>2002</Year>
<Month>02</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>02</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0003-9950</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>120</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2002</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Archives of ophthalmology</Title>
<ISOAbbreviation>Arch. Ophthalmol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Republication of color figures.</ArticleTitle>
<Pagination>
<MedlinePgn>234-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dushku</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>John</LastName>
<ForeName>Molykutty K</ForeName>
<Initials>MK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schultz</LastName>
<ForeName>Gregory S</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reid</LastName>
<ForeName>Ted W</ForeName>
<Initials>TW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Ophthalmol</MedlineTA>
<NlmUniqueID>7706534</NlmUniqueID>
<ISSNLinking>0003-9950</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance>Matrix Metalloproteinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Arch Ophthalmol. 2001 May;119(5):695-706</RefSource>
<PMID Version="1">11346397</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Limbus Corneae</DescriptorName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Matrix Metalloproteinases</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pterygium</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11838066</PMID>
<DateCreated>
<Year>2002</Year>
<Month>02</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>02</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0023-7205</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>99</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2002</Year>
<Month>Jan</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Lkartidningen</Title>
<ISOAbbreviation>Lakartidningen</ISOAbbreviation>
</Journal>
<ArticleTitle>[Unequal distribution of health resources. Research is not supported with consideration to the global significance of the diseases].</ArticleTitle>
<Pagination>
<MedlinePgn>148-9</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Milerad</LastName>
<ForeName>Josef</ForeName>
<Initials>J</Initials>
<Affiliation>josef.milerad@lakartidningen.se</Affiliation>
</Author>
</AuthorList>
<Language>swe</Language>
<PublicationTypeList>
<PublicationType>Biography</PublicationType>
<PublicationType>Historical Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Portraits</PublicationType>
</PublicationTypeList>
<VernacularTitle>Ojmn frdelning av hlsoresurser. Forskningspengar satsas inte i proportion till sjukdomars globala betydelse.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Sweden</Country>
<MedlineTA>Lakartidningen</MedlineTA>
<NlmUniqueID>0027707</NlmUniqueID>
<ISSNLinking>0023-7205</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Care Rationing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nobel Prize</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Research Support as Topic</DescriptorName>
<QualifierName MajorTopicYN="N">economics</QualifierName>
<QualifierName MajorTopicYN="N">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">World Health</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Varmus</LastName>
<ForeName>Harold</ForeName>
<Initials>H</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">11858276</PMID>
<DateCreated>
<Year>2002</Year>
<Month>02</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0094-5765</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>48</Volume>
<Issue>5-12</Issue>
<PubDate>
<MedlineDate>2001 Mar-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Acta astronautica</Title>
<ISOAbbreviation>Acta Astronaut</ISOAbbreviation>
</Journal>
<ArticleTitle>Phase 1 research program overview.</ArticleTitle>
<Pagination>
<MedlinePgn>845-51</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The Phase 1 research program was unprecedented in its scope and ambitious in its objectives. The National Aeronautics and Space Administration committed to conducting a multidisciplinary long-duration research program on a platform whose capabilities were not well known, not to mention belonging to another country. For the United States, it provided the first opportunity to conduct research in a long-duration space flight environment since the Skylab program in the 1970's. Multiple technical as well as cultural challenges were successfully overcome through the dedicated efforts of a relatively small cadre of individuals. The program developed processes to successfully plan, train for and execute research in a long-duration environment, with significant differences identified from short-duration space flight science operations. Between August 1994 and June 1998, thousands of kilograms of research hardware was prepared and launched to Mir, and thousands of kilograms of hardware and data products were returned to Earth. More than 150 Principal Investigators from eight countries were involved in the program in seven major research disciplines: Advanced Technology; Earth Sciences; Fundamental Biology; Human Life Sciences; International Space Station Risk Mitigation; Microgravity; and Space Sciences. Approximately 75 long-duration investigations were completed on Mir, with additional investigations performed on the Shuttle flights that docked with Mir. The flight phase included the participation of seven US astronauts and 20 Russian cosmonauts. The successful completion of the Phase 1 research program not only resulted in high quality science return but also in numerous lessons learned to make the ISS experience more productive. The cooperation developed during the program was instrumental in its success.</AbstractText>
<CopyrightInformation>c2001 AIAA. Published by Elsevier Science Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Uri</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
<Affiliation>NASA Johnson Space Center, Houston, TX, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lebedev</LastName>
<ForeName>O N</ForeName>
<Initials>ON</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Acta Astronaut</MedlineTA>
<NlmUniqueID>9890631</NlmUniqueID>
<ISSNLinking>0094-5765</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biological Science Disciplines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Equipment Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Exobiology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Extraterrestrial Environment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Research</DescriptorName>
<QualifierName MajorTopicYN="N">instrumentation</QualifierName>
<QualifierName MajorTopicYN="Y">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Russia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Space Flight</DescriptorName>
<QualifierName MajorTopicYN="N">instrumentation</QualifierName>
<QualifierName MajorTopicYN="Y">organization &amp; administration</QualifierName>
<QualifierName MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spacecraft</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">USSR</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">United States National Aeronautics and Space Administration</DescriptorName>
<QualifierName MajorTopicYN="Y">organization &amp; administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Weightlessness</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NASA">00027286</OtherID>
<SpaceFlightMission>Flight Experiment</SpaceFlightMission>
<SpaceFlightMission>Mir Project</SpaceFlightMission>
<SpaceFlightMission>STS Shuttle Project</SpaceFlightMission>
<SpaceFlightMission>long duration</SpaceFlightMission>
<SpaceFlightMission>manned</SpaceFlightMission>
<SpaceFlightMission>short duration</SpaceFlightMission>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11858625</PMID>
<DateCreated>
<Year>2002</Year>
<Month>02</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0002-838X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>65</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2002</Year>
<Month>Feb</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American family physician</Title>
<ISOAbbreviation>Am Fam Physician</ISOAbbreviation>
</Journal>
<ArticleTitle>Information from your family doctor. Exercise for the elderly.</ArticleTitle>
<Pagination>
<MedlinePgn>427-8</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Patient Education Handout</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am Fam Physician</MedlineTA>
<NlmUniqueID>1272646</NlmUniqueID>
<ISSNLinking>0002-838X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="OriginalReportIn">
<RefSource>Am Fam Physician. 2002 Feb 1;65(3):419-26</RefSource>
<PMID Version="1">11858624</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Exercise</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Family Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Health Promotion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11869993</PMID>
<DateCreated>
<Year>2002</Year>
<Month>02</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1052-1577</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>27</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2002</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Harvard health letter / from Harvard Medical School</Title>
<ISOAbbreviation>Harv Health Lett</ISOAbbreviation>
</Journal>
<ArticleTitle>By the way doctor... I'm 72 and was recently told that I am losing a bit of my sight because of macular degeneration. My doctor assured me that it was progressing very slowly, but also said there wasn't really anything to do about it. But I read that zinc or vitamins might help. Should I be taking them?</ArticleTitle>
<Pagination>
<MedlinePgn>8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Thomas H</ForeName>
<Initials>TH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Harv Health Lett</MedlineTA>
<NlmUniqueID>9425764</NlmUniqueID>
<ISSNLinking>1052-1577</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Vitamins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-66-6</RegistryNumber>
<NameOfSubstance>Zinc</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>K</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Macular Degeneration</DescriptorName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vitamins</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zinc</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">11876201</PMID>
<DateCreated>
<Year>2002</Year>
<Month>03</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1069-9422</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>5</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1998</Year>
</PubDate>
</JournalIssue>
<Title>Life support &amp; biosphere science : international journal of earth space</Title>
<ISOAbbreviation>Life Support Biosph Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Consumer acceptance of vegetarian sweet potato products intended for space missions.</ArticleTitle>
<Pagination>
<MedlinePgn>339-46</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Sweet potato is one of the crops selected for NASA's Advanced Life Support Program for potential long-duration lunar/Mars missions. This article presents recipes of products made from sweet potato and determines the consumer acceptability of products containing from 6% to 20% sweet potato on a dry weight basis. These products were developed for use in nutritious and palatable meals for future space explorers. Sensory evaluation (appearance/color, aroma, texture, flavor/taste, and overall acceptability) studies were conducted to determine the consumer acceptability of vegetarian products made with sweet potato using panelists at NASA/Johnson Space Center in Houston, TX. None of these products including the controls, contained any ingredient of animal origin with the exception of sweet potato pie. A 9-point hedonic scale (9 being like extremely and 1 being dislike extremely) was used to evaluate 10 products and compare them to similar commercially available products used as controls. The products tested were pancakes, waffles, tortillas, bread, pie, pound cake, pasta, vegetable patties, doughnuts, and pretzels. All of the products were either liked moderately or liked slightly with the exception of the sweet potato vegetable patties, which were neither liked nor disliked. Mean comparisons of sensory scores of sweet potato recipes and their controls were accomplished by using the Student t-test. Because of their nutritional adequacy and consumer acceptability, these products are being recommended to NASA's Advanced Life Support Program for inclusion in a vegetarian menu plan designed for lunar/Mars space missions.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>C D</ForeName>
<Initials>CD</Initials>
<Affiliation>Center for Food and Environmental Systems for Human Exploration of Space, George Washington Carver Agricultural Experiment Station, Tuskegee University, Tuskegee, AL 36088, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pace</LastName>
<ForeName>R D</ForeName>
<Initials>RD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bromfield</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Life Support Biosph Sci</MedlineTA>
<NlmUniqueID>9431217</NlmUniqueID>
<ISSNLinking>1069-9422</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diet, Vegetarian</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ecological Systems, Closed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Evaluation Studies as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Food Habits</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Food Preferences</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Food Technology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ipomoea batatas</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Life Support Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Menu Planning</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nutritive Value</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Space Flight</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">United States National Aeronautics and Space Administration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Weightlessness</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NASA">00027330</OtherID>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Discipline Life Support Systems</Keyword>
<Keyword MajorTopicYN="N">Non-NASA Center</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Mortley</LastName>
<ForeName>D G</ForeName>
<Initials>DG</Initials>
<Affiliation>Tuskegee U, AL</Affiliation>
</Investigator>
</InvestigatorList>
<GeneralNote Owner="NASA">Grant numbers:  NCC 9-51, ALX-FS-2.</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11892742</PMID>
<DateCreated>
<Year>2002</Year>
<Month>03</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>07</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0012-1606</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>242</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2002</Year>
<Month>Feb</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Developmental biology</Title>
<ISOAbbreviation>Dev. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The major subacrosomal occupant of bull spermatozoa is a novel histone H2B        variant associated with the forming acrosome during spermiogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>376-87</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Recent studies on the structural composition of mammalian sperm heads have shown a congregate of unidentified proteins occupying the periphery of the mammalian sperm nucleus, forming a layer of condensed cytosol. These proteins are the perinuclear theca (PT) and can be categorized into SDS-soluble and SDS-insoluble components. The present study focused on identifying the major SDS-insoluble PT protein, which we localized to the subacrosomal layer of bovine spermatozoa and cloned by immunoscreening a bull testicular cDNA library. The isolated clones encode a protein of 122 amino acids that bears 67% similarity with histone H2B and contains a predicted histone fold motif. The novel amino terminus of the protein contains a potential bipartite nuclear targeting sequence. Hence, we identified this prominent subacrosomal component as a novel H2B variant, SubH2Bv. Northern blot analyses of SubH2Bv mRNA expression showed that it is testis-specific and is also present in murid testes. Immunocytochemical analysis showed SubH2Bv intimately associates, temporally and spatially, with acrosome formation. While the molecular features of SubH2Bv are common to nuclear proteins, it is never seen developmentally within the nucleus of the spermatid. Considering its developmental and molecular characteristics, we have postulated roles of SubH2Bv in acrosome assembly and acrosome-nuclear docking.</AbstractText>
<CopyrightInformation>Copyright 2001 Academic Press.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aul</LastName>
<ForeName>Ritu B</ForeName>
<Initials>RB</Initials>
<Affiliation>Department of Anatomy and Cell Biology, Queen's University, Kingston, Ontario, Canada, K7L 3N6.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Oko</LastName>
<ForeName>Richard J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Corrected and Republished Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Biol</MedlineTA>
<NlmUniqueID>0372762</NlmUniqueID>
<ISSNLinking>0012-1606</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA, Complementary</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance>RNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="RepublishedFrom">
<RefSource>Dev Biol. 2001 Nov 15;239(2):376-87</RefSource>
<PMID Version="1">11784042</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acrosome</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Blotting, Northern</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cattle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA, Complementary</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Histones</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunoblotting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Seminiferous Epithelium</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spermatogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spermatozoa</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Testis</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">11909345</PMID>
<DateCreated>
<Year>2002</Year>
<Month>03</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2003</Year>
<Month>11</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0031-9007</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>88</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2002</Year>
<Month>Mar</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Physical review letters</Title>
<ISOAbbreviation>Phys. Rev. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Measurement of B --&gt; K*gamma branching fractions and charge asymmetries.</ArticleTitle>
<Pagination>
<MedlinePgn>101805</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The branching fractions of the exclusive decays B0--&gt;K(*0)gamma and B+--&gt;K(*+)gamma are measured from a sample of (22.74+/-0.36)x10(6) BB decays collected with the BABAR detector at the PEP-II asymmetric e(+)e(-) collider. We find B (B0--&gt;K(*0)gamma) = [4.23+/-0.40(stat)+/-0.22(syst)]x10(-5), B(B+--&gt;K(*+)gamma) = [3.83+/-0.62(stat)+/-0.22(syst)]x10(-5) and constrain the CP-violating charge asymmetry to be -0.170&lt;A(CP)(B--&gt;K(*)gamma)&lt;0.082 at 90% C.L.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aubert</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<Affiliation>Laboratoire de Physique des Particules, F-74941 Annecy-le-Vieux, France.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Boutigny</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gaillard</LastName>
<ForeName>J-M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hicheur</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karyotakis</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lees</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robbe</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tisserand</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Palano</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>G P</ForeName>
<Initials>GP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>N D</ForeName>
<Initials>ND</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rong</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Y S</ForeName>
<Initials>YS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eigen</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reinertsen</LastName>
<ForeName>P L</ForeName>
<Initials>PL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stugu</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abbott</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abrams</LastName>
<ForeName>G S</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Borgland</LastName>
<ForeName>A W</ForeName>
<Initials>AW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Breon</LastName>
<ForeName>A B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>D N</ForeName>
<Initials>DN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Button-Shafer</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cahn</LastName>
<ForeName>R N</ForeName>
<Initials>RN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gill</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gritsan</LastName>
<ForeName>A V</ForeName>
<Initials>AV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Groysman</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jacobsen</LastName>
<ForeName>R G</ForeName>
<Initials>RG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kadel</LastName>
<ForeName>R W</ForeName>
<Initials>RW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kadyk</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kerth</LastName>
<ForeName>L T</ForeName>
<Initials>LT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kluth</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kolomensky</LastName>
<ForeName>Yu G</ForeName>
<Initials>YG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kral</LastName>
<ForeName>J F</ForeName>
<Initials>JF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>LeClerc</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Levi</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lynch</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meyer</LastName>
<ForeName>A B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Momayezi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oddone</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perazzo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pripstein</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roe</LastName>
<ForeName>N A</ForeName>
<Initials>NA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Romosan</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ronan</LastName>
<ForeName>M T</ForeName>
<Initials>MT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shelkov</LastName>
<ForeName>V G</ForeName>
<Initials>VG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Telnov</LastName>
<ForeName>A V</ForeName>
<Initials>AV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wenzel</LastName>
<ForeName>W A</ForeName>
<Initials>WA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zisman</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bright-Thomas</LastName>
<ForeName>P G</ForeName>
<Initials>PG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harrison</LastName>
<ForeName>T J</ForeName>
<Initials>TJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hawkes</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Knowles</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Neale</LastName>
<ForeName>S W</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Penny</LastName>
<ForeName>R C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watson</LastName>
<ForeName>A T</ForeName>
<Initials>AT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watson</LastName>
<ForeName>N K</ForeName>
<Initials>NK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deppermann</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goetzen</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koch</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krug</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kunze</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lewandowski</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peters</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schmuecker</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Steinke</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Andress</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barlow</LastName>
<ForeName>N R</ForeName>
<Initials>NR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhimji</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chevalier</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cottingham</LastName>
<ForeName>W N</ForeName>
<Initials>WN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Groot</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dyce</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Foster</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McFall</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wallom</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>F F</ForeName>
<Initials>FF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abe</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hearty</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mattison</LastName>
<ForeName>T S</ForeName>
<Initials>TS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McKenna</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thiessen</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jolly</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McKemey</LastName>
<ForeName>A K</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tinslay</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blinov</LastName>
<ForeName>V E</ForeName>
<Initials>VE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bukin</LastName>
<ForeName>A D</ForeName>
<Initials>AD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bukin</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buzykaev</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Golubev</LastName>
<ForeName>V B</ForeName>
<Initials>VB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ivanchenko</LastName>
<ForeName>V N</ForeName>
<Initials>VN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Korol</LastName>
<ForeName>A A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kravchenko</LastName>
<ForeName>E A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Onuchin</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Salnikov</LastName>
<ForeName>A A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Serednyakov</LastName>
<ForeName>S I</ForeName>
<Initials>SI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Skovpen</LastName>
<ForeName>Yu I</ForeName>
<Initials>YI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Telnov</LastName>
<ForeName>V I</ForeName>
<Initials>VI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yushkov</LastName>
<ForeName>A N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Best</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lankford</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mandelkern</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McMahon</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stoker</LastName>
<ForeName>D P</ForeName>
<Initials>DP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahsan</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Arisaka</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buchanan</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chun</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Branson</LastName>
<ForeName>J G</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacFarlane</LastName>
<ForeName>D B</ForeName>
<Initials>DB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Prell</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rahatlou</LastName>
<ForeName>Sh</ForeName>
<Initials>Sh</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raven</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sharma</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Campagnari</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dahmes</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hart</LastName>
<ForeName>P A</ForeName>
<Initials>PA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuznetsova</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Levy</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Long</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Richman</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Verkerke</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Witherell</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yellin</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beringer</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dorfan</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eisner</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frey</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grillo</LastName>
<ForeName>A A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grothe</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heusch</LastName>
<ForeName>C A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>R P</ForeName>
<Initials>RP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kroeger</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lockman</LastName>
<ForeName>W S</ForeName>
<Initials>WS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pulliam</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sadrozinski</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schalk</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schmitz</LastName>
<ForeName>R E</ForeName>
<Initials>RE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schumm</LastName>
<ForeName>B A</ForeName>
<Initials>BA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seiden</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Turri</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Walkowiak</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>D C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>M G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dubois-Felsmann</LastName>
<ForeName>G P</ForeName>
<Initials>GP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dvoretskii</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hitlin</LastName>
<ForeName>D G</ForeName>
<Initials>DG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Metzler</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oyang</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Porter</LastName>
<ForeName>F C</ForeName>
<Initials>FC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ryd</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Samuel</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weaver</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>R Y</ForeName>
<Initials>RY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Devmal</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Geld</LastName>
<ForeName>T L</ForeName>
<Initials>TL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jayatilleke</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mancinelli</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meadows</LastName>
<ForeName>B T</ForeName>
<Initials>BT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sokoloff</LastName>
<ForeName>M D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barillari</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bloom</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dima</LastName>
<ForeName>M O</ForeName>
<Initials>MO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fahey</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ford</LastName>
<ForeName>W T</ForeName>
<Initials>WT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>D R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nauenberg</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olivas</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rankin</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roy</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sen</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>J G</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>van Hoek</LastName>
<ForeName>W C</ForeName>
<Initials>WC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>D L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blouw</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harton</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krishnamurthy</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soffer</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Toki</LastName>
<ForeName>W H</ForeName>
<Initials>WH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brandt</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brose</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Colberg</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dahlinger</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dickopp</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dubitzky</LastName>
<ForeName>R S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hauke</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Maly</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mller-Pfefferkorn</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Otto</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schubert</LastName>
<ForeName>K R</ForeName>
<Initials>KR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schwierz</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Spaan</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilden</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Behr</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bernard</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bonneaud</LastName>
<ForeName>G R</ForeName>
<Initials>GR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brochard</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cohen-Tanugi</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferrag</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roussot</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>T'Jampens</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thiebaux</LastName>
<ForeName>Ch</ForeName>
<Initials>Ch</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vasileiadis</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Verderi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anjomshoaa</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bernet</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khan</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lavin</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Muheim</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Playfer</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Swain</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Falbo</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Borean</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bozzi</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dittongo</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Folegani</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piemontese</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Treadwell</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anulli</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baldini-Ferroli</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Calcaterra</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Sangro</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Falciai</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Finocchiaro</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Patteri</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peruzzi</LastName>
<ForeName>I M</ForeName>
<Initials>IM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piccolo</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zallo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bagnasco</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buzzo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Contri</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Crosetti</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fabbricatore</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Farinon</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lo Vetere</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Macri</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Monge</LastName>
<ForeName>M R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Musenich</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pallavicini</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Parodi</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Passaggio</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pastore</LastName>
<ForeName>F C</ForeName>
<Initials>FC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Patrignani</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pia</LastName>
<ForeName>M G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Priano</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robutti</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santroni</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morii</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bartoldus</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dignan</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamilton</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mallik</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cochran</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Crawley</LastName>
<ForeName>H B</ForeName>
<Initials>HB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fischer</LastName>
<ForeName>P-A</ForeName>
<Initials>PA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lamsa</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meyer</LastName>
<ForeName>W T</ForeName>
<Initials>WT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rosenberg</LastName>
<ForeName>E I</ForeName>
<Initials>EI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benkebil</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grosdidier</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hast</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hcker</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lacker</LastName>
<ForeName>H M</ForeName>
<Initials>HM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Laplace</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lepeltier</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lutz</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Plaszczynski</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schune</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trincaz-Duvoid</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Valassi</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wormser</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bionta</LastName>
<ForeName>R M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brigljevi</LastName>
<ForeName>V V</ForeName>
<Initials>VV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lange</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mugge</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>van Bibber</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wenaus</LastName>
<ForeName>T J</ForeName>
<Initials>TJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wright</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wuest</LastName>
<ForeName>C R</ForeName>
<Initials>CR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carroll</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fry</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gabathuler</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gamet</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>George</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kay</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Payne</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sloane</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Touramanis</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aspinwall</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bowerman</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dauncey</LastName>
<ForeName>P D</ForeName>
<Initials>PD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Egede</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eschrich</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gunawardane</LastName>
<ForeName>N J W</ForeName>
<Initials>NJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nash</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sanders</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Azzopardi</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Back</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dixon</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harrison</LastName>
<ForeName>P F</ForeName>
<Initials>PF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Potter</LastName>
<ForeName>R J L</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shorthouse</LastName>
<ForeName>H W</ForeName>
<Initials>HW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Strother</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vidal</LastName>
<ForeName>P B</ForeName>
<Initials>PB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>M I</ForeName>
<Initials>MI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cowan</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>George</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Green</LastName>
<ForeName>M G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kurup</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marker</LastName>
<ForeName>C E</ForeName>
<Initials>CE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McGrath</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McMahon</LastName>
<ForeName>T R</ForeName>
<Initials>TR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ricciardi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Salvatore</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scott</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vaitsas</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Davis</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Allison</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barlow</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boyd</LastName>
<ForeName>J T</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Forti</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fullwood</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jackson</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lafferty</LastName>
<ForeName>G D</ForeName>
<Initials>GD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Savvas</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Simopoulos</LastName>
<ForeName>E T</ForeName>
<Initials>ET</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weatherall</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Farbin</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jawahery</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lillard</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olsen</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schieck</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blaylock</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dallapiccola</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Flood</LastName>
<ForeName>K T</ForeName>
<Initials>KT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hertzbach</LastName>
<ForeName>S S</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kofler</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moore</LastName>
<ForeName>T B</ForeName>
<Initials>TB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Staengle</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Willocq</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brau</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cowan</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sciolla</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taylor</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>R K</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Milek</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Patel</LastName>
<ForeName>P M</ForeName>
<Initials>PM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trischuk</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lanni</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Palombo</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bauer</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Booke</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cremaldi</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eschenburg</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kroeger</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reidy</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sanders</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Summers</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martin</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nief</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seitz</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taras</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zacek</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nicholson</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sutton</LastName>
<ForeName>C S</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cartaro</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cavallo</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Nardo</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fabozzi</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gatto</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lista</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paolucci</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piccolo</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sciacca</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>LoSecco</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alsmiller</LastName>
<ForeName>J R G</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gabriel</LastName>
<ForeName>T A</ForeName>
<Initials>TA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Handler</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brau</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frey</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iwasaki</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sinev</LastName>
<ForeName>N B</ForeName>
<Initials>NB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Strom</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Colecchia</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dal Corso</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dorigo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Galeazzi</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Margoni</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Michelon</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morandin</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Posocco</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rotondo</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Simonetto</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stroili</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Torassa</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Voci</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benayoun</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Briand</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chauveau</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>David</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de La Vaissire</LastName>
<ForeName>Ch</ForeName>
<Initials>Ch</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Del Buono</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamon</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Le Diberder</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leruste</LastName>
<ForeName>Ph</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lory</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roos</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stark</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Versill</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manfredi</LastName>
<ForeName>P F</ForeName>
<Initials>PF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Re</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Speziali</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frank</LastName>
<ForeName>E D</ForeName>
<Initials>ED</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gladney</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Q H</ForeName>
<Initials>QH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Panetta</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Angelini</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Batignani</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bettarini</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bondioli</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carpinelli</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Forti</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Giorgi</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lusiani</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martinez-Vidal</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morganti</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neri</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paoloni</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rama</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rizzo</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sandrelli</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Simi</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Triggiani</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Walsh</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haire</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Judd</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paick</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Turnbull</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagoner</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Albert</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bula</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elmer</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McDonald</LastName>
<ForeName>K T</ForeName>
<Initials>KT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miftakov</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schaffner</LastName>
<ForeName>S F</ForeName>
<Initials>SF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>A J S</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tumanov</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Varnes</LastName>
<ForeName>E W</ForeName>
<Initials>EW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cavoto</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>del Re</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Faccini</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferrarotto</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferroni</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fratini</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lamanna</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leonardi</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mazzoni</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morganti</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piredda</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Safai Tehrani</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Serra</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Voena</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Christ</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Waldi</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adye</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Franek</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Geddes</LastName>
<ForeName>N I</ForeName>
<Initials>NI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gopal</LastName>
<ForeName>G P</ForeName>
<Initials>GP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xella</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aleksan</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Domenico</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Emery</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gaidot</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ganzhur</LastName>
<ForeName>S F</ForeName>
<Initials>SF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Giraud</LastName>
<ForeName>P-F</ForeName>
<Initials>PF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamel Monchenault</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kozanecki</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Langer</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>London</LastName>
<ForeName>G W</ForeName>
<Initials>GW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mayer</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Serfass</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vasseur</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yche</LastName>
<ForeName>Ch</ForeName>
<Initials>Ch</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zito</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Copty</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Purohit</LastName>
<ForeName>M V</ForeName>
<Initials>MV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yumiceva</LastName>
<ForeName>F X</ForeName>
<Initials>FX</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adam</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anthony</LastName>
<ForeName>P L</ForeName>
<Initials>PL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aston</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baird</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berger</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bloom</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boyarski</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bulos</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Calderini</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Claus</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Convery</LastName>
<ForeName>M R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Coupal</LastName>
<ForeName>D P</ForeName>
<Initials>DP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Coward</LastName>
<ForeName>D H</ForeName>
<Initials>DH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dorfan</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doser</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dunwoodie</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Field</LastName>
<ForeName>R C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Glanzman</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Godfrey</LastName>
<ForeName>G L</ForeName>
<Initials>GL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gowdy</LastName>
<ForeName>S J</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grosso</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Himel</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hryn'ova</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huffer</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Innes</LastName>
<ForeName>W R</ForeName>
<Initials>WR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jessop</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kelsey</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kocian</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Langenegger</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leith</LastName>
<ForeName>D W G S</ForeName>
<Initials>DW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luitz</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luth</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lynch</LastName>
<ForeName>H L</ForeName>
<Initials>HL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marsiske</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Menke</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Messner</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moffeit</LastName>
<ForeName>K C</ForeName>
<Initials>KC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mount</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Muller</LastName>
<ForeName>D R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Grady</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perl</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Petrak</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Quinn</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ratcliff</LastName>
<ForeName>B N</ForeName>
<Initials>BN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robertson</LastName>
<ForeName>S H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rochester</LastName>
<ForeName>L S</ForeName>
<Initials>LS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roodman</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schietinger</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schindler</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schwiening</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seeman</LastName>
<ForeName>J T</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Serbo</LastName>
<ForeName>V V</ForeName>
<Initials>VV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Snyder</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soha</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Spanier</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stelzer</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Su</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sullivan</LastName>
<ForeName>M K</ForeName>
<Initials>MK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>H A</ForeName>
<Initials>HA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Va'vra</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weinstein</LastName>
<ForeName>A J R</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wienands</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wisniewski</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wright</LastName>
<ForeName>D H</ForeName>
<Initials>DH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Young</LastName>
<ForeName>C C</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Burchat</LastName>
<ForeName>P R</ForeName>
<Initials>PR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>C H</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kirkby</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meyer</LastName>
<ForeName>T I</ForeName>
<Initials>TI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roat</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Silva</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Henderson</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bugg</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cohn</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weidemann</LastName>
<ForeName>A W</ForeName>
<Initials>AW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Izen</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kitayama</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lou</LastName>
<ForeName>X C</ForeName>
<Initials>XC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Turcotte</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bianchi</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bona</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Di Girolamo</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gamba</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smol</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zanin</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bosisio</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Della Ricca</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lanceri</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pompili</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Poropat</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vuagnin</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Panvini</LastName>
<ForeName>R S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kowalewski</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roney</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Band</LastName>
<ForeName>H R</ForeName>
<Initials>HR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Charles</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dasu</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Di Lodovico</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eichenbaum</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nielsen</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Prepost</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scott</LastName>
<ForeName>I J</ForeName>
<Initials>IJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sekula</LastName>
<ForeName>S J</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>von Wimmersperg-Toeller</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zobernig</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kordich</LastName>
<ForeName>T M B</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neal</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>BABAR Collaborations</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2002</Year>
<Month>02</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Phys Rev Lett</MedlineTA>
<NlmUniqueID>0401141</NlmUniqueID>
<ISSNLinking>0031-9007</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11916658</PMID>
<DateCreated>
<Year>2002</Year>
<Month>03</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1070-910X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2002</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Harvard women's health watch</Title>
<ISOAbbreviation>Harv Womens Health Watch</ISOAbbreviation>
</Journal>
<ArticleTitle>By the way, doctor. A few months ago, I was surprised to read that a new study has raised a question about the value of screening mammograms. Is that true? I thought the importance of having such mammograms was well-established. I'm 52 and have been getting annual mammograms for 10 years. Should I stop?</ArticleTitle>
<Pagination>
<MedlinePgn>8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Robb-Nicholson</LastName>
<ForeName>Celeste</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Harv Womens Health Watch</MedlineTA>
<NlmUniqueID>9423147</NlmUniqueID>
<ISSNLinking>1070-910X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>K</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
<QualifierName MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mammography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Patient Education as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Research Design</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11966386</PMID>
<DateCreated>
<Year>2002</Year>
<Month>04</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>05</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0098-7484</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>287</Volume>
<Issue>16</Issue>
<PubDate>
<Year>2002</Year>
<Month>Apr</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>JAMA : the journal of the American Medical Association</Title>
<ISOAbbreviation>JAMA</ISOAbbreviation>
</Journal>
<ArticleTitle>The 2001 Bethesda System: terminology for reporting results of cervical cytology.</ArticleTitle>
<Pagination>
<MedlinePgn>2114-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The Bethesda 2001 Workshop was convened to evaluate and update the 1991 Bethesda System terminology for reporting the results of cervical cytology. A primary objective was to develop a new approach to broaden participation in the consensus process.</AbstractText>
<AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Forum groups composed of 6 to 10 individuals were responsible for developing recommendations for discussion at the workshop. Each forum group included at least 1 cytopathologist, cytotechnologist, clinician, and international representative to ensure a broad range of views and interests. More than 400 cytopathologists, cytotechnologists, histopathologists, family practitioners, gynecologists, public health physicians, epidemiologists, patient advocates, and attorneys participated in the workshop, which was convened by the National Cancer Institute and cosponsored by 44 professional societies. More than 20 countries were represented.</AbstractText>
<AbstractText Label="EVIDENCE" NlmCategory="METHODS">Literature review, expert opinion, and input from an Internet bulletin board were all considered in developing recommendations. The strength of evidence of the scientific data was considered of paramount importance.</AbstractText>
<AbstractText Label="CONSENSUS PROCESS" NlmCategory="METHODS">Bethesda 2001 was a year-long iterative review process. An Internet bulletin board was used for discussion of issues and drafts of recommendations. More than 1000 comments were posted to the bulletin board over the course of 6 months. The Bethesda Workshop, held April 30-May 2, 2001, was open to the public. Postworkshop recommendations were posted on the bulletin board for a last round of critical review prior to finalizing the terminology.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bethesda 2001 was developed with broad participation in the consensus process. The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Solomon</LastName>
<ForeName>Diane</ForeName>
<Initials>D</Initials>
<Affiliation>EPN Room 2130, 6130 Executive Blvd, Bethesda, MD 20892, USA. ds87v@nih.gov</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Davey</LastName>
<ForeName>Diane</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kurman</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moriarty</LastName>
<ForeName>Ann</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Connor</LastName>
<ForeName>Dennis</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Prey</LastName>
<ForeName>Marianne</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raab</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sherman</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilbur</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wright</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author ValidYN="Y">
<LastName>Young</LastName>
<ForeName>Nancy</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>Forum Group Members</CollectiveName>
</Author>
<Author ValidYN="Y">
<CollectiveName>Bethesda 2001 Workshop</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Consensus Development Conference</PublicationType>
<PublicationType>Consensus Development Conference, NIH</PublicationType>
<PublicationType>Guideline</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>JAMA</MedlineTA>
<NlmUniqueID>7501160</NlmUniqueID>
<ISSNLinking>0098-7484</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>JAMA. 2002 Apr 24;287(16):2140-1</RefSource>
<PMID Version="1">11966390</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cervical Intraepithelial Neoplasia</DescriptorName>
<QualifierName MajorTopicYN="N">classification</QualifierName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Laboratories</DescriptorName>
<QualifierName MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Quality Control</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Terminology as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Uterine Cervical Dysplasia</DescriptorName>
<QualifierName MajorTopicYN="N">classification</QualifierName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vaginal Smears</DescriptorName>
<QualifierName MajorTopicYN="N">classification</QualifierName>
<QualifierName MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>28</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11953811</PMID>
<DateCreated>
<Year>2002</Year>
<Month>05</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1432-2218</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2002</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Surgical endoscopy</Title>
<ISOAbbreviation>Surg Endosc</ISOAbbreviation>
</Journal>
<ArticleTitle>Disruptive visions:  surgeon responsibility during the era of change.</ArticleTitle>
<Pagination>
<MedlinePgn>733-4</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Satava</LastName>
<ForeName>R M</ForeName>
<Initials>RM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Surg Endosc</MedlineTA>
<NlmUniqueID>8806653</NlmUniqueID>
<ISSNLinking>0930-2794</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Biomedical Technology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Commerce</DescriptorName>
<QualifierName MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Delivery of Health Care</DescriptorName>
<QualifierName MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">General Surgery</DescriptorName>
<QualifierName MajorTopicYN="N">standards</QualifierName>
<QualifierName MajorTopicYN="Y">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Services Needs and Demand</DescriptorName>
<QualifierName MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">12038483</PMID>
<DateCreated>
<Year>2002</Year>
<Month>05</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>07</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0273-1177</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>26</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2000</Year>
</PubDate>
</JournalIssue>
<Title>Advances in space research : the official journal of the Committee on Space Research (COSPAR)</Title>
<ISOAbbreviation>Adv Space Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Planetary protection issues for Mars sample acquisition flight projects.</ArticleTitle>
<Pagination>
<MedlinePgn>1911-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The planned NASA sample acquisition flight missions to Mars pose several interesting planetary protection issues. In addition to the usual forward contamination procedures for the adequate protection of Mars for the sake of future missions, there are reasons to ensure that the sample is not contaminated by terrestrial microbes from the acquisition mission. Recent recommendations by the Space Studies Board (SSB) of the National Research Council (United States), would indicate that the scientific integrity of the sample is a planetary protection concern (SSB, 1997). Also, as a practical matter, a contaminated sample would interfere with the process for its release from quarantine after return for distribution to the interested scientists. These matters are discussed in terms of the first planned acquisition mission.</AbstractText>
<CopyrightInformation>c2001 COSPAR Published by Elsevier Science Ltd.  All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barengoltz</LastName>
<ForeName>J B</ForeName>
<Initials>JB</Initials>
<Affiliation>Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Adv Space Res</MedlineTA>
<NlmUniqueID>9878935</NlmUniqueID>
<ISSNLinking>0273-1177</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>7722-84-1</RegistryNumber>
<NameOfSubstance>Hydrogen Peroxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Containment of Biohazards</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Environmental Microbiology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Extraterrestrial Environment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hot Temperature</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mars</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Space Flight</DescriptorName>
<QualifierName MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spacecraft</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Specimen Handling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sterilization</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">United States National Aeronautics and Space Administration</DescriptorName>
<QualifierName MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NASA">00027913</OtherID>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Center JPL</Keyword>
<Keyword MajorTopicYN="N">NASA Discipline Exobiology</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Barengoltz</LastName>
<ForeName>J B</ForeName>
<Initials>JB</Initials>
<Affiliation>JPL</Affiliation>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12101218</PMID>
<DateCreated>
<Year>2002</Year>
<Month>07</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0021-9258</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>277</Volume>
<Issue>28</Issue>
<PubDate>
<Year>2002</Year>
<Month>Jul</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interaction between FtsZ and FtsW of Mycobacterium tuberculosis.</ArticleTitle>
<Pagination>
<MedlinePgn>24983-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The recruitment of FtsZ to the septum and its subsequent interaction with other cell division proteins in a spatially and temporally controlled manner are the keys to bacterial cell division. In the present study, we have tested the hypothesis that FtsZ and FtsW of Mycobacterium tuberculosis could be binding partners. Using gel renaturation, pull-down, and solid-phase assays, we confirm that FtsZ and FtsW interact through their C-terminal tails, which carry extensions absent in their Escherichia coli counterparts. Crucial to these interactions is the cluster of aspartate residues Asp(367) to Asp(370) of FtsZ, which most likely interact with a cluster of positively charged residues in the C-terminal tail of FtsW. Mutations of the aspartate residues 367-370 showed that changing three aspartate residues to alanine resulted in complete loss of interaction. This is the first demonstration of the direct interaction between FtsZ and FtsW. We speculate that this interaction between FtsZ and FtsW could serve to anchor FtsZ to the membrane and link septum formation to peptidoglycan synthesis in M. tuberculosis. The findings assume particular significance in view of the global efforts to explore new targets in M. tuberculosis for chemotherapeutic intervention.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Datta</LastName>
<ForeName>Pratik</ForeName>
<Initials>P</Initials>
<Affiliation>Department of Chemistry, Bose Institute, 93/1 Acharya Prafulla Chandra Road, Kolkata 700009, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Dasgupta</LastName>
<ForeName>Arunava</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhakta</LastName>
<ForeName>Sanjib</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Basu</LastName>
<ForeName>Joyoti</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2002</Year>
<Month>05</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Bacterial Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cytoskeletal Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA Primers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>FtsZ protein, Bacteria</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>125724-13-2</RegistryNumber>
<NameOfSubstance>FtsW protein, Bacteria</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacterial Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cytoskeletal Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Primers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Membrane Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12145319</PMID>
<DateCreated>
<Year>2002</Year>
<Month>07</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0021-9258</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>277</Volume>
<Issue>31</Issue>
<PubDate>
<Year>2002</Year>
<Month>Aug</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly.</ArticleTitle>
<Pagination>
<MedlinePgn>28271-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The regulation of SNARE complex assembly likely plays an important role in governing the specificity as well as the timing of membrane fusion. Here we identify a novel brain-enriched protein, amisyn, with a tomosyn- and VAMP-like coiled-coil-forming domain that binds specifically to syntaxin 1a and syntaxin 4 both in vitro and in vivo, as assessed by co-immunoprecipitation from rat brain. Amisyn is mostly cytosolic, but a fraction co-sediments with membranes. The amisyn coil domain can form SNARE complexes of greater thermostability than can VAMP2 with syntaxin 1a and SNAP-25 in vitro, but it lacks a transmembrane anchor and so cannot act as a v-SNARE in this complex. The amisyn coil domain prevents the SNAP-25 C-terminally mediated rescue of botulinum neurotoxin E inhibition of norepinephrine exocytosis in permeabilized PC12 cells to a greater extent than it prevents the regular exocytosis of these vesicles. We propose that amisyn forms nonfusogenic complexes with syntaxin 1a and SNAP-25, holding them in a conformation ready for VAMP2 to replace it to mediate the membrane fusion event, thereby contributing to the regulation of SNARE complex formation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Scales</LastName>
<ForeName>Suzie J</ForeName>
<Initials>SJ</Initials>
<Affiliation>Howard Hughes Medical Institute, Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305-5345, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hesser</LastName>
<ForeName>Boris A</ForeName>
<Initials>BA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Masuda</LastName>
<ForeName>Esteban S</ForeName>
<Initials>ES</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scheller</LastName>
<ForeName>Richard H</ForeName>
<Initials>RH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>AF391153</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2002</Year>
<Month>05</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Qa-SNARE Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>SNAP25 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>SNARE Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>STX1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>STXBP6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Snap25 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Stx1a protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Synaptosomal-Associated Protein 25</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Syntaxin 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Vesicular Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-41-2</RegistryNumber>
<NameOfSubstance>Norepinephrine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.5.1.18</RegistryNumber>
<NameOfSubstance>Glutathione Transferase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Exocytosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Glutathione Transferase</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Norepinephrine</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">PC12 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pheochromocytoma</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Structure, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Qa-SNARE Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">SNARE Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Alignment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Synaptosomal-Associated Protein 25</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Syntaxin 1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Thermodynamics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Vesicular Transport Proteins</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">12159900</PMID>
<DateCreated>
<Year>2002</Year>
<Month>08</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>08</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>06</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0362-4331</ISSN>
<JournalIssue CitedMedium="Print">
<PubDate>
<Year>2002</Year>
<Month>Jul</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>The New York times on the Web</Title>
<ISOAbbreviation>N Y Times Web</ISOAbbreviation>
</Journal>
<ArticleTitle>Weighing medical ethics for many years to come: a conversation with Harold Shapiro. Interview by Howard Markel.</ArticleTitle>
<Pagination>
<MedlinePgn>F6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shapiro</LastName>
<ForeName>Harold</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Interview</PublicationType>
<PublicationType>Newspaper Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Y Times Web</MedlineTA>
<NlmUniqueID>9877126</NlmUniqueID>
<ISSNLinking>0362-4331</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Advisory Committees</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Bioethical Issues</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biomedical Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biotechnology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cloning, Organism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Conflict of Interest</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Mammalian</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Financing, Government</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Priorities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Human Experimentation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Research Support as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stem Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">103061</OtherID>
<OtherID Source="NRCBL">VF 2.1</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Bioethics and Professional Ethics</Keyword>
<Keyword MajorTopicYN="N">National Bioethics Advisory Commission</Keyword>
<Keyword MajorTopicYN="N">Popular Approach/Source</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">KIE Bib: bioethics</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">12174865</PMID>
<DateCreated>
<Year>2002</Year>
<Month>08</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>08</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1145-0762</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>11</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2000</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal international de biothique = International journal of bioethics</Title>
<ISOAbbreviation>J Int Bioethique</ISOAbbreviation>
</Journal>
<ArticleTitle>Physicians' attitudes towards medical ethics issues in Turkey.</ArticleTitle>
<Pagination>
<MedlinePgn>57-67</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pelin</LastName>
<ForeName>S S</ForeName>
<Initials>SS</Initials>
<Affiliation>Dept. of Deontology, Faculty of Medicine, University of Ankara, Tip. Fak. Dekanligi, Morfoloji Terleskesi, Anakara, Sihhiye - 06100 Turkey.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Arda</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>J Int Bioethique</MedlineTA>
<NlmUniqueID>9015754</NlmUniqueID>
<ISSNLinking>1145-0762</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Abortion, Induced</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animal Experimentation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Attitude of Health Personnel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Bioethical Issues</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biomedical Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Complementary Therapies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Confidentiality</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Data Collection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ethics, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ethics, Research</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Euthanasia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Physicians</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prejudice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Reproductive Techniques, Assisted</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Truth Disclosure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">102894</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Bioethics and Professional Ethics</Keyword>
<Keyword MajorTopicYN="N">Empirical Approach</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">Pelin, Serap Sahinoglu; Arda, Berna</GeneralNote>
<GeneralNote Owner="KIE">KIE Bib: bioethics; medical ethics</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">12192682</PMID>
<DateCreated>
<Year>2002</Year>
<Month>08</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0018-9251</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>35</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1999</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>IEEE transactions on aerospace and electronic systems</Title>
<ISOAbbreviation>IEEE Trans Aerosp Electron Syst</ISOAbbreviation>
</Journal>
<ArticleTitle>Intelligent control of a planning system for astronaut training.</ArticleTitle>
<Pagination>
<MedlinePgn>1055-70</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This work intends to design, analyze and solve, from the systems control perspective, a complex, dynamic, and multiconstrained planning system for generating training plans for crew members of the NASA-led International Space Station. Various intelligent planning systems have been developed within the framework of artificial intelligence. These planning systems generally lack a rigorous mathematical formalism to allow a reliable and flexible methodology for their design, modeling, and performance analysis in a dynamical, time-critical, and multiconstrained environment. Formulating the planning problem in the domain of discrete-event systems under a unified framework such that it can be modeled, designed, and analyzed as a control system will provide a self-contained theory for such planning systems. This will also provide a means to certify various planning systems for operations in the dynamical and complex environments in space. The work presented here completes the design, development, and analysis of an intricate, large-scale, and representative mathematical formulation for intelligent control of a real planning system for Space Station crew training. This planning system has been tested and used at NASA-Johnson Space Center.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ortiz</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<Affiliation>Johnson Space Center, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>IEEE Trans Aerosp Electron Syst</MedlineTA>
<NlmUniqueID>9876802</NlmUniqueID>
<ISSNLinking>0018-9251</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Artificial Intelligence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Astronauts</DescriptorName>
<QualifierName MajorTopicYN="Y">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Inservice Training</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Space Flight</DescriptorName>
<QualifierName MajorTopicYN="Y">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spacecraft</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Systems Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Management</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">United States National Aeronautics and Space Administration</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NASA">00028138</OtherID>
<GeneralNote Owner="NASA">Grant numbers: DAAG55-98-1-0198.</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12211241</PMID>
<DateCreated>
<Year>2002</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>03</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>297</Volume>
<Issue>5586</Issue>
<PubDate>
<Year>2002</Year>
<Month>Aug</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Mycobacterium leprae and demyelination.</ArticleTitle>
<Pagination>
<MedlinePgn>1475-6; author reply 1475-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ottenhoff</LastName>
<ForeName>Tom H M</ForeName>
<Initials>TH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Science. 2002 May 3;296(5569):927-31</RefSource>
<PMID Version="1">11988579</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacterial Adhesion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Demyelinating Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="Y">microbiology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Leprosy</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="Y">microbiology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mycobacterium leprae</DescriptorName>
<QualifierName MajorTopicYN="Y">pathogenicity</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Schwann Cells</DescriptorName>
<QualifierName MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">12211266</PMID>
<DateCreated>
<Year>2002</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1054-6863</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2002</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Kennedy Institute of Ethics journal</Title>
<ISOAbbreviation>Kennedy Inst Ethics J</ISOAbbreviation>
</Journal>
<ArticleTitle>Public policy and the sale of human organs.</ArticleTitle>
<Pagination>
<MedlinePgn>47-64</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Gill and Sade, in the preceding article in this issue of the Kennedy Institute of Ethics Journal, argue that living individuals should be free from legal constraints against selling their organs. The present commentary responds to several of their claims. It explains why an analogy between kidneys and blood fails; why, as a matter of public policy, we prohibit the sale of human solid organs, yet allow the sale of blood; and why their attack on Kant's putative argument against the sale of human body parts is misplaced. Finally, it rejects the claim that the state is entitled to interfere with the actions of individuals only if such actions would harm others. We draw certain lines grounded in what Rawls has termed "public reason" beyond which we do not give effect to the autonomous self-regarding decisions of individuals. Public resistance to the sale of human body parts, no matter how voluntary or well informed, is grounded in the conviction that such a practice would diminish human dignity and our sense of solidarity. A system of organ donation, in contrast, conveys our respect for persons and honors our common humanity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cohen</LastName>
<ForeName>Cynthia B</ForeName>
<Initials>CB</Initials>
<Affiliation>Kennedy Institute of Ethics, Georgetown University, Washington, DC, USA.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Kennedy Inst Ethics J</MedlineTA>
<NlmUniqueID>9109135</NlmUniqueID>
<ISSNLinking>1054-6863</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Blood Donors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Commodification</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ethical Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fees and Charges</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Human Body</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Kidney</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kidney Transplantation</DescriptorName>
<QualifierName MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Living Donors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Public Policy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tissue and Organ Procurement</DescriptorName>
<QualifierName MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">103573</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Analytical Approach</Keyword>
<Keyword MajorTopicYN="N">Health Care and Public Health</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">24 refs. 4 fn.</GeneralNote>
<GeneralNote Owner="KIE">KIE Bib: blood donation; organ and tissue donation</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="HMD" Status="MEDLINE">
<PMID Version="1">12219757</PMID>
<DateCreated>
<Year>2002</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>09</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1225-505X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>10</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2001</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>i sahak</Title>
<ISOAbbreviation>Uisahak</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of neurophysiology in the early twentieth century: Charles Scott Sherrington and The Integrative action of the nervous system.</ArticleTitle>
<Pagination>
<MedlinePgn>1-21</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>O J</ForeName>
<Initials>OJ</Initials>
<Affiliation>Department of the Medical History and Medical Humanities, Seoul National University College of Medicine.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Biography</PublicationType>
<PublicationType>Historical Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Korea (South)</Country>
<MedlineTA>Uisahak</MedlineTA>
<NlmUniqueID>9605018</NlmUniqueID>
<ISSNLinking>1225-505X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>Q</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Books</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, 19th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neurophysiology</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Sherrington</LastName>
<ForeName>C S</ForeName>
<Initials>CS</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>
<MedlineCitation Owner="HMD" Status="MEDLINE">
<PMID Version="1">12227380</PMID>
<DateCreated>
<Year>2002</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0269-8897</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2002</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Science in context</Title>
<ISOAbbreviation>Sci Context</ISOAbbreviation>
</Journal>
<ArticleTitle>Paracelsus, Paracelsianism, and the secularization of the worldview.</ArticleTitle>
<Pagination>
<MedlinePgn>9-27</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This paper examines Paracelsus and Paracelsianism in the light of the ideas of Max Weber concerning the social consequences of the Reformation, with special reference to his theories of Entzauberung and secularization. He linked these tendencies both to the rise of capitalism and the growth of experimental science. The detailed case study of Paracelsus' account of diseases linked with saints, in common with his interpretation of many other conditions, demonstrates that he self-consciously extended the boundaries of medicine and eroded the role of magic and witchcraft associated with the church. On the other hand, Paracelsus adopted the Neoplatonic worldview, was immersed in popular magic, and evolved a system of medicine that self-consciously revolved around magic. These factors seem to place a distinct limit on his role in the demystification of knowledge. However, the magic of Paracelsus entailed a decisive break with the entrenched elitist and esoteric tradition of the occultists and hermeticists. It is argued that this reconstructed magic re-establishes the credentials of Paracelsus as a significant contributor to the disenchantment and secularization of the worldview.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Webster</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
<Affiliation>All Souls College, Oxford.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Biography</PublicationType>
<PublicationType>Historical Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Sci Context</MedlineTA>
<NlmUniqueID>8904113</NlmUniqueID>
<ISSNLinking>0269-8897</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>Q</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Europe</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, 17th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, 20th Century</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, Early Modern 1451-1600</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Magic</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Philosophy</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Religion and Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sciatica</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Paracelsus</LastName>
</PersonalNameSubject>
<PersonalNameSubject>
<LastName>Weber</LastName>
<ForeName>Max</ForeName>
<Initials>M</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12230355</PMID>
<DateCreated>
<Year>2002</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1539-3704</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>137</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2002</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Annals of internal medicine</Title>
<ISOAbbreviation>Ann. Intern. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Screening for osteoporosis in postmenopausal women: recommendations and rationale.</ArticleTitle>
<Pagination>
<MedlinePgn>526-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<CollectiveName>U.S. Preventive Services Task Force</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Guideline</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Practice Guideline</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Ann Intern Med</MedlineTA>
<NlmUniqueID>0372351</NlmUniqueID>
<ISSNLinking>0003-4819</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Ann Intern Med. 2003 Apr 15;138(8):689; author reply 389-90</RefSource>
<PMID Version="1">12693905</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="SummaryForPatientsIn">
<RefSource>Ann Intern Med. 2002 Sep 17;137(6):I59</RefSource>
<PMID Version="1">12230384</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fractures, Bone</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mass Screening</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Osteoporosis, Postmenopausal</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12230384</PMID>
<DateCreated>
<Year>2002</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2002</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1539-3704</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>137</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2002</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Annals of internal medicine</Title>
<ISOAbbreviation>Ann. Intern. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Summaries for patients. Screening for osteoporosis: recommendations from the U.S. Preventive Services Task Force.</ArticleTitle>
<Pagination>
<MedlinePgn>I59</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Patient Education Handout</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Ann Intern Med</MedlineTA>
<NlmUniqueID>0372351</NlmUniqueID>
<ISSNLinking>0003-4819</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="OriginalReportIn">
<RefSource>Ann Intern Med. 2002 Sep 17;137(6):526-8</RefSource>
<PMID Version="1">12230355</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="OriginalReportIn">
<RefSource>Ann Intern Med. 2002 Sep 17;137(6):529-41</RefSource>
<PMID Version="1">12230356</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone Density</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fractures, Bone</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mass Screening</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Osteoporosis, Postmenopausal</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12369570</PMID>
<DateCreated>
<Year>2002</Year>
<Month>10</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>02</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">8750-7587</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>93</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2002</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of applied physiology (Bethesda, Md. : 1985)</Title>
<ISOAbbreviation>J. Appl. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Human unilateral lower limb suspension as a model for spaceflight effects on skeletal muscle.</ArticleTitle>
<Pagination>
<MedlinePgn>1563-5; author reply 1565-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Adams</LastName>
<ForeName>Gregory R</ForeName>
<Initials>GR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Appl Physiol</MedlineTA>
<NlmUniqueID>8502536</NlmUniqueID>
<ISSNLinking>0161-7567</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CitationSubset>S</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>J Appl Physiol. 2002 Jul;93(1):354-60</RefSource>
<PMID Version="1">12070225</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Bed Rest</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Immobilization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Leg</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Space Flight</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Weight-Bearing</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Discipline Musculoskeletal</Keyword>
<Keyword MajorTopicYN="N">Non-NASA Center</Keyword>
</KeywordList>
<SpaceFlightMission>Flight Experiment</SpaceFlightMission>
<SpaceFlightMission>STS-78 Shuttle Project</SpaceFlightMission>
<SpaceFlightMission>manned</SpaceFlightMission>
<SpaceFlightMission>short duration</SpaceFlightMission>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Adams</LastName>
<ForeName>G R</ForeName>
<Initials>GR</Initials>
<Affiliation>U CA, Irvine</Affiliation>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Fitts</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
<Affiliation>Vanderbilt U, Nashville, TN</Affiliation>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12416895</PMID>
<DateCreated>
<Year>2002</Year>
<Month>11</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>04</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1528-9117</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2002 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Cancer journal (Sudbury, Mass.)</Title>
<ISOAbbreviation>Cancer J</ISOAbbreviation>
</Journal>
<ArticleTitle>Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.</ArticleTitle>
<Pagination>
<MedlinePgn>377-83</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of the study was to analyze the results with radiotherapy alone in a select group of asymptomatic adults with nonbulky, early-stage lymphocyte-predominant Hodgkin's disease.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between 1963 and 1995, 36 patients with nonbulky stage IA (N = 27) or IIA (N = 9) supradiaphragmatic (N = 27) or subdiaphragmatic (N = 9) lymphocyte-predominant Hodgkin's disease were treated with radiotherapy alone. Eleven of the patients underwent laparotomy. Limited-field radiotherapy involving only one side of the diaphragm and extended-field radiotherapy encompassing both sides of the diaphragm were used in 28 and 8 cases, respectively. Median dose to involved areas was 40.0 Gy given daily in 20 2.0-Gy fractions. Salvage treatmentconsisted of MOPP (mechlorethamine, vincristine, prednisone, procarbazine), CVPP/ABDIC (cyclophosphamide, vinblastine, procarbazine and prednisone/doxorubicin, bleomycin, dacarbazine, lomustine, and prednisone), or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and/or involved-field radiotherapy.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Median follow-up was 8.8 years (range, 3.0-34.4 years). None of the 15 patients with supradiaphragmatic disease who received limited-field radiotherapy to regions that did not include the mediastinal or hilar nodes subsequently experienced relapse there. Only one of 20 patients who received supradiaphragmatic limited-field radiotherapy alone experienced relapse in the paraaortic nodes or spleen. The 5-year relapse-free and overall survival rates for the 20 patients with stage IA lymphocyte-predominant Hodgkin's disease treated with involved-field or regional radiotherapy were 95% and 100%, respectively. There were no cases of severe or life-threatening cardiac toxicity. No solid tumors have been observed in-field in patients treated with limited-field radiotherapy, even though they have been followed up longer than those treated with extended-field radiotherapy (median follow-up, 11.6 vs 5.5 years); two solid tumors have developed in-field in patients who received extended-field radiotherapy.</AbstractText>
<AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Involved-field or regional radiotherapy alone may be adequate in stage IA lymphocyte-predominant Hodgkin's disease patients. Longer follow-up will help to more clearly define the risks of cardiac toxicity and solid tumors that result from involved-field or regional radiotherapy, which appear to be low based on follow-up to date.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schlembach</LastName>
<ForeName>Pamela J</ForeName>
<Initials>PJ</Initials>
<Affiliation>Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Wilder</LastName>
<ForeName>Richard B</ForeName>
<Initials>RB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ha</LastName>
<ForeName>Chul S</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fayad</LastName>
<ForeName>Luis E</ForeName>
<Initials>LE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Younes</LastName>
<ForeName>Anas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hagemeister</LastName>
<ForeName>Fredrick</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hess</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cabanillas</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cox</LastName>
<ForeName>James D</ForeName>
<Initials>JD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA 16672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA 6294</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer J</MedlineTA>
<NlmUniqueID>100931981</NlmUniqueID>
<ISSNLinking>1528-9117</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>11056-06-7</RegistryNumber>
<NameOfSubstance>Bleomycin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>13010-47-4</RegistryNumber>
<NameOfSubstance>Lomustine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>23214-92-8</RegistryNumber>
<NameOfSubstance>Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4342-03-4</RegistryNumber>
<NameOfSubstance>Dacarbazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-75-2</RegistryNumber>
<NameOfSubstance>Mechlorethamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53-03-2</RegistryNumber>
<NameOfSubstance>Prednisone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>57-22-7</RegistryNumber>
<NameOfSubstance>Vincristine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>671-16-9</RegistryNumber>
<NameOfSubstance>Procarbazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>865-21-4</RegistryNumber>
<NameOfSubstance>Vinblastine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Protocol">ABDIC protocol</SupplMeshName>
<SupplMeshName Type="Protocol">ABVD protocol</SupplMeshName>
<SupplMeshName Type="Protocol">CVPP protocol</SupplMeshName>
<SupplMeshName Type="Protocol">MOPP protocol</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Cancer J. 2002 Sep-Oct;8(5):367-8</RefSource>
<PMID Version="1">12416892</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bleomycin</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dacarbazine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hodgkin Disease</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lomustine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mechlorethamine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prednisone</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Procarbazine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiotherapy Dosage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Salvage Therapy</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vinblastine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vincristine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12501715</PMID>
<DateCreated>
<Year>2002</Year>
<Month>12</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>01</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0559-7765</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1998</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Sheng li ke xue jin zhan [Progress in physiology]</Title>
<ISOAbbreviation>Sheng Li Ke Xue Jin Zhan</ISOAbbreviation>
</Journal>
<ArticleTitle>[Mechanism of bone mineral loss in microgravity].</ArticleTitle>
<Pagination>
<MedlinePgn>84-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Sheng Li Ke Xue Jin Zhan</MedlineTA>
<NlmUniqueID>20730140R</NlmUniqueID>
<ISSNLinking>0559-7765</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone Demineralization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Space Flight</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Weightlessness</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Weightlessness Simulation</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>10</NumberOfReferences>
<SpaceFlightMission>Cosmos 1129 Project</SpaceFlightMission>
<SpaceFlightMission>Cosmos 2044 Project</SpaceFlightMission>
<SpaceFlightMission>Flight Experiment</SpaceFlightMission>
<SpaceFlightMission>STS-51B Shuttle Project</SpaceFlightMission>
<SpaceFlightMission>STS-54 Shuttle Project</SpaceFlightMission>
<SpaceFlightMission>manned</SpaceFlightMission>
<SpaceFlightMission>short duration</SpaceFlightMission>
<SpaceFlightMission>unmanned</SpaceFlightMission>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">12599353</PMID>
<DateCreated>
<Year>2003</Year>
<Month>02</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>03</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0025-4282</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>53</Volume>
<Issue>4</Issue>
<PubDate>
<Year>1994</Year>
</PubDate>
</JournalIssue>
<Title>Maryland law review (Baltimore, Md. : 1936)</Title>
<ISOAbbreviation>MD Law Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>The new Uniform Health Care Decisions Act: paving a health care decisions superhighway?</ArticleTitle>
<Pagination>
<MedlinePgn>1238-54</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sabatino</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
<Affiliation>American Bar Association, Commission on Legal Problems of the Elderly, USA.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>MD Law Rev</MedlineTA>
<NlmUniqueID>100971842</NlmUniqueID>
<ISSNLinking>0025-4282</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Advance Directives</DescriptorName>
<QualifierName MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Legislation, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Life Support Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Personal Autonomy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proxy</DescriptorName>
<QualifierName MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Records as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">106309</OtherID>
<OtherID Source="NRCBL">Special Issue</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Death and Euthanasia</Keyword>
<Keyword MajorTopicYN="N">Legal Approach</Keyword>
<Keyword MajorTopicYN="N">Uniform Health-Care Decisions Act</Keyword>
<Keyword MajorTopicYN="Y">Uniform Rights of the Terminally Ill Act</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">Sabatino, Charles P</GeneralNote>
<GeneralNote Owner="KIE">102 fn.</GeneralNote>
<GeneralNote Owner="KIE">KIE Bib: advance directives</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="KIE" Status="MEDLINE">
<PMID Version="1">12599354</PMID>
<DateCreated>
<Year>2003</Year>
<Month>02</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>03</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0025-4282</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>53</Volume>
<Issue>4</Issue>
<PubDate>
<Year>1994</Year>
</PubDate>
</JournalIssue>
<Title>Maryland law review (Baltimore, Md. : 1936)</Title>
<ISOAbbreviation>MD Law Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>The right to refuse life-sustaining medical treatment: national trend and recent changes in Maryland law.</ArticleTitle>
<Pagination>
<MedlinePgn>1306-43</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Goldmeier</LastName>
<ForeName>K E</ForeName>
<Initials>KE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>MD Law Rev</MedlineTA>
<NlmUniqueID>100971842</NlmUniqueID>
<ISSNLinking>0025-4282</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Decision Making</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Euthanasia, Passive</DescriptorName>
<QualifierName MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Family</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Legal Guardians</DescriptorName>
<QualifierName MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Life Support Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Maryland</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Persistent Vegetative State</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Right to Die</DescriptorName>
<QualifierName MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Treatment Refusal</DescriptorName>
<QualifierName MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="KIE">106310</OtherID>
<OtherID Source="NRCBL">Special Issue</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Death and Euthanasia</Keyword>
<Keyword MajorTopicYN="N">Legal Approach</Keyword>
<Keyword MajorTopicYN="N">Mack v. Mack</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">Goldmeier, Karen E</GeneralNote>
<GeneralNote Owner="KIE">235 fn.</GeneralNote>
<GeneralNote Owner="KIE">KIE Bib: allowing to die/legal aspects; treatment refusal</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12742516</PMID>
<DateCreated>
<Year>2003</Year>
<Month>05</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2009</Year>
<Month>02</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1879-0712</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>468</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2003</Year>
<Month>May</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>European journal of pharmacology</Title>
<ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties.</ArticleTitle>
<Pagination>
<MedlinePgn>93-101</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Mitochondrial Ca(2+) accumulation can induce a sudden increase in the permeability of the inner membrane. This phenomenon is due to the generation of a large nonselective ion channel, termed the permeability transition pore (PTP), which contributes to cellular injury during ischemia and reperfusion. Inhibition of PTP generation constitutes a relevant pharmacological target to protect a cell from death. In this study, we examined the effect of S-15176 ((N-[(3,5-di-tertiobutyl-4-hydroxy-1-thiophenyl)]-3-propyl-N'-(2,3,4-trimethoxybenzyl)piperazine), a novel anti-ischemic agent, on PTP in rat liver mitochondria. S-15176 prevented PTP opening generated by various triggering agents, as attested by the concentration-dependent inhibition of mitochondrial swelling, of mitochondrial membrane potential dissipation and of NADPH oxidation. These effects were associated with an increase in the Ca(2+) loading capacity of mitochondria. S-15176 was a strong inhibitor of lipid peroxidation, but experiments with another trimetazidine derivative devoid of antioxidant activity indicated that this activity was not essential to the inhibitory effect. Binding studies demonstrated that [3H]S-15176 bound to mitochondrial binding sites, especially those localized in the inner membrane. These sites were shared by several well-known inhibitors of PTP opening. These results demonstrate that the mechanism by which S-15176 protects mitochondria against the deleterious effects of ischemia-reperfusion involves inhibition of PTP opening and provide evidence that the drug operates through low structural specificity binding sites located in the inner mitochondrial membrane.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Elimadi</LastName>
<ForeName>Aziz</ForeName>
<Initials>A</Initials>
<Affiliation>Dpartement de Pharmacologie, Facult de Mdecine de Paris XII, Crteil, France</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Jullien</LastName>
<ForeName>Vincent</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tillement</LastName>
<ForeName>Jean Paul</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morin</LastName>
<ForeName>Didier</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Eur J Pharmacol</MedlineTA>
<NlmUniqueID>1254354</NlmUniqueID>
<ISSNLinking>0014-2999</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Mitochondrial Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>S 15176</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>mitochondrial permeability transition pore</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53-59-8</RegistryNumber>
<NameOfSubstance>NADP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">NADP</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12742518</PMID>
<DateCreated>
<Year>2003</Year>
<Month>05</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2009</Year>
<Month>02</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1879-0712</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>468</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2003</Year>
<Month>May</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>European journal of pharmacology</Title>
<ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Behavioral effects of rimcazole analogues alone and in combination with cocaine.</ArticleTitle>
<Pagination>
<MedlinePgn>109-19</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Several sigma receptor ligands have been reported to also have affinity for the dopamine transporter, among them rimcazole (9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride). However, rimcazole lacks behavioral effects like those of other dopamine uptake inhibitors, such as cocaine and GBR 12909 (1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride). Because of this profile, the interactions with cocaine of rimcazole and several of its novel analogues were assessed. The compounds studied were rimcazole, its N-methyl analogue, SH 1-73 (9-[3-(cis-3,5-dimethyl-4-methyl-1-piperazinyl)-propyl]carbazole hydrobromide), the dibrominated analogue, SH 1-76 (3,6-dibromo-9-[3-(cis-3,5-dimethyl-1-piperazinyl)-propyl]carbazole hydrochloride), and the N-propylphenyl analogues, SH 3-24 ([3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]diphenylamine hydrochloride) and SH 3-28 (9-[3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]carbazole hydrobromide). The former has a diphenyl-amine group in place of the carbazole moiety of rimcazole, giving the compound additional structural similarity to GBR 12909. The rimcazole analogues produced dose-related decreases in locomotor activity, and also decreased cocaine-stimulated activity in mice. In rats trained to discriminate 10 mg/kg cocaine (i.p.) from saline injections, cocaine and GBR 12909 each produced a dose-related increase in cocaine-appropriate responding. Cocaine also increased rates of responding. SH 3-28 decreased cocaine-appropriate responding at the cocaine training dose to about 58% (SH 3-28) with two of five subjects selecting the cocaine response key. Neither rimcazole nor SH 3-24 produced a significant attenuation of the discriminative effects of cocaine. Rimcazole and its analogs all attenuated the increases in rates of responding produced by cocaine. In contrast to effects obtained with rimcazole analogs, GBR 12909 potentiated the cocaine-induced increases in locomotor activity and operant behavior, as well as the discriminative-stimulus effects of cocaine. The present results indicate that analogues of rimcazole can attenuate the behavioral effects of cocaine, and though the mechanism for these effects is not presently clear, it is possible that this attenuation maybe mediated by actions of the rimcazole analogues at the dopamine transporter and/or sigma receptors.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Katz</LastName>
<ForeName>Jonathan L</ForeName>
<Initials>JL</Initials>
<Affiliation>Department of Health and Human Services, Medications Discovery Research Branch, NIDA Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA. jkatz@intra.nida.nih.gov</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Libby</LastName>
<ForeName>Therissa A</ForeName>
<Initials>TA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kopajtic</LastName>
<ForeName>Theresa</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Husbands</LastName>
<ForeName>Stephen M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Newman</LastName>
<ForeName>Amy Hauck</ForeName>
<Initials>AH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Eur J Pharmacol</MedlineTA>
<NlmUniqueID>1254354</NlmUniqueID>
<ISSNLinking>0014-2999</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Carbazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Dopamine Plasma Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Dopamine Uptake Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, sigma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-36-2</RegistryNumber>
<NameOfSubstance>Cocaine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>75859-04-0</RegistryNumber>
<NameOfSubstance>rimcazole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Behavior, Animal</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Carbazoles</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N">agonists</QualifierName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cocaine</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Conditioning, Operant</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dopamine Uptake Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, sigma</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12742519</PMID>
<DateCreated>
<Year>2003</Year>
<Month>05</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2009</Year>
<Month>02</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1879-0712</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>468</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2003</Year>
<Month>May</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>European journal of pharmacology</Title>
<ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Risperidone reduces limited access alcohol drinking in alcohol-preferring rats.</ArticleTitle>
<Pagination>
<MedlinePgn>121-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>An atypical antipsychotic drug risperidone reduced ethanol drinking of ethanol-preferring Alko, Alcohol (AA) rats in a limited access paradigm. Its effect was transient at a dose known to preferentially antagonize the 5-HT(2) receptors (0.1 mg/kg, s.c.), but long-lasting when the dose was increased to 1.0 mg/kg that also blocks dopamine D(2) receptors. Risperidone also reduced dose-dependently locomotor activity and limited access saccharin intake of the AA rats, indicating that its effect on ethanol drinking was not selective. Risperidone at 0.1 mg/kg given before four successive daily ethanol-drinking sessions significantly reduced the ethanol intake. These data from an animal model of high ethanol intake suggest that risperidone should be tested in various populations of alcoholics for reducing ethanol consumption.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ingman</LastName>
<ForeName>Kimmo</ForeName>
<Initials>K</Initials>
<Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Honkanen</LastName>
<ForeName>Aapo</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hyyti</LastName>
<ForeName>Petri</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huttunen</LastName>
<ForeName>Matti O</ForeName>
<Initials>MO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Korpi</LastName>
<ForeName>Esa R</ForeName>
<Initials>ER</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Eur J Pharmacol</MedlineTA>
<NlmUniqueID>1254354</NlmUniqueID>
<ISSNLinking>0014-2999</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Dopamine D2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Serotonin 5-HT2 Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>106266-06-2</RegistryNumber>
<NameOfSubstance>Risperidone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>81-07-2</RegistryNumber>
<NameOfSubstance>Saccharin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Alcohol Drinking</DescriptorName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Alcoholism</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risperidone</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Saccharin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Self Administration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Serotonin 5-HT2 Receptor Antagonists</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14594616</PMID>
<DateCreated>
<Year>2003</Year>
<Month>11</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1087-2108</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>9</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2003</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Dermatology online journal</Title>
<ISOAbbreviation>Dermatol. Online J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Epidermal nevus.</ArticleTitle>
<Pagination>
<MedlinePgn>43</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A 20-year-old woman presented with an asymptomatic, life-long, verrucous, hyperpigmented plaque on the face and neck that corresponded to the lines of Blaschko. Histopathologic examination shows an epidermal nevus. This nevus presents a challenge in management because of the location and extent of the lesion.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cassetty</LastName>
<ForeName>Christopher T</ForeName>
<Initials>CT</Initials>
<Affiliation>Ronald O. Perelman Department of Dermatology, New York University, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Leonard</LastName>
<ForeName>Aimee L</ForeName>
<Initials>AL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dermatol Online J</MedlineTA>
<NlmUniqueID>9610776</NlmUniqueID>
<ISSNLinking>1087-2108</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Facial Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nevus</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Data-Review">
<PMID Version="1">14668029</PMID>
<DateCreated>
<Year>2003</Year>
<Month>12</Month>
<Day>11</Day>
</DateCreated>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1024-5332</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2003</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Hematology (Amsterdam, Netherlands)</Title>
<ISOAbbreviation>Hematology</ISOAbbreviation>
</Journal>
<ArticleTitle>Clopidogrel: Interactions with the P2Y12 Receptor and Clinical Relevance.</ArticleTitle>
<Pagination>
<MedlinePgn>359-65</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dorsam</LastName>
<ForeName>Robert T</ForeName>
<Initials>RT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Murugappan</LastName>
<ForeName>Swaminathan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Zhongren</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kunapuli</LastName>
<ForeName>Satya P</ForeName>
<Initials>SP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Hematology</MedlineTA>
<NlmUniqueID>9708388</NlmUniqueID>
<ISSNLinking>1024-5332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Data-Review">
<PMID Version="1">14668030</PMID>
<DateCreated>
<Year>2003</Year>
<Month>12</Month>
<Day>11</Day>
</DateCreated>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1024-5332</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2003</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Hematology (Amsterdam, Netherlands)</Title>
<ISOAbbreviation>Hematology</ISOAbbreviation>
</Journal>
<ArticleTitle>Platelet counts and interleukin-6 (IL-6) promoter polymorphism in patients with Gaucher disease.</ArticleTitle>
<Pagination>
<MedlinePgn>367-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Elstein</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Altarescu</LastName>
<ForeName>Gheona</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zimran</LastName>
<ForeName>Ari</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Hematology</MedlineTA>
<NlmUniqueID>9708388</NlmUniqueID>
<ISSNLinking>1024-5332</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14695699</PMID>
<DateCreated>
<Year>2003</Year>
<Month>12</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2005</Year>
<Month>04</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1226-0479</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2003</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Taehan Kan Hakhoe chi = The Korean journal of hepatology</Title>
<ISOAbbreviation>Taehan Kan Hakhoe Chi</ISOAbbreviation>
</Journal>
<ArticleTitle>[The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].</ArticleTitle>
<Pagination>
<MedlinePgn>324-31</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">The diagnosis of refractory ascites means a poor prognosis for patients with liver cirrhosis. The definition of refractory ascites has already been established, but using the dosage of diuretics that correlates with the definition of refractory ascites in an out-patient department will lower the compliance of the patient, as well as causing serious complications, such as hepatic encephalopathy and hyponatremia, as the dosage of diuretics is increased. Due to this fact, it is very difficult to apply this definition of refractory ascites to patients in a domestic out-patient department. In this study, in situations where there are difficulties in applying the diuretics dosage according to definition of refractory ascites, we tried to find out whether measuring the value of urine sodium after the administration of intravenous furosemide can be the standard in early differentiation of the response to diuretics treatment.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed 16 cases of liver cirrhosis with ascites and classified them into two groups by the response to diuretics. The diuretics-responsive ascites group was 8 cases and the diuretics-unresponsive ascites group consisted of 8 cases. After admission, we examined the patients' CBC, biochemical liver function test, spot urine sodium, and 24 hour creatinine clearance. After the beginning of the experiment, all diuretic therapy was stopped for 3 days. Daily we examined the patients' CBC, biochemical liver function test, and in the 3rd experiment day, we measured 24-hour urine volume and sodium. In the 4th experiment day, after sampling for ADH, plasma renin activity and plasma aldosterone level, we administrated the furosemide 80 mg I.V, and measured the amount of 8 hour urine volume and sodium.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The plasma aldosterone level was significantly higher in the diuretics- unresponsive ascites group than in the diuretics-responsive ascites group. In the 4th experiment day, the amount of urine volume and sodium was very significantly lower in the diuretics-unresponsive ascites group than in the diuretics-responsive ascites group (1297.5 +/-80.9 vs 2003.7 +/-114.6 ml, p&lt;0.005, 77.3 +/-8.2 vs 211.8 +/-12.6 mEq, p&lt;0.001).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In out-patient departments, the measurement of urine sodium 8 hours after administrating 80 mg of intravenous furosemide, will help in differentiating ascites patients with lower treatment response to diuretics.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Hyun Seok</ForeName>
<Initials>HS</Initials>
<Affiliation>Research Institute of Digestive Disease, Hanyang University College of Medicine, Seoul, Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Geun Tae</ForeName>
<Initials>GT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Young Hoon</ForeName>
<Initials>YH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shim</LastName>
<ForeName>Sung Gon</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jin Bae</ForeName>
<Initials>JB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Oh Young</ForeName>
<Initials>OY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Ho Soon</ForeName>
<Initials>HS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hahm</LastName>
<ForeName>Joon Soo</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Min Ho</ForeName>
<Initials>MH</Initials>
</Author>
</AuthorList>
<Language>kor</Language>
<PublicationTypeList>
<PublicationType>English Abstract</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Korea (South)</Country>
<MedlineTA>Taehan Kan Hakhoe Chi</MedlineTA>
<NlmUniqueID>9607534</NlmUniqueID>
<ISSNLinking>1226-0479</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Diuretics</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>54-31-9</RegistryNumber>
<NameOfSubstance>Furosemide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-23-5</RegistryNumber>
<NameOfSubstance>Sodium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ascites</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">urine</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diuretics</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Furosemide</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sodium</DescriptorName>
<QualifierName MajorTopicYN="Y">urine</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14729922</PMID>
<DateCreated>
<Year>2004</Year>
<Month>01</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>02</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1362-4962</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2004</Year>
</PubDate>
</JournalIssue>
<Title>Nucleic acids research</Title>
<ISOAbbreviation>Nucleic Acids Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Local homology recognition and distance measures in linear time using compressed amino acid alphabets.</ArticleTitle>
<Pagination>
<MedlinePgn>380-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Methods for discovery of local similarities and estimation of evolutionary distance by identifying k-mers (contiguous subsequences of length k) common to two sequences are described. Given unaligned sequences of length L, these methods have O(L) time complexity. The ability of compressed amino acid alphabets to extend these techniques to distantly related proteins was investigated. The performance of these algorithms was evaluated for different alphabets and choices of k using a test set of 1848 pairs of structurally alignable sequences selected from the FSSP database. Distance measures derived from k-mer counting were found to correlate well with percentage identity derived from sequence alignments. Compressed alphabets were seen to improve performance in local similarity discovery, but no evidence was found of improvements when applied to distance estimates. The performance of our local similarity discovery method was compared with the fast Fourier transform (FFT) used in MAFFT, which has O(L log L) time complexity. The method for achieving comparable coverage to FFT is revealed here, and is more than an order of magnitude faster. We suggest using k-mer distance for fast, approximate phylogenetic tree construction, and show that a speed improvement of more than three orders of magnitude can be achieved relative to standard distance methods, which require alignments.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Edgar</LastName>
<ForeName>Robert C</ForeName>
<Initials>RC</Initials>
<Affiliation>bob@drive5.com</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2004</Year>
<Month>01</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nucleic Acids Res</MedlineTA>
<NlmUniqueID>0411011</NlmUniqueID>
<ISSNLinking>0305-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Amino Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Proteins. 2000 Feb 1;38(2):149-64</RefSource>
<PMID Version="1">10656262</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2002 Jul 15;30(14):3059-66</RefSource>
<PMID Version="1">12136088</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Comput Biol. 2000 Feb-Apr;7(1-2):1-46</RefSource>
<PMID Version="1">10890386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Evol. 2002 Jan;19(1):8-13</RefSource>
<PMID Version="1">11752185</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1998 Jan 1;26(1):316-9</RefSource>
<PMID Version="1">9399863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 2003 Feb 7;326(1):317-36</RefSource>
<PMID Version="1">12547212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioinformatics. 2003 Mar 1;19(4):513-23</RefSource>
<PMID Version="1">12611807</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Protein Eng. 2003 May;16(5):323-30</RefSource>
<PMID Version="1">12826723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Theor Biol. 1986 Mar 21;119(2):205-18</RefSource>
<PMID Version="1">3461222</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Evol. 1987 Jul;4(4):406-25</RefSource>
<PMID Version="1">3447015</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444-8</RefSource>
<PMID Version="1">3162770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1990 Oct 5;215(3):403-10</RefSource>
<PMID Version="1">2231712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1991 Jun 5;219(3):555-65</RefSource>
<PMID Version="1">2051488</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Comput Appl Biosci. 1992 Jun;8(3):275-82</RefSource>
<PMID Version="1">1633570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10915-9</RefSource>
<PMID Version="1">1438297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1994 Nov 11;22(22):4673-80</RefSource>
<PMID Version="1">7984417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Int Conf Intell Syst Mol Biol. 1996;4:230-40</RefSource>
<PMID Version="1">8877523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Protein Eng. 2000 Mar;13(3):149-52</RefSource>
<PMID Version="1">10775656</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acids</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Computational Biology</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Evolution, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phylogeny</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sequence Alignment</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Sequence Homology, Amino Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Software</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC373290</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14744982</PMID>
<DateCreated>
<Year>2004</Year>
<Month>01</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1362-4962</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2004</Year>
</PubDate>
</JournalIssue>
<Title>Nucleic acids research</Title>
<ISOAbbreviation>Nucleic Acids Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Superior 5' homogeneity of RNA from ATP-initiated transcription under the T7 phi 2.5 promoter.</ArticleTitle>
<Pagination>
<MedlinePgn>e14</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Transcription from the commonly used GTP- initiating T7 class III promoter phi6.5 frequently produces heterogeneous RNA at both 3' and 5' ends. We demonstrate here that RNA transcripts from the T7 class II promoter phi2.5 have superior 5' homogeneity over those from the phi6.5 promoter, with comparable total RNA yields. The overall homogeneity of RNA transcripts is improved to different degrees depending on RNA sequences, although transcription under phi2.5 does not affect the 3' heterogeneity of RNA. In combination with 3' RNA trimming by DNAzymes or ribozymes, this ATP- initiated transcription system based on the T7 phi2.5 promoter can provide excellent quality of RNA for applications requiring a high degree of RNA size homogeneity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Coleman</LastName>
<ForeName>Tricia M</ForeName>
<Initials>TM</Initials>
<Affiliation>Department of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, MS 39406-5043, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Guocan</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Faqing</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2004</Year>
<Month>01</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nucleic Acids Res</MedlineTA>
<NlmUniqueID>0411011</NlmUniqueID>
<ISSNLinking>0305-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>5' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-65-5</RegistryNumber>
<NameOfSubstance>Adenosine Triphosphate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Struct Biol. 2000 Jun;10(3):298-302</RefSource>
<PMID Version="1">10851189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 2000 Dec 19;39(50):15548-55</RefSource>
<PMID Version="1">11112541</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods. 2001 Mar;23(3):201-5</RefSource>
<PMID Version="1">11243833</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2002 Jun 15;30(12):e56</RefSource>
<PMID Version="1">12060694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chem Biol. 2002 Nov;9(11):1227-36</RefSource>
<PMID Version="1">12445773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2003 Feb 1;31(3):e8</RefSource>
<PMID Version="1">12560511</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2003 Aug 1;31(15):e82</RefSource>
<PMID Version="1">12888534</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1996 Sep 20;273(5282):1678-85</RefSource>
<PMID Version="1">8781224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1996 Mar 1;24(5):977-8</RefSource>
<PMID Version="1">8600468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods Enzymol. 1995;261:350-80</RefSource>
<PMID Version="1">8569503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods Enzymol. 1995;261:300-22</RefSource>
<PMID Version="1">8569501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1995 Jun 2;249(2):398-408</RefSource>
<PMID Version="1">7540213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>RNA. 1999 Sep;5(9):1268-72</RefSource>
<PMID Version="1">10496227</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>RNA. 1999 May;5(5):618-21</RefSource>
<PMID Version="1">10334331</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1998 Oct 9;282(5387):259-64</RefSource>
<PMID Version="1">9841391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>RNA. 1998 Oct;4(10):1313-7</RefSource>
<PMID Version="1">9769105</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4262-6</RefSource>
<PMID Version="1">9113977</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chembiochem. 2003 Oct 6;4(10):936-62</RefSource>
<PMID Version="1">14523911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>RNA. 2003 Dec;9(12):1562-70</RefSource>
<PMID Version="1">14624011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1983 Jun 5;166(4):477-535</RefSource>
<PMID Version="1">6864790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1987 Nov 11;15(21):8783-98</RefSource>
<PMID Version="1">3684574</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1988 Dec 5;263(34):18123-7</RefSource>
<PMID Version="1">3192528</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1992 Jan 9;355(6356):184-6</RefSource>
<PMID Version="1">1370345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1992 Sep 11;20(17):4515-23</RefSource>
<PMID Version="1">1383928</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3680-4</RefSource>
<PMID Version="1">7682716</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1994 Nov 3;372(6501):68-74</RefSource>
<PMID Version="1">7969422</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">3' Untranslated Regions</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">5' Untranslated Regions</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacteriophage T7</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Weight</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC373309</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14749521</PMID>
<DateCreated>
<Year>2004</Year>
<Month>01</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>02</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1539-6150</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>2004</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2004</Year>
<Month>Jan</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Science of aging knowledge environment : SAGE KE</Title>
<ISOAbbreviation>Sci Aging Knowledge Environ</ISOAbbreviation>
</Journal>
<ArticleTitle>Hampering a heartbreaker. Antibiotic might stem injury from heart attack.</ArticleTitle>
<Pagination>
<MedlinePgn>nf13</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A TV ad urges people who think they're having a heart attack to pop an aspirin before rushing to the emergency room. They might be even better off taking antibiotics, according to a new study. The work shows that an antibiotic stems a previously untreatable form of heart damage not by killing bugs but by suppressing cellular enzymes.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leslie</LastName>
<ForeName>Mitch</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>News</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2004</Year>
<Month>01</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Sci Aging Knowledge Environ</MedlineTA>
<NlmUniqueID>101146039</NlmUniqueID>
<ISSNLinking>1539-6150</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-75-7</RegistryNumber>
<NameOfSubstance>Chloramphenicol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chloramphenicol</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Infarction</DescriptorName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Ischemia</DescriptorName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14991249</PMID>
<DateCreated>
<Year>2004</Year>
<Month>04</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2005</Year>
<Month>03</Month>
<Day>15</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0364-2348</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>33</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2004</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Skeletal radiology</Title>
<ISOAbbreviation>Skeletal Radiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Spontaneous resolution of solitary osteochondroma in the young adult.</ArticleTitle>
<Pagination>
<MedlinePgn>303-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Spontaneous resolution of a solitary osteochondroma is rare. Such a case is presented in a patient nearing skeletal maturity. Based on a search of the English literature this is the first such report in a patient of this age.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Reston</LastName>
<ForeName>S C</ForeName>
<Initials>SC</Initials>
<Affiliation>Department of Orthopaedics, Queen Alexandra Hospital, Portsmouth, UK.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Savva</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Richards</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2004</Year>
<Month>02</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Skeletal Radiol</MedlineTA>
<NlmUniqueID>7701953</NlmUniqueID>
<ISSNLinking>0364-2348</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Femur</DescriptorName>
<QualifierName MajorTopicYN="Y">radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Osteochondroma</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Remission, Spontaneous</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">11431089</PMID>
<DateCreated>
<Year>2004</Year>
<Month>04</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2005</Year>
<Month>06</Month>
<Day>08</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0924-7947</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>7</Volume>
<PubDate>
<Year>2001</Year>
</PubDate>
</JournalIssue>
<Title>Archives of gerontology and geriatrics. Supplement</Title>
<ISOAbbreviation>Arch Gerontol Geriatr Suppl</ISOAbbreviation>
</Journal>
<ArticleTitle>An investigation on behavioral problems in centenarians.</ArticleTitle>
<Pagination>
<MedlinePgn>375-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tafaro</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<Affiliation>Department of Aging Science, Policlinico Umberto I, University La Sapienza, Roma, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cicconetti</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martella</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tedeschi</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zannino</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Troisi</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pastena</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fioravanti</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marigliano</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Arch Gerontol Geriatr Suppl</MedlineTA>
<NlmUniqueID>8911786</NlmUniqueID>
<ISSNLinking>0924-7947</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15110832</PMID>
<DateCreated>
<Year>2004</Year>
<Month>04</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>12</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0968-0896</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2004</Year>
<Month>May</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Bioorganic &amp; medicinal chemistry</Title>
<ISOAbbreviation>Bioorg. Med. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Aminyl and iminyl radicals from arylhydrazones in the photo-induced DNA cleavage.</ArticleTitle>
<Pagination>
<MedlinePgn>2509-15</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Photolytic cleavage of the nitrogen-nitrogen single bond in benzaldehyde phenylhydrazones produced aminyl (R2N*) and iminyl (R2C=N*) radicals. This photochemical property was utilized in the development of hydrazones as photo-induced DNA-cleaving agents. Irradiation with 350 nm UV light of arylhydrazones bearing substituents of various types in a phosphate buffer solution containing the supercoiled circular phiX174 RFI DNA at pH 6.0 resulted in single-strand cleavage of DNA. Attachment of the electron-donating OMe group to arylhydrazones increased their DNA-cleaving activity. Results from systematic studies indicate that both the aminyl and the iminyl radicals possessed DNA-cleaving ability.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hwu</LastName>
<ForeName>Jih Ru</ForeName>
<Initials>JR</Initials>
<Affiliation>Institute of Chemistry, Academia Sinica, Nankang, Taipei 11529, Taiwan, ROC. jrhwu@mx.nthu.edu.tw</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Chun Chieh</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chuang</LastName>
<ForeName>Shih Hsien</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>King</LastName>
<ForeName>Ke Yung</ForeName>
<Initials>KY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Su</LastName>
<ForeName>Tzu-Rong</ForeName>
<Initials>TR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tsay</LastName>
<ForeName>Shwu-Chen</ForeName>
<Initials>SC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Bioorg Med Chem</MedlineTA>
<NlmUniqueID>9413298</NlmUniqueID>
<ISSNLinking>0968-0896</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Hydrazones</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hydrazones</DescriptorName>
<QualifierName MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Photolysis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">15117668</PMID>
<DateCreated>
<Year>2004</Year>
<Month>04</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>05</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-2895</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>22</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1990</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of motor behavior</Title>
<ISOAbbreviation>J Mot Behav</ISOAbbreviation>
</Journal>
<ArticleTitle>The First Conference on Motor Control in Down Syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>444-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Latash</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Mot Behav</MedlineTA>
<NlmUniqueID>0236512</NlmUniqueID>
<ISSNLinking>0022-2895</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15206831</PMID>
<DateCreated>
<Year>2004</Year>
<Month>06</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>07</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0896-4289</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>29</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2003</Year>
<Season>Fall</Season>
</PubDate>
</JournalIssue>
<Title>Behavioral medicine (Washington, D.C.)</Title>
<ISOAbbreviation>Behav Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Warm partner contact is related to lower cardiovascular reactivity.</ArticleTitle>
<Pagination>
<MedlinePgn>123-30</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The authors investigated the relationship between brief warm social and physical contact among cohabitating couples and blood pressure (BP) reactivity to stress in a sample of healthy adults (66 African American, 117 Caucasian; 74 women, 109 men). Prior to stress, the warm contact group underwent a 10-minute period of handholding while viewing a romantic video. Followed by a 20-second hug with their partner, while the no contact group rested quietly for 10 minutes and 20 seconds. In response to a public speaking task, individuals receiving prestress partner contact demonstrated lower systolic BP diastolic BP, and heart rate increases compared with the no contact group. The effects of warm contact were comparable for men and women and were greater for African Americans compared with Caucasians. These findings suggest that affectionate relationships with a supportive partner may contribute to lower reactivity to stressful life events and may partially mediate the benefit of marital support on better cardiovascular health.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Grewen</LastName>
<ForeName>Karen M</ForeName>
<Initials>KM</Initials>
<Affiliation>Department of Psychiatry, University of North Carolina at Chapel Hill, 27599-7175, USA. karen_grewen@med.unc.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Anderson</LastName>
<ForeName>Bobbi J</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Girdler</LastName>
<ForeName>Susan S</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Light</LastName>
<ForeName>Kathleen C</ForeName>
<Initials>KC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HL64927</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RR00046</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Behav Med</MedlineTA>
<NlmUniqueID>8804264</NlmUniqueID>
<ISSNLinking>0896-4289</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Affect</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Blood Pressure</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Body Temperature</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Rate</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Life Change Events</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Marriage</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Speech</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Spouses</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Touch</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15228064</PMID>
<DateCreated>
<Year>2004</Year>
<Month>07</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>08</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1080-6032</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2004</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Wilderness &amp; environmental medicine</Title>
<ISOAbbreviation>Wilderness Environ Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Acute coronary ischemia following centipede envenomation: case report and review of the literature.</ArticleTitle>
<Pagination>
<MedlinePgn>109-12</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This is the first known case report of electrocardiographic (ECG) changes suggestive of coronary vasospasm following a centipede envenomation. A 60-year-old man presented to the emergency department (ED) 1 hour after being stung by a 12-cm centipede. He complained of right great toe pain that did not radiate to his leg. The patient had no known ischemic heart disease. He did not describe any exertional symptoms but admitted experiencing weakness. During the ED course, concurrent with obtaining peripheral intravenous access, the patient experienced diaphoresis, dizziness, hypotension, and bradycardia. His ECG showed new ST-T wave changes, which suggested an acute ischemic process. The patient's blood pressure was 89/60 mm Hg, his pulse rate was 47 beats/min, and his respiration rate was 28 breaths/min. In the following hours, ECG findings returned to baseline. His blood pressure improved gradually with fluid resuscitation after approximately 5 hours. Cardiac markers returned to normal in the 13th hour after the event, and the patient underwent exercise stress testing, which was negative. The patient was discharged with cardiology follow-up. Adult patients with centipede envenomation should be closely monitored in anticipation of possible myocardial ischemia due to vasospasm, hypotension, and myocardial toxic effects of the venom. A child receiving the same amount of venom would be potentially at greater risk.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ozsarac</LastName>
<ForeName>Murat</ForeName>
<Initials>M</Initials>
<Affiliation>Dokuz Eylul University School of Medicine, Department of Emergency Medicine, Inciralti, Izmir, Turkey. mozsarac@hotmail.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Karcioglu</LastName>
<ForeName>Ozgur</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ayrik</LastName>
<ForeName>Cuneyt</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Somuncu</LastName>
<ForeName>Fatih</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gumrukcu</LastName>
<ForeName>Serhat</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Wilderness Environ Med</MedlineTA>
<NlmUniqueID>9505185</NlmUniqueID>
<ISSNLinking>1080-6032</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Arachnidism</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Arthropods</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electrocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Emergency Treatment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Ischemia</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>18</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">15278624</PMID>
<DateCreated>
<Year>2004</Year>
<Month>07</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted>
<Year>2005</Year>
<Month>02</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0913-8668</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>5</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1991</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Journal of anesthesia</Title>
<ISOAbbreviation>J Anesth</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypoxic ventilatory response in cats lightly anesthetized with ketamine: effects of halothane and sevoflurane in low concentrations.</ArticleTitle>
<Pagination>
<MedlinePgn>233-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The effect of low concentration sevoflurane and halothane on the ventilatory response to isocapnic hypoxia was studied in sixteen cats. The cats were divided into two groups, sevoflurane group and halothane group, of eight subjects each. As parameters of the hypoxic ventilatory response, A value [the slope of the hyperbolic curve, V(E) = V(0) + A/(Pa(O)(2)-32)] and ratio of V(50) (the minute volume obtained from the hyperbolic equation when Pa(O)(2) = 50 mmHg) to V(0) were studied. These two parameters were examined at three states, sedative state with ketamine as the control, ketamine plus 0.1 MAC inhalation anesthetic, and ketamine plus 0.5 MAC inhalation anesthetic. In the sevoflurane group, the A values were 4789 +/- 1518, 2187 +/- 1214, 1730 +/- 880 (mean +/- SE. ml.min(-1).mmHg) at the control state, 0.1 MAC and 0.5 MAC, respectively. In the halothane group, the A values were 6411 +/- 2368, 2529 +/- 842 and 2372 +/- 545, respectively. The ratios of V(50) to V(0) were 1.32 +/- 0.09, 1.22 +/- 0.09, 1.25 +/- 0.08 in the sevoflurane group, 1.47 +/- 0.18, 1.32 +/- 0.11, 1.54 +/- 0.18 in the halothane group, respectively. The A value at 0.1 MAC of the halothane group was less than the control value significantly. This proved that even low concentration halothane depressed the hypoxic ventilatory responses. The depression of hypoxic ventilatory response could cause postanesthetic hypoventilation. On the other hand, we could not find significant depression on the hypoxic ventilatory response in the sevoflurane group, but we should notice that variances of the hypoxic ventilatory response were large.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tamura</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<Affiliation>Department of Anesthesiology and Critical Care Medicine, Hamamatsu University School of Medicine, Japan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Doi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ikeda</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>J Anesth</MedlineTA>
<NlmUniqueID>8905667</NlmUniqueID>
<ISSNLinking>0913-8668</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">15284444</PMID>
<DateCreated>
<Year>2004</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>09</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2010</Year>
<Month>09</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>101</Volume>
<Issue>32</Issue>
<PubDate>
<Year>2004</Year>
<Month>Aug</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tubular precipitation and redox gradients on a bubbling template.</ArticleTitle>
<Pagination>
<MedlinePgn>11537-41</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Tubular structures created by precipitation abound in nature, from chimneys at hydrothermal vents to soda straws in caves. Their formation is controlled by chemical gradients within which precipitation occurs, defining a surface that templates the growing structure. We report a self-organized periodic templating mechanism producing tubular structures electrochemically in iron-ammonium-sulfate solutions; iron oxides precipitate on the surface of bubbles that linger at the tube rim and then detach, leaving behind a ring of material. The acid-base and redox gradients spontaneously generated by diffusion of ammonia from the bubble into solution organize radial compositional layering within the tube wall, a mechanism studied on a larger scale by complex Liesegang patterns of iron oxides formed as ammonia diffuses through a gel containing FeSO(4). When magnetite forms within the wall, a tube may grow curved in an external magnetic field. Connections with free-boundary problems in speleothem formation are emphasized.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stone</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
<Affiliation>Department of Soil, Water, and Environmental Science, Program in Applied Mathematics, University of Arizona, Tucson, AZ 85721, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Goldstein</LastName>
<ForeName>Raymond E</ForeName>
<Initials>RE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2004</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>J Geol Soc London. 1997 May;154(3):377-402</RefSource>
<PMID Version="1">11541234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2002 May 9;417(6885):139</RefSource>
<PMID Version="1">12000951</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Philos Trans R Soc Lond B Biol Sci. 2003 Jan 29;358(1429):59-83; discussion 83-5</RefSource>
<PMID Version="1">12594918</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Chem Soc. 2003 Apr 9;125(14):4338-41</RefSource>
<PMID Version="1">12670257</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2003 Oct 24;302(5645):580-1</RefSource>
<PMID Version="1">14576411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2004 Mar 12;303(5664):1656-8</RefSource>
<PMID Version="1">15016997</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<OtherID Source="NLM">PMC511016</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">5757641</PMID>
<DateCreated>
<Year>1970</Year>
<Month>03</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>1970</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2003</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<PubDate>
<Year>1968</Year>
</PubDate>
</JournalIssue>
<Title>Trudy Instituta fiziologii, Akademiia nauk Gruzinsko SSR</Title>
<ISOAbbreviation>Tr Inst Fiz Akad Nauk Gruz Ssr</ISOAbbreviation>
</Journal>
<ArticleTitle>[The effect of immediate stimulation of the hippocampus on reflex reactions in animals].</ArticleTitle>
<Pagination>
<MedlinePgn>86-96</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tevzadze</LastName>
<ForeName>V G</ForeName>
<Initials>VG</Initials>
</Author>
</AuthorList>
<Language>geo</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>O vliianii neposredstvennogo razdrazheniia gippokampa na reflektornye reaktsii zhivotnykh.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>USSR</Country>
<MedlineTA>Tr Inst Fiz Akad Nauk Gruz Ssr</MedlineTA>
<NlmUniqueID>7507618</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electric Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hippocampus</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Reflex</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">973217</PMID>
<DateCreated>
<Year>1976</Year>
<Month>12</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>1976</Year>
<Month>12</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2002</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0095-3814</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>3</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1976</Year>
<Season>Fall</Season>
</PubDate>
</JournalIssue>
<Title>Topics in health care financing</Title>
<ISOAbbreviation>Top Health Care Financ</ISOAbbreviation>
</Journal>
<ArticleTitle>Hospital debt management and cost reimbursement.</ArticleTitle>
<Pagination>
<MedlinePgn>69-81</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Blume</LastName>
<ForeName>F R</ForeName>
<Initials>FR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Top Health Care Financ</MedlineTA>
<NlmUniqueID>7509107</NlmUniqueID>
<ISSNLinking>0095-3814</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Accounting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Economics, Hospital</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Hospital Administration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">3549656</PMID>
<DateCreated>
<Year>1987</Year>
<Month>05</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>1987</Year>
<Month>05</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0021-8820</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>40</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1987</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of antibiotics</Title>
<ISOAbbreviation>J. Antibiot.</ISOAbbreviation>
</Journal>
<ArticleTitle>Semisynthetic beta-lactam antibiotics. III. Effect on antibacterial activity and comt-susceptibility of chlorine-introduction into the catechol nucleus of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic acid.</ArticleTitle>
<Pagination>
<MedlinePgn>22-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The resistance of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic acid (1a) to metabolism by catechol-O-methyl-transferase (COMT) was increased by introduction of the chlorine atom into the catechol moiety. Penicillins (1b-1d) having one or two chlorine atoms at the positions adjacent to the hydroxyl group were found to have greater stability to COMT. This resulted in greater efficiency in vivo in experimental Pseudomonas aeruginosa and Escherichia coli infections. In vitro activities were essentially unchanged.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ohi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aoki</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuroki</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matsumoto</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kojima</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nehashi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>JAPAN</Country>
<MedlineTA>J Antibiot (Tokyo)</MedlineTA>
<NlmUniqueID>0151115</NlmUniqueID>
<ISSNLinking>0021-8820</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Indicators and Reagents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Penicillins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>beta-Lactams</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>88852-54-4</RegistryNumber>
<NameOfSubstance>6-(2-(3-(5-chloro-3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido)-2-phenylacetamido)penicillanic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>92773-65-4</RegistryNumber>
<NameOfSubstance>6-(2-(3-(2-chloro-3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido)-2-phenylacetamido)penicillanic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>92773-66-5</RegistryNumber>
<NameOfSubstance>6-(2-(3-(2,5-dichloro-3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido)-2-phenylacetamido)penicillanic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.6</RegistryNumber>
<NameOfSubstance>Catechol O-Methyltransferase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacteria</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Escherichia coli Infections</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Indicators and Reagents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Penicillins</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pseudomonas Infections</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">beta-Lactams</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">1875346</PMID>
<DateCreated>
<Year>1991</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>1991</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-2623</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>34</Volume>
<Issue>8</Issue>
<PubDate>
<Year>1991</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of medicinal chemistry</Title>
<ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives.</ArticleTitle>
<Pagination>
<MedlinePgn>2489-95</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Modification of the hexahydronaphthalene ring 5-position in simvastatin 2a via oxygenation and oxa replacement afforded two series of derivatives which were evaluated in vitro for inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and acutely in vivo for oral effectiveness as inhibitors of cholesterogenesis in the rat. Of the compounds selected for further biological evaluation, the 6 beta-methyl-5-oxa 10 and 5 alpha-hydroxy 16 derivatives of 3,4,4a,5-tetrahydro 2a, as well as, the 6 beta-epimer 14 of 16 proved orally active as hypocholesterolemic agents in cholestyramine-primed dogs. Subsequent acute oral metabolism studies in dogs demonstrated that compounds 14 and 16 evoke lower peak plasma drug activity and area-under-the-curve values than does compound 10 and led to the selection of 14 and 16 for toxicological evaluation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="N">
<Author ValidYN="Y">
<LastName>Duggan</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
<Affiliation>Merck Sharp &amp; Dohme Research Laboratories, West Point, Pennsylvania 19486.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Alberts</LastName>
<ForeName>A W</ForeName>
<Initials>AW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bostedor</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chao</LastName>
<ForeName>Y S</ForeName>
<Initials>YS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Germershausen</LastName>
<ForeName>J I</ForeName>
<Initials>JI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gilfillan</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Halczenko</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hartman</LastName>
<ForeName>G D</ForeName>
<Initials>GD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hunt</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Imagire</LastName>
<ForeName>J S</ForeName>
<Initials>JS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>J Med Chem</MedlineTA>
<NlmUniqueID>9716531</NlmUniqueID>
<ISSNLinking>0022-2623</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>6-(2-(8-(2,2-dimethylbutyryl)oxy)-2,6-dimethyl-5-hydroxy-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Acetates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anticholesteremic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>57-88-5</RegistryNumber>
<NameOfSubstance>Cholesterol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>75330-75-5</RegistryNumber>
<NameOfSubstance>Lovastatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7782-44-7</RegistryNumber>
<NameOfSubstance>Oxygen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>79902-63-9</RegistryNumber>
<NameOfSubstance>Simvastatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acetates</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anticholesteremic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chemical Phenomena</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cholesterol</DescriptorName>
<QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lovastatin</DescriptorName>
<QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Oxygen</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Simvastatin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">1669026</PMID>
<DateCreated>
<Year>1993</Year>
<Month>11</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>1993</Year>
<Month>11</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0377-8231</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>Anniv No Pt 1</Volume>
<PubDate>
<Year>1991</Year>
</PubDate>
</JournalIssue>
<Title>Bulletin et mmoires de l'Acadmie royale de mdecine de Belgique</Title>
<ISOAbbreviation>Bull. Mem. Acad. R. Med. Belg.</ISOAbbreviation>
</Journal>
<ArticleTitle>[150th Anniversary Celebration of the Royal Academy of Medicine of Belgium. Part 1. Bruxelles, 26-28 September 1991].</ArticleTitle>
<Pagination>
<MedlinePgn>1-191</MedlinePgn>
</Pagination>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType>Congresses</PublicationType>
<PublicationType>Overall</PublicationType>
<PublicationType>Portraits</PublicationType>
</PublicationTypeList>
<VernacularTitle>Clbration du CL Anniversaire de l'Acadmie Royal de Mdecine de Belgique. Premire partie. Bruxelles, 26-28 septembre 1991.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>BELGIUM</Country>
<MedlineTA>Bull Mem Acad R Med Belg</MedlineTA>
<NlmUniqueID>7608462</NlmUniqueID>
<ISSNLinking>0377-8231</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Academies and Institutes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">8219565</PMID>
<DateCreated>
<Year>1993</Year>
<Month>12</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>1993</Year>
<Month>12</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1051-0443</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>1993 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of vascular and interventional radiology : JVIR</Title>
<ISOAbbreviation>J Vasc Interv Radiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Transcatheter manipulation of asymmetrically opened titanium Greenfield filters.</ArticleTitle>
<Pagination>
<MedlinePgn>687-90</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The problem of asymmetric opening of the modified hook titanium Greenfield inferior vena cava filter necessitating transcatheter manipulation was evaluated in a retrospective study.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Titanium Greenfield filters were placed in 166 patients over a 36-month period. The radiographic reports of all patients were reviewed to identify cases in which the filter failed to open symmetrically after deployment and catheter or wire manipulation of the filter was performed. The reports and angiograms from these patients were reviewed with respect to the circumstances surrounding filter placement and methods to achieve more symmetric opening.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Transcatheter manipulation of asymmetrically opened filters was performed in 15 of 166 cases (9%). In 12 of these patients, acceptable and uneventful opening of the filter was achieved with a guide wire, pigtail catheter, or occlusion balloon catheter. In one case manipulation only partly improved orientation of the limbs, while in another case successful manipulation was complicated by distal migration. In the final case, the asymmetric filter covered only part of the lumen of the vena cava despite manipulations and a second filter was placed for optimal caval interruption. No specific cause for incomplete expansion was identified in any case.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Marked asymmetry in opening of the modified hook titanium Greenfield filter that warrants manipulation occurs infrequently, but recognition and proper management may be important to ensure optimal caval interruption.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moore</LastName>
<ForeName>B S</ForeName>
<Initials>BS</Initials>
<Affiliation>Department of Radiology, University of California at San Diego 92103.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Valji</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bookstein</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>J Vasc Interv Radiol</MedlineTA>
<NlmUniqueID>9203369</NlmUniqueID>
<ISSNLinking>1051-0443</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>7440-32-6</RegistryNumber>
<NameOfSubstance>Titanium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Vasc Interv Radiol. 1993 Sep-Oct;4(5):617-20</RefSource>
<PMID Version="1">8219555</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Vasc Interv Radiol. 1994 May-Jun;5(3):526-7</RefSource>
<PMID Version="1">8054760</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Vasc Interv Radiol. 1994 May-Jun;5(3):528-32</RefSource>
<PMID Version="1">8054761</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Catheterization, Central Venous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Titanium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Vena Cava Filters</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vena Cava, Inferior</DescriptorName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">8119288</PMID>
<DateCreated>
<Year>1994</Year>
<Month>04</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1994</Year>
<Month>04</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>07</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0014-2956</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>220</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1994</Year>
<Month>Feb</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>European journal of biochemistry / FEBS</Title>
<ISOAbbreviation>Eur. J. Biochem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Purification and characterisation of a water-soluble ferrochelatase from Bacillus subtilis.</ArticleTitle>
<Pagination>
<MedlinePgn>201-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Bacillus subtilis ferrochelatase is encoded by the hemH gene of the hemEHY gene cluster and catalyses the incorporation of Fe2+ into protoporphyrin IX. B. subtilis ferrochelatase produced in Escherichia coli was purified. It was found to be a monomeric, water-soluble enzyme of molecular mass 35 kDa which in addition to Fe2+ can incorporate Zn2+ and Cu2+ into protoporphyrin IX. Chemical modification experiments indicated that the single cysteine residue in the ferrochelatase is required for enzyme activity although it is not a conserved residue compared to other ferrochelatases. In growing B. subtilis, the ferrochelatase constitutes approximately 0.05% (by mass) of the total cell protein, which corresponds to some 600 ferrochelatase molecules/cell. The turnover number of isolated ferrochelatase, 18-29 min-1, was found to be consistent with the rate of haem synthesis in exponentially growing cells (0.2 mol haem formed/min/mol enzyme). It is concluded that the B. subtilis ferrochelatase has enzymic properties which are similar to those of other characterised ferrochelatases of known primary structure, i.e. ferrochelatases of the mitochondrial inner membrane of yeast and mammalian cells. However, in contrast to these enzymes the B. subtilis enzyme is a water-soluble protein and should be more amenable to structural analysis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hansson</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Microbiology, Lund University, Sweden.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hederstedt</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Eur J Biochem</MedlineTA>
<NlmUniqueID>0107600</NlmUniqueID>
<ISSNLinking>0014-2956</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>7732-18-5</RegistryNumber>
<NameOfSubstance>Water</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.99.1.1</RegistryNumber>
<NameOfSubstance>Ferrochelatase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<GeneSymbolList>
<GeneSymbol>hemE</GeneSymbol>
<GeneSymbol>hemH</GeneSymbol>
<GeneSymbol>hemY</GeneSymbol>
</GeneSymbolList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacillus subtilis</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Catalysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Escherichia coli</DescriptorName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ferrochelatase</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genes, Bacterial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Weight</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Water</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">11537092</PMID>
<DateCreated>
<Year>1995</Year>
<Month>06</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1995</Year>
<Month>06</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0033-183X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>163</Volume>
<PubDate>
<Year>1991</Year>
</PubDate>
</JournalIssue>
<Title>Protoplasma</Title>
<ISOAbbreviation>Protoplasma</ISOAbbreviation>
</Journal>
<ArticleTitle>Cytoplasmic calcium levels in protoplasts from the cap and elongation zone of maize roots.</ArticleTitle>
<Pagination>
<MedlinePgn>181-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Calcium has been implicated as a key component in the signal transduction process of root gravitropism.  We measured cytoplasmic free calcium in protoplasts isolated from the elongation zone and cap of primary roots of light-grown, vertically oriented seedlings of Zea mays L.  Protoplasts were loaded with the penta-potassium salts of fura-2 and indo-1 by incubation in acidic solutions of these calcium indicators.  Loading increased with decreasing pH but the pH dependence was stronger for indo-1 than for fura-2.  In the case of fura-2, loading was enhanced only at the lowest pH (4.5) tested.  Dyes loaded in this manner were distributed predominantly in the cytoplasm as indicated by fluorescence patterns.  As an alternative method of loading, protoplasts were incubated with the acetoxymethylesters of fura-2 and indo-1.  Protoplasts loaded by this method exhibited fluorescence both in the cytoplasm and in association with various organelles.  Cytoplasmic calcium levels measured using spectrofluorometry, were found to be 160 +/- 40 nM and 257 +/- 27 nM, respectively, in populations of protoplasts from the root cap and elongation zone.  Cytoplasmic free calcium did not increase upon addition of calcium to the incubation medium, indicating that the passive permeability to calcium was low.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kiss</LastName>
<ForeName>H G</ForeName>
<Initials>HG</Initials>
<Affiliation>Department of Plant Biology, Ohio State University, Columbus.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DMB 8608673</GrantID>
<Acronym>MB</Acronym>
<Agency>BHP HRSA HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>AUSTRIA</Country>
<MedlineTA>Protoplasma</MedlineTA>
<NlmUniqueID>9806853</NlmUniqueID>
<ISSNLinking>0033-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Fluorescent Dyes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>96314-96-4</RegistryNumber>
<NameOfSubstance>indo-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>96314-98-6</RegistryNumber>
<NameOfSubstance>Fura-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cytoplasm</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fluorescent Dyes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fura-2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gravitropism</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gravity Sensing</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Indoles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plant Root Cap</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plant Roots</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protoplasts</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zea mays</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NASA">00015446</OtherID>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Discipline Number 40-50</Keyword>
<Keyword MajorTopicYN="N">NASA Discipline Plant Biology</Keyword>
<Keyword MajorTopicYN="N">NASA Program Space Biology</Keyword>
<Keyword MajorTopicYN="N">Non-NASA Center</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
<Affiliation>Ohio St U, Columbus, Dept Physiological Chemistry</Affiliation>
</Investigator>
</InvestigatorList>
<GeneralNote Owner="NASA">Grant numbers: NAGW 297</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NASA" Status="MEDLINE">
<PMID Version="1">11540070</PMID>
<DateCreated>
<Year>1995</Year>
<Month>12</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>1995</Year>
<Month>12</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0735-2689</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>6</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1987</Year>
</PubDate>
</JournalIssue>
<Title>Critical reviews in plant sciences</Title>
<ISOAbbreviation>CRC Crit Rev Plant Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Calcium messenger system in plants.</ArticleTitle>
<Pagination>
<MedlinePgn>47-103</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Poovaiah</LastName>
<ForeName>B W</ForeName>
<Initials>BW</Initials>
<Affiliation>Department of Horticulture, Washington State University, Pullman, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Reddy</LastName>
<ForeName>A S</ForeName>
<Initials>AS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DCB-8502215</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>CRC Crit Rev Plant Sci</MedlineTA>
<NlmUniqueID>9889759</NlmUniqueID>
<ISSNLinking>0735-2689</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Calcium-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Calmodulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Plant Growth Regulators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance>Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calmodulin</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gene Expression Regulation, Plant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gravitropism</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plant Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plant Growth Regulators</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Plant Physiological Phenomena</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plants</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Second Messenger Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>363</NumberOfReferences>
<OtherID Source="NASA">00012050</OtherID>
<OtherAbstract Type="NASA" Language="eng">
<AbstractText>The purpose of this review is to delineate the ubiquitous and pivotal role of Ca2+ in diverse physiological processes.  Emphasis will be given to the role of Ca2+ in stimulus-response coupling.  In addition to reviewing the present status of research, our intention is to critically evaluate the existing data and describe the newly developing areas of Ca2+ research in plants.</AbstractText>
<CopyrightInformation>NASA Edited</CopyrightInformation>
</OtherAbstract>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Discipline Number 40-30</Keyword>
<Keyword MajorTopicYN="N">NASA Discipline Plant Biology</Keyword>
<Keyword MajorTopicYN="N">NASA Program Space Biology</Keyword>
<Keyword MajorTopicYN="N">Non-NASA Center</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Poovaiah</LastName>
<ForeName>B W</ForeName>
<Initials>BW</Initials>
<Affiliation>WA St U, Pullman, Dept Horticulture</Affiliation>
</Investigator>
</InvestigatorList>
<GeneralNote Owner="NASA">Grant numbers: NAG-10-0032</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">8655018</PMID>
<DateCreated>
<Year>1996</Year>
<Month>07</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>07</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0017-0011</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>67</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1996</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Ginekologia polska</Title>
<ISOAbbreviation>Ginekol. Pol.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Effect of fetal and neonatal growth on the occurrence of some diseases in adults].</ArticleTitle>
<Pagination>
<MedlinePgn>34-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The findings of many authors show that reduced fetal growth is followed by increased mortality from cardiovascular disease in adult life. They are further evidence that cardiovascular disease originates, among other risk factors, through programming of the bodies structure and metabolism during fetal and early post-natal life. Wrong maternal nutrition may have an important influence on programming.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jendryczko</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Affiliation>Katedry i Zakadu Chemii i Analizy Lekw, AM w Katowicach.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Poreba</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>pol</Language>
<PublicationTypeList>
<PublicationType>English Abstract</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Retracted Publication</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Wpyw przebiegu rozwoju podu i noworodka na ujawnienie sie niektrych chorb okresu dorosego.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>POLAND</Country>
<MedlineTA>Ginekol Pol</MedlineTA>
<NlmUniqueID>0374641</NlmUniqueID>
<ISSNLinking>0017-0011</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Ginekol Pol. 1998 Jul;69(7):561</RefSource>
<PMID Version="1">9867475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="RetractionIn">
<RefSource>Ginekol Pol. 1998 Jul;69(7):559-60</RefSource>
<PMID Version="1">9867474</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child Development</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryonic and Fetal Development</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fetal Growth Retardation</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nutritional Physiological Phenomena</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>11</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9110943</PMID>
<DateCreated>
<Year>1996</Year>
<Month>10</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1059-2725</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>Doc No 200-201</Volume>
<PubDate>
<Year>1996</Year>
<Month>Jul</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>The Online journal of current clinical trials</Title>
<ISOAbbreviation>Online J Curr Clin Trials</ISOAbbreviation>
</Journal>
<ArticleTitle>Conservative management of mechanical neck disorders. A systematic overview and meta-analysis.</ArticleTitle>
<Pagination>
<MedlinePgn>[34457 words; 185 paragraphs]</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This overview reports the efficacy of conservative treatments (drug therapy, manual therapy, patient education, physical medicine modalities) in reducing pain in adults with mechanical neck disorders.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Computerized bibliographic database searches from 1985 to December 1993, information requests from authors, and bibliography screenings were used to identify published and unpublished research. Applying strict criteria, two investigators independently reviewed the blinded articles. Each selected trial was evaluated independently for methodologic quality.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-four randomized controlled trials (RCTs) and eight before-after studies met our selection criteria. Twenty RCTs rated moderately strong or better in terms of methodologic quality. Five trials using manual therapy in combination with other treatments were clinically similar, were statistically not heterogeneous (p = 0.98), and were combined to yield an effect size of -0.6 (95% CI: -0.9, -0.4), equivalent to a 16 point improvement on a 100 point pain scale. Four RCTs using physical medicine modalities were combined using the inverse chi-square method: two using electromagnetic therapy produced a significant reduction in pain (p &lt; 0.01); and two using laser therapy did not differ significantly from a placebo (p = 0.63). Little or no scientific evidence exists for other therapies, including such commonly used treatments as medication, rest and exercise.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within the limits of methodologic quality, the best available evidence supports the use of manual therapies in combination with other treatments for short-term relief of neck pain. There is some support for the use of electromagnetic therapy and against the use of laser therapy. In general, other interventions have not been studied in enough detail adequately to assess efficacy or effectiveness. This overview provides the foundation for an evidence-based approach to practice. More robust design and methodology should be used in future research, in particular, the use of valid and reliable outcomes measures.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gross</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
<Affiliation>Chedoke-McMaster Hospitals &amp; Schools of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Aker</LastName>
<ForeName>P D</ForeName>
<Initials>PD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goldsmith</LastName>
<ForeName>C H</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peloso</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Meta-Analysis</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Online J Curr Clin Trials</MedlineTA>
<NlmUniqueID>9300367A</NlmUniqueID>
<ISSNLinking>1059-2725</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acupuncture Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chiropractic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Databases, Bibliographic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Manipulation, Orthopedic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Neck Injuries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pain</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Pain Management</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Patient Education as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Physical Therapy Modalities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Wounds and Injuries</DescriptorName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">rehabilitation</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="HMD" Status="MEDLINE">
<PMID Version="1">11612527</PMID>
<DateCreated>
<Year>1991</Year>
<Month>03</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>1991</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0032-4728</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>44</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1990</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Population studies</Title>
<ISOAbbreviation>Popul Stud (Camb)</ISOAbbreviation>
</Journal>
<ArticleTitle>On the origins of the United States Government's international population policy.</ArticleTitle>
<Pagination>
<MedlinePgn>385-99</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Donaldson</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Historical Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Popul Stud (Camb)</MedlineTA>
<NlmUniqueID>0376427</NlmUniqueID>
<ISSNLinking>0032-4728</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>E</CitationSubset>
<CitationSubset>Q</CitationSubset>
<CitationSubset>QO</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Demography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, Modern 1601-</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Politics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Statistics as Topic</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">World Health</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NRCBL">36117</OtherID>
<KeywordList Owner="KIE">
<Keyword MajorTopicYN="N">Agency for International Development</Keyword>
<Keyword MajorTopicYN="N">Genetics and Reproduction</Keyword>
</KeywordList>
<GeneralNote Owner="KIE">50 fn.</GeneralNote>
<GeneralNote Owner="KIE">KIE Bib: population control</GeneralNote>
</MedlineCitation>
<MedlineCitation Owner="HMD" Status="MEDLINE">
<PMID Version="1">11620107</PMID>
<DateCreated>
<Year>1988</Year>
<Month>11</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1988</Year>
<Month>11</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0511-0726</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<PubDate>
<Year>1984</Year>
</PubDate>
</JournalIssue>
<Title>A.A.G. bijdragen / Afdeling Agrarische Geschiedenis, Landbouwhogeschool</Title>
<ISOAbbreviation>A A G Bijdr</ISOAbbreviation>
</Journal>
<ArticleTitle>Demographic transition in the Netherlands: a statisticsl analysis of regional differences in the level and development of the birth rate and of fertility, 1850-1890.</ArticleTitle>
<Pagination>
<MedlinePgn>1-57</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Boonstra</LastName>
<ForeName>O W</ForeName>
<Initials>OW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>van der Woude</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Historical Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>A A G Bijdr</MedlineTA>
<NlmUniqueID>100966038</NlmUniqueID>
<ISSNLinking>0511-0726</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>Q</CitationSubset>
<CitationSubset>QO</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Demography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, Modern 1601-</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Statistics as Topic</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="HMD" Status="MEDLINE">
<PMID Version="1">11675721</PMID>
<DateCreated>
<Year>1976</Year>
<Month>07</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1976</Year>
<Month>07</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0024-2160</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1974</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>The Library</Title>
<ISOAbbreviation>Library (Lond)</ISOAbbreviation>
</Journal>
<ArticleTitle>Thomas Dover's "Ancient physician's legacy".</ArticleTitle>
<Pagination>
<MedlinePgn>228</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Payne</LastName>
<ForeName>L M</ForeName>
<Initials>LM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Biography</PublicationType>
<PublicationType>Historical Article</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Library (Lond)</MedlineTA>
<NlmUniqueID>100969413</NlmUniqueID>
<ISSNLinking>0024-2160</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>Q</CitationSubset>
<CitationSubset>QO</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Bibliography as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">History, Modern 1601-</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Printing</DescriptorName>
<QualifierName MajorTopicYN="Y">history</QualifierName>
</MeshHeading>
</MeshHeadingList>
<PersonalNameSubjectList>
<PersonalNameSubject>
<LastName>Dover</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</PersonalNameSubject>
</PersonalNameSubjectList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">8863847</PMID>
<DateCreated>
<Year>1996</Year>
<Month>11</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>11</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0026-895X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>50</Volume>
<Issue>4</Issue>
<PubDate>
<Year>1996</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular pharmacology</Title>
<ISOAbbreviation>Mol. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1000-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The mitogenic effect of extracellular ATP was examined in cultured rat aortic smooth muscle cells (VSMCs). ATP, 2-methylthio-ATP, and ADP stimulated [3H]thymidine and [3H]leucine incorporation and cell growth. AMP, adenosine, UTP, and P2x agonists showed little of these effects. Reactive blue 2, a P2Y purinoceptor antagonist, was effective in suppressing the mitogenic effect of ATP and 2-methylthio-ATP, indicating that extracellular ATP-induced VSMC proliferation is mediated by P2Y purinoceptors. The P2Y purinoceptor activation was coupled to a pertussis toxin (PTX)-insensitive G protein (Gq) and triggered phosphoinositide hydrolysis with subsequent activation of protein kinase C (PKC), Raf-1, and mitogen-activated protein kinase (MAPK) in VSMCs. In response to ATP, both 42-and 44-kDa MAPKs were activated, and tyrosine was phosphorylated. Western blot analysis using PKC isozyme-specific antibodies indicated that VSMCs express PKC-alpha, PKC-delta, and PKC-zeta. A complete down-regulation of PKC-alpha and PKC-delta was seen after 24-hr treatment with 12-O-tetradecanoylphorbol-13-acetate. When cells were pretreated with 12-O-tetradecanoyl-phorbol-13-acetate for 24 hr and subsequently challenged with ATP, Raf-1 activation and 42-kDa as well as 44-kDa MAPK tyrosine phosphorylation failed to be induced. These results demonstrate that ATP-induced Raf-1 and MAPK activations involve the activation of PKC-alpha and PKC-delta. P2Y purinoceptor stimulation with ATP also caused accumulation of c-fos and c-myc mRNAs. Both Reactive blue 2 and staurosporine significantly blocked this increase by ATP. In conclusion, the mitogenic effect of ATP seemed to be triggered by activation of the Gq protein-coupled P2Y purinoceptor that led to the formation of inositol trisphosphate and activation of PKC. PKC and, in turn, Raf-1 and MAPK were then activated, leading eventually to DNA synthesis and cell proliferation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
<Affiliation>Department of Pharmacology, Chang Gung College of Medicine and Technology, Kwei-San, Tao-Yuan, Taiwan. smyu@cguaplo.cgu.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>S F</ForeName>
<Initials>SF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lau</LastName>
<ForeName>Y T</ForeName>
<Initials>YT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>In Vitro</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Retracted Publication</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Mol Pharmacol</MedlineTA>
<NlmUniqueID>0035623</NlmUniqueID>
<ISSNLinking>0026-895X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Purinergic P2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>10028-17-8</RegistryNumber>
<NameOfSubstance>Tritium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-89-5</RegistryNumber>
<NameOfSubstance>Thymidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-65-5</RegistryNumber>
<NameOfSubstance>Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>61-90-5</RegistryNumber>
<NameOfSubstance>Leucine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance>DNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance>Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance>Proto-Oncogene Proteins c-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance>Protein Kinase C</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.17</RegistryNumber>
<NameOfSubstance>Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance>GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Mol Pharmacol 1997 Mar;51(3):533</RefSource>
</CommentsCorrections>
<CommentsCorrections RefType="RetractionIn">
<RefSource>Wu D, Yang CM, Lau YT, Chen JC. Mol Pharmacol. 1998 Feb;53(2):346</RefSource>
<PMID Version="1">9499167</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Division</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA</DescriptorName>
<QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Extracellular Space</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Leucine</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Kinase C</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Proto-Oncogene Proteins c-raf</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Purinergic P2</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Thymidine</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tritium</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">8941094</PMID>
<DateCreated>
<Year>1997</Year>
<Month>01</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>1997</Year>
<Month>01</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0009-7322</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>94</Volume>
<Issue>11</Issue>
<PubDate>
<Year>1996</Year>
<Month>Dec</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Circulation</Title>
<ISOAbbreviation>Circulation</ISOAbbreviation>
</Journal>
<ArticleTitle>Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography.</ArticleTitle>
<Pagination>
<MedlinePgn>2712-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To date, late redistribution after resting 201Tl injection has not been evaluated. In addition, the concordance between resting 201Tl imaging and dobutamine echocardiography in identifying viable myocardium has not been assessed.</AbstractText>
<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Forty patients with coronary artery disease underwent rest-4-hour-24-hour 201Tl tomography and dobutamine echocardiography (5 to 10 micrograms.kg-1.min-1). Late redistribution occurred in 46 (21%) of 219 persistent defects at 4 hours. Systolic function and contractile reserve were similar among persistent defects at 4 hours with and without late redistribution. Contractile reserve was more frequent in segments with normal 201Tl uptake (59%), completely reversible defects (53%), or mild to moderate defects at 4 hours (56%) compared with severe defects (14%; P &lt; .02 versus all). Of 105 hypokinetic segments, 99 (94%) were viable by 201Tl, and 88 (84%) showed contractile reserve. In contrast, of 155 akinetic segments, 119 (77%) were viable by 201Tl, but only 34 (22%) had contractile reserve. Concordance between 201Tl and dobutamine was 82% in hypokinetic segments but 43% in akinetic segments. In 109 revascularized segments, positive accuracy for functional recovery was 72% for 201Tl and 92% for dobutamine, whereas negative accuracy was 100% and 65%, respectively. Sensitivity was 100% for 201Tl and 79% for dobutamine.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Late redistribution occurs in one fifth of persistent defects at 4 hours, and it does not correlate to systolic function or contractile reserve. Dobutamine and 201Tl yield concordant information in the majority of hypokinetic segments, whereas concordance is low in akinetic segments. Dobutamine demonstrates higher positive accuracy and sensitivity in predicting recovery of dysfunctional myocardium, whereas 201Tl shows higher negative predictive accuracy but reduced positive accuracy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Perrone-Filardi</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<Affiliation>Division of Cardiology, Federico II University Medical School, Naples, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pace</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Prastaro</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Squame</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Betocchi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soricelli</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piscione</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Indolfi</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Crisci</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Salvatore</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chiariello</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Circulation</MedlineTA>
<NlmUniqueID>0147763</NlmUniqueID>
<ISSNLinking>0009-7322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Thallium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>34368-04-2</RegistryNumber>
<NameOfSubstance>Dobutamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Circulation. 1997 Oct 21;96(8):2740-2</RefSource>
<PMID Version="1">9355926</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Circulation. 1996 Dec 1;94(11):2681-4</RefSource>
<PMID Version="1">8941086</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Circulation. 1996 Dec 1;94(11):2674-80</RefSource>
<PMID Version="1">8941085</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Circulation. 1996 Dec 1;94(11):2685-8</RefSource>
<PMID Version="1">8941087</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Circadian Rhythm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Coronary Disease</DescriptorName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName>
<QualifierName MajorTopicYN="Y">ultrasonography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dobutamine</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Echocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart</DescriptorName>
<QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Contraction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Revascularization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rest</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Systole</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Thallium Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
<QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName>
<QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
<QualifierName MajorTopicYN="N">ultrasonography</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10168751</PMID>
<DateCreated>
<Year>1997</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>1997</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0168-8510</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>40</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1997</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Health policy (Amsterdam, Netherlands)</Title>
<ISOAbbreviation>Health Policy</ISOAbbreviation>
</Journal>
<ArticleTitle>Health technology assessment: decentralized and fragmented in the US compared to other countries.</ArticleTitle>
<Pagination>
<MedlinePgn>177-98</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This paper presents the results of the first comprehensive international survey to catalogue health technology assessment (HTA) activities. By 1995, there were formal HTA programs in 24 countries established mostly in the late 1980s and early 1990s. European countries generally have one or two federal or provincial HTA programs each, Canada has an extensive network of federal and regional organizations coordinated by a central body and the US has 53 HTA organizations, the vast majority of which are in the private sector. While the commitment of the US government to HTA has been erratic, the private sector has been witness to an expansion of HTA activities by insurance companies, hospitals, medical/device manufacturers, consulting firms and health professional societies. In contrast to other developed countries, the current state of technology assessment in the US is decentralized, fragmented and duplicative. We conclude by discussing the importance of a US HTA agency at the national level.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Perry</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<Affiliation>Medical Technology and Practice Patterns Institute, WHO Collaborating Center on Health Technology Assessment, Washington, DC 20007, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thamer</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>IRELAND</Country>
<MedlineTA>Health Policy</MedlineTA>
<NlmUniqueID>8409431</NlmUniqueID>
<ISSNLinking>0168-8510</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="RepublishedIn">
<RefSource>Health Policy 1997 Dec;42(3):269-90</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diffusion of Innovation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Europe</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Health Care Surveys</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Policy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Information Services</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Private Sector</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Technology Assessment, Biomedical</DescriptorName>
<QualifierName MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
<QualifierName MajorTopicYN="Y">organization &amp; administration</QualifierName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">United States Office of Technology Assessment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9394824</PMID>
<DateCreated>
<Year>1998</Year>
<Month>01</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>01</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0014-2980</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>27</Volume>
<Issue>11</Issue>
<PubDate>
<Year>1997</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>European journal of immunology</Title>
<ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypermutation, diversity and dissemination of human intestinal lamina propria plasma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>2959-64</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>In this work we have microdissected lamina propria plasma cells and used polymerase chain reaction and sequencing to investigate immunoglobulin (Ig) gene rearrangements and mutations in human intestine. In addition, specific primers were designed for individual Ig gene rearrangements to analyze the distribution of related B cell and plasma cell clones at different sites along the bowel. Confirming our earlier work, intestinal IgVH genes were highly mutated in plasma cells from older individuals (&gt; 30 years). IgVH genes were significantly less mutated in samples taken from patients aged 11-30 years, and there were fewer mutations again in samples from young children (&lt; 11 years). In age-matched specimens the number of mutations was equivalent in the duodenum and colon. Using complementarity-determining region 3 primers to amplify specific Ig gene rearrangements, evidence was also found for the existence of related lamina propria plasma cells along the small bowel and colon, although these were quite scarce. In addition, analysis of the numbers of related clones in a random sampling from discrete areas of lamina propria indicates that the local population is diverse. These results suggest that the highly mutated IgVH genes in adult intestinal plasma cells are a consequence of chronic antigen exposure with age. Duodenal plasma cells are as highly mutated as colonic plasma cells, despite the fact that the upper bowel has no indigenous microbial flora (the stimulus for intestinal plasma cells). They also show that the plasma cell population is diverse and can be widely disseminated along the bowel.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dunn-Walters</LastName>
<ForeName>D K</ForeName>
<Initials>DK</Initials>
<Affiliation>Department of Histopathology, UMDS, London, Great Britain.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Boursier</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Spencer</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="N">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>Z93128</AccessionNumber>
<AccessionNumber>Z93129</AccessionNumber>
<AccessionNumber>Z93130</AccessionNumber>
<AccessionNumber>Z93131</AccessionNumber>
<AccessionNumber>Z93132</AccessionNumber>
<AccessionNumber>Z93133</AccessionNumber>
<AccessionNumber>Z93134</AccessionNumber>
<AccessionNumber>Z93135</AccessionNumber>
<AccessionNumber>Z93136</AccessionNumber>
<AccessionNumber>Z93137</AccessionNumber>
<AccessionNumber>Z93138</AccessionNumber>
<AccessionNumber>Z93139</AccessionNumber>
<AccessionNumber>Z93140</AccessionNumber>
<AccessionNumber>Z93141</AccessionNumber>
<AccessionNumber>Z93142</AccessionNumber>
<AccessionNumber>Z93143</AccessionNumber>
<AccessionNumber>Z93144</AccessionNumber>
<AccessionNumber>Z93145</AccessionNumber>
<AccessionNumber>Z93146</AccessionNumber>
<AccessionNumber>Z93147</AccessionNumber>
<AccessionNumber>Z93148</AccessionNumber>
<AccessionNumber>Z93149</AccessionNumber>
<AccessionNumber>Z93150</AccessionNumber>
<AccessionNumber>Z93151</AccessionNumber>
<AccessionNumber>Z93152</AccessionNumber>
<AccessionNumber>Z93153</AccessionNumber>
<AccessionNumber>Z93154</AccessionNumber>
<AccessionNumber>Z93155</AccessionNumber>
<AccessionNumber>Z93156</AccessionNumber>
<AccessionNumber>Z93157</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Eur J Immunol</MedlineTA>
<NlmUniqueID>1273201</NlmUniqueID>
<ISSNLinking>0014-2980</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulin Heavy Chains</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulin Variable Region</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aging</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Colon</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Duodenum</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Rearrangement</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genes, Immunoglobulin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunoglobulin Heavy Chains</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunoglobulin Variable Region</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intestinal Mucosa</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Organ Specificity</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plasma Cells</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9482442</PMID>
<DateCreated>
<Year>1998</Year>
<Month>03</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0140-6736</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>351</Volume>
<Issue>9101</Issue>
<PubDate>
<Year>1998</Year>
<Month>Feb</Month>
<Day>14</Day>
</PubDate>
</JournalIssue>
<Title>Lancet</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>A woman with nodules in her lungs.</ArticleTitle>
<Pagination>
<MedlinePgn>494</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jrvelinen</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<Affiliation>Department of Medicine, Turku University Central Hospital, Finland.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Vainionp</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuopio</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lehtonen</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Powders</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7631-86-9</RegistryNumber>
<NameOfSubstance>Silicon Dioxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Lancet 1998 Jun 27;351(9120):1968</RefSource>
</CommentsCorrections>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Lancet 1998 Mar 7;351(9104):760</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Naturopathy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Powders</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Silicon Dioxide</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Silicosis</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">radiography</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9505772</PMID>
<DateCreated>
<Year>1998</Year>
<Month>03</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0007-0912</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>80</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1998</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>British journal of anaesthesia</Title>
<ISOAbbreviation>Br J Anaesth</ISOAbbreviation>
</Journal>
<ArticleTitle>Myocardial ischaemia after coronary artery bypass grafting: early vs late extubation.</ArticleTitle>
<Pagination>
<MedlinePgn>20-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The technique of early extubation after coronary artery bypass grafting is increasing in popularity, but its safety and effect on myocardial ischaemia remain to be established. In a randomized, prospective study, patients undergoing routine elective coronary artery bypass grafting were managed with either early or late tracheal extubation. The incidence and severity of electrocardiographic myocardial ischaemia were compared. Data were analysed from 85 patients (43 early extubation; 42 late extubation). Median time to extubation was 110 min in the early extubation patients and 757 min in the late extubation patients. After correction for randomization bias, there were no significant differences between groups in ischaemic burden, maximal ST-segment deviation, incidence of ischaemia and area under the ST deviation-time curve (integral of ST deviation and time). Similarly, there were no differences between groups in postoperative creatine kinase MB-isoenzyme concentrations and duration of stay in the ICU or hospital. Therefore, this study provides evidence for the safety of early extubation after routine coronary artery bypass grafting.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Berry</LastName>
<ForeName>P D</ForeName>
<Initials>PD</Initials>
<Affiliation>Cardiothoracic Centre Liverpool-NHS Trust.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>S D</ForeName>
<Initials>SD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mahon</LastName>
<ForeName>S P</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jackson</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fox</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fabri</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weir</LastName>
<ForeName>W I</ForeName>
<Initials>WI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Russell</LastName>
<ForeName>G N</ForeName>
<Initials>GN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Br J Anaesth</MedlineTA>
<NlmUniqueID>0372541</NlmUniqueID>
<ISSNLinking>0007-0912</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Br J Anaesth 1998 Apr;80(4):572</RefSource>
</CommentsCorrections>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Br J Anaesth 1998 Jul;81(1):111</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Coronary Artery Bypass</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electrocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intubation, Intratracheal</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Ischemia</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Postoperative Care</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Postoperative Period</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9575322</PMID>
<DateCreated>
<Year>1998</Year>
<Month>05</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0002-838X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>57</Volume>
<Issue>8</Issue>
<PubDate>
<Year>1998</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American family physician</Title>
<ISOAbbreviation>Am Fam Physician</ISOAbbreviation>
</Journal>
<ArticleTitle>Lumbar spine stenosis: a common cause of back and leg pain.</ArticleTitle>
<Pagination>
<MedlinePgn>1825-34, 1839-40</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Lumbar spine stenosis most commonly affects the middle-aged and elderly population. Entrapment of the cauda equina roots by hypertrophy of the osseous and soft tissue structures surrounding the lumbar spinal canal is often associated with incapacitating pain in the back and lower extremities, difficulty ambulating, leg paresthesias and weakness and, in severe cases, bowel or bladder disturbances. The characteristic syndrome associated with lumbar stenosis is termed neurogenic intermittent claudication. This condition must be differentiated from true claudication, which is caused by atherosclerosis of the pelvofemoral vessels. Although many conditions may be associated with lumbar canal stenosis, most cases are idiopathic. Imaging of the lumbar spine performed with computed tomography or magnetic resonance imaging often demonstrates narrowing of the lumbar canal with compression of the cauda equina nerve roots by thickened posterior vertebral elements, facet joints, marginal osteophytes or soft tissue structures such as the ligamentum flavum or herniated discs. Treatment for symptomatic lumbar stenosis is usually surgical decompression. Medical treatment alternatives, such as bed rest, pain management and physical therapy, should be reserved for use in debilitated patients or patients whose surgical risk is prohibitive as a result of concomitant medical conditions.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Alvarez</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
<Affiliation>University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hardy</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
<Suffix>Jr</Suffix>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Am Fam Physician</MedlineTA>
<NlmUniqueID>1272646</NlmUniqueID>
<ISSNLinking>0002-838X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Am Fam Physician. 1999 Jan 15;59(2):280, 283-4</RefSource>
<PMID Version="1">9930124</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Low Back Pain</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lumbosacral Region</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pain</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Patient Education as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spinal Stenosis</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Teaching Materials</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>13</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9626910</PMID>
<DateCreated>
<Year>1998</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0047-1828</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>62</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1998</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Japanese circulation journal</Title>
<ISOAbbreviation>Jpn. Circ. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hepatitis C virus infection and heart diseases: a multicenter study in Japan.</ArticleTitle>
<Pagination>
<MedlinePgn>389-91</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>As a collaborative research project of the Committees for the Study of Idiopathic Cardiomyopathy, a questionnaire was sent out to 19 medical institutions in Japan in order to examine the possible association between hepatitis C virus (HCV) infection and cardiomyopathies. Hepatitis C virus antibody was found in 74 of 697 patients (10.6%) with hypertrophic cardiomyopathy (mean age, 57.7 years) and in 42 of 663 patients (6.3%) with dilated cardiomyopathy (mean age, 56.5 years); these prevalences were significantly higher than that found in volunteer blood donors in Japan (2.4%, 50-59 years of age, each p&lt;0.0001). The prevalence was significantly higher in patients suffering from hypertrophic cardiomyopathy as opposed to those with dilated cardiomyopathy (p&lt;0.01). The presence of HCV antibody was detected in 650 of 11,967 patients (5.4%) patients seeking care in 5 academic hospitals. Various cardiac abnormalities were found among these patients, arrhythmias being the most frequent. These observations suggest that HCV infection is an important cause of a variety of otherwise unexplained heart diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="N">
<Author ValidYN="Y">
<LastName>Matsumori</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Affiliation>Kyoto University, Japan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ohashi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hasegawa</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sasayama</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eto</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Imaizumi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Izumi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawamura</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawana</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kimura</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kitabatake</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matsuzaki</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nagai</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hiroe</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hori</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Inoko</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seko</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sekiguchi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shimotohno</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sugishita</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takeda</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takihara</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yokoyama</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Multicenter Study</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>AUSTRALIA</Country>
<MedlineTA>Jpn Circ J</MedlineTA>
<NlmUniqueID>7806868</NlmUniqueID>
<ISSNLinking>0047-1828</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Hepatitis C Antibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiomyopathies</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart</DescriptorName>
<QualifierName MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hepatitis C</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hepatitis C Antibodies</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardium</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9627170</PMID>
<DateCreated>
<Year>1998</Year>
<Month>08</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>08</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>05</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1435-2443</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>383</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1998</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Langenbeck's archives of surgery / Deutsche Gesellschaft fr Chirurgie</Title>
<ISOAbbreviation>Langenbecks Arch Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Outcome of patients with sepsis and septic shock after ICU treatment.</ArticleTitle>
<Pagination>
<MedlinePgn>44-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Today, sepsis syndrome is the leading cause of death in adult, non-coronary intensive care units (ICUs) and is of great clinical importance. The purpose of this review was to evaluate recent prospective studies concerning the short- and long-term prognosis of patients suffering from systemic inflammatory-response syndrome (SIRS), sepsis, severe sepsis and septic shock. It has been shown in multicentre prospective surveys that 1% and 0.3% of all patients admitted to hospitals suffer, respectively, from bacteraemia alone and bacteraemia with severe sepsis. This rate increases, of course, when only admissions to the ICUs are considered: the above-mentioned rates increase then by a factor of 8 and 30, respectively. Thus, approximately 10% of patients in the ICU suffer from sepsis, 6% from severe sepsis and 2-3% from septic shock. SIRS occurs more frequently and its occurrence ranges from 40% to 70% of all patients admitted to ICUs. Thereby, 40-70% suffering from SIRS progress to a more severe septic-disease state. The overall prognosis is still poor, despite the recent advances in ICU treatment. The mortality rate of SIRS ranges from 6% to 7% and in septic shock amounts to over 50%. In particular, abdominal sepsis exhibits the highest mortality rate with 72%. The long-term prognosis is equally poor; only approximately 30% survived the first year after hospital admission.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prognosis of sepsis and septic shock remains poor, despite the advances in ICU treatment. Although prognostic factors have been identified for some patients, groups have not yet been able to identify the immediate or long-term prognosis for the majority of these septic patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schoenberg</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
<Affiliation>Department of General Surgery, University of Ulm, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Weiss</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Radermacher</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Langenbecks Arch Surg</MedlineTA>
<NlmUniqueID>9808285</NlmUniqueID>
<ISSNLinking>1435-2443</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacteremia</DescriptorName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cause of Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Intensive Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Shock, Septic</DescriptorName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surgical Wound Infection</DescriptorName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>21</NumberOfReferences>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9634358</PMID>
<DateCreated>
<Year>1998</Year>
<Month>06</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>06</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>03</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-1899</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>177</Volume>
<Issue>6</Issue>
<PubDate>
<Year>1998</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of infectious diseases</Title>
<ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Retraction: A rabbit model for human cytomeglovirus--induced chorioretinal disease (J Infect Dis 1993;168:336-44).</ArticleTitle>
<Pagination>
<MedlinePgn>1778</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dunkel</LastName>
<ForeName>E C</ForeName>
<Initials>EC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scheer</LastName>
<ForeName>D I</ForeName>
<Initials>DI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Whitley</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schaffer</LastName>
<ForeName>P A</ForeName>
<Initials>PA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pavan-Langston</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="N">
<LastName>Whitely</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Retraction of Publication</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>J Infect Dis</MedlineTA>
<NlmUniqueID>0413675</NlmUniqueID>
<ISSNLinking>0022-1899</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>J Infect Dis 1998 Aug;178(2):601</RefSource>
<Note>Whitely RJ [corrected to Whitley RJ]</Note>
</CommentsCorrections>
<CommentsCorrections RefType="RetractionOf">
<RefSource>Dunkel EC, de Freitas D, Scheer DI, Siegel ML, Zhu Q, Whitley RJ, Schaffer PA, Pavan-Langston D. J Infect Dis. 1993 Aug;168(2):336-44</RefSource>
<PMID Version="1">8393056</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9861576</PMID>
<DateCreated>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2010</Year>
<Month>02</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0268-1315</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>13</Volume>
<Issue>6</Issue>
<PubDate>
<Year>1998</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>International clinical psychopharmacology</Title>
<ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients.</ArticleTitle>
<Pagination>
<MedlinePgn>263-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Selective serotonin reuptake inhibitors (SSRIs) are the 'new' drugs of first choice for the treatment of depression in the older patient. Systematic studies on the effects of SSRIs on cardiac function are scarce, despite the high prevalence of cardiac disorders in the older depressed patient. This is a study which systematically assessed cardiac function by echocardiography in middle-aged and elderly depressed patients treated with SSRI. In a double-blind randomized trial, 20 patients were assigned to receive fluvoxamine 100 mg/day [DOSAGE ERROR CORRECTED] or fluoxetine 20 mg/day [DOSAGE ERROR CORRECTED] for 6 weeks. Cardiac function was assessed by left ventricle ejection fraction, aortic flow integral and early or passive/late or active mitral inflow, and electrocardiography. Neither SSRI significantly affected cardiac function. Compared with patients without a history of myocardial infarction and/or hypertension, patients with such a history showed a significant improvement in left ventricular ejection fraction. Despite our small study sample, these data indicate that both fluoxetine and fluvoxamine do not affect cardiac function adversely.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Strik</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
<Affiliation>Department of Psychiatry, Maastricht University Hospital, The Netherlands.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Honig</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lousberg</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheriex</LastName>
<ForeName>E C</ForeName>
<Initials>EC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Praag</LastName>
<ForeName>H M</ForeName>
<Initials>HM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Int Clin Psychopharmacol</MedlineTA>
<NlmUniqueID>8609061</NlmUniqueID>
<ISSNLinking>0268-1315</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Serotonin Uptake Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>54739-18-3</RegistryNumber>
<NameOfSubstance>Fluvoxamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>54910-89-3</RegistryNumber>
<NameOfSubstance>Fluoxetine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Int Clin Psychopharmacol 1999 Mar;14(2):138</RefSource>
<Note>Dosage error in published abstract; MEDLINE/PubMed abstract corrected</Note>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Depressive Disorder</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Echocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electrocardiography</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fluoxetine</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fluvoxamine</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9885794</PMID>
<DateCreated>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>05</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0893-133X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>20</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title>
<ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation>
</Journal>
<ArticleTitle>Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.</ArticleTitle>
<Pagination>
<MedlinePgn>141-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. However, clinical trials of CCK agonists in schizophrenia patients showed mixed results. To re-examine the antipsychotic potential of CCK-based treatments, we examined systemic injections of CCK analogs in an animal model with strong face and construct validity for sensorimotor-gating deficits seen in schizophrenia patients and with strong predictive validity for antipsychotic drug activity. Prepulse inhibition (PPI) occurs when a weak acoustic lead stimulus ("prepulse") inhibits the startle response to a sudden loud sound ("pulse"). PPI is significantly reduced in schizophrenia patients and rats treated with dopamine agonists. Antipsychotics reverse decreased PPI in rats to a degree highly correlated with their clinical efficacy. Subcutaneous (s.c.) injections of caerulein (10 micrograms/kg) a mixed CCKA/B agonist, partially reversed amphetamine-induced reduction of PPI; whereas, s.c. haloperidol (0.5 mg/kg) totally reversed amphetamine-induced disruption of PPI. Caerulein's effect on PPI was blocked by pretreatment with a CCKA antagonist (devazepide) but not a CCKB antagonist (L-365,260). CCK-4, a preferential CCKB agonist, had no significant effect on PPI. These results suggest that caerulein produces a weak neuroleptic-like effect on PPI that is mediated by stimulation of CCKA receptors. Possible circuities in this effect are discussed. In a separate experiment, s.c. caerulein produced to a more potent neuroleptic-like profile on amphetamine-induced hyperlocomotion, suggesting that selection of preclinical paradigms may be important in evaluating the antipsychotic potential of CCK-based treatments.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Feifel</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla 92093-8620, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Reza</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robeck</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Neuropsychopharmacology</MedlineTA>
<NlmUniqueID>8904907</NlmUniqueID>
<ISSNLinking>0006-3223</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Gastrointestinal Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Cholecystokinin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>17650-98-5</RegistryNumber>
<NameOfSubstance>Caerulein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1947-37-1</RegistryNumber>
<NameOfSubstance>Tetragastrin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>52-86-8</RegistryNumber>
<NameOfSubstance>Haloperidol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9011-97-6</RegistryNumber>
<NameOfSubstance>Cholecystokinin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Behavior, Animal</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Caerulein</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cholecystokinin</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastrointestinal Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Haloperidol</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Psychotic Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Cholecystokinin</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Startle Reaction</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tetragastrin</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">9929727</PMID>
<DateCreated>
<Year>1999</Year>
<Month>04</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>04</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0300-2896</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>34</Volume>
<Issue>11</Issue>
<PubDate>
<Year>1998</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Archivos de bronconeumologa</Title>
<ISOAbbreviation>Arch. Bronconeumol.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Tobacco control in children, adolescents and young people: knowledge, prevention and action].</ArticleTitle>
<Pagination>
<MedlinePgn>564</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>de Granda Orive</LastName>
<ForeName>J I</ForeName>
<Initials>JI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pea Miguel</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morato Arniz</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>spa</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
<VernacularTitle>La lucha contra el tabaco en los nios, adolescentes y jvenes: conocimiento, prevencin y actuacin.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>SPAIN</Country>
<MedlineTA>Arch Bronconeumol</MedlineTA>
<NlmUniqueID>0354720</NlmUniqueID>
<ISSNLinking>0300-2896</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Arch Bronconeumol. 1998 Apr;34(4):199-203</RefSource>
<PMID Version="1">9611655</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10078868</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0041-0101</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>37</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Toxicon : official journal of the International Society on Toxinology</Title>
<ISOAbbreviation>Toxicon</ISOAbbreviation>
</Journal>
<ArticleTitle>Bibliography of toxinology.</ArticleTitle>
<Pagination>
<MedlinePgn>399-404</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Bibliography</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Toxicon</MedlineTA>
<NlmUniqueID>1307333</NlmUniqueID>
<ISSNLinking>0041-0101</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Toxins, Biological</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Toxins, Biological</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10083987</PMID>
<DateCreated>
<Year>1999</Year>
<Month>05</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>05</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0832-610X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>46</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Canadian journal of anaesthesia = Journal canadien d'anesthsie</Title>
<ISOAbbreviation>Can J Anaesth</ISOAbbreviation>
</Journal>
<ArticleTitle>Complete airway obstruction.</ArticleTitle>
<Pagination>
<MedlinePgn>99-104</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Crosby</LastName>
<ForeName>E T</ForeName>
<Initials>ET</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>CANADA</Country>
<MedlineTA>Can J Anaesth</MedlineTA>
<NlmUniqueID>8701709</NlmUniqueID>
<ISSNLinking>0832-610X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anesthetics, Local</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentOn">
<RefSource>Can J Anaesth. 1999 Feb;46(2):176-8</RefSource>
<PMID Version="1">10083999</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Airway Obstruction</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anesthesiology</DescriptorName>
<QualifierName MajorTopicYN="N">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anesthetics, Local</DescriptorName>
<QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cervical Vertebrae</DescriptorName>
<QualifierName MajorTopicYN="N">injuries</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Conscious Sedation</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intubation, Intratracheal</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Laryngoscopes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Laryngoscopy</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tracheostomy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10097079</PMID>
<DateCreated>
<Year>1999</Year>
<Month>05</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>96</Volume>
<Issue>7</Issue>
<PubDate>
<Year>1999</Year>
<Month>Mar</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Thermal adaptation analyzed by comparison of protein sequences from mesophilic and extremely thermophilic Methanococcus species.</ArticleTitle>
<Pagination>
<MedlinePgn>3578-83</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The genome sequence of the extremely thermophilic archaeon Methanococcus jannaschii provides a wealth of data on proteins from a thermophile. In this paper, sequences of 115 proteins from M. jannaschii are compared with their homologs from mesophilic Methanococcus species. Although the growth temperatures of the mesophiles are about 50 degrees C below that of M. jannaschii, their genomic G+C contents are nearly identical. The properties most correlated with the proteins of the thermophile include higher residue volume, higher residue hydrophobicity, more charged amino acids (especially Glu, Arg, and Lys), and fewer uncharged polar residues (Ser, Thr, Asn, and Gln). These are recurring themes, with all trends applying to 83-92% of the proteins for which complete sequences were available. Nearly all of the amino acid replacements most significantly correlated with the temperature change are the same relatively conservative changes observed in all proteins, but in the case of the mesophile/thermophile comparison there is a directional bias. We identify 26 specific pairs of amino acids with a statistically significant (P &lt; 0.01) preferred direction of replacement.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Haney</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
<Affiliation>Department of Microbiology, University of Illinois, B103 Chemical and Life Sciences Laboratory, 601 South Goodwin Avenue, Urbana, IL 61801, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Badger</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buldak</LastName>
<ForeName>G L</ForeName>
<Initials>GL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reich</LastName>
<ForeName>C I</ForeName>
<Initials>CI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Woese</LastName>
<ForeName>C R</ForeName>
<Initials>CR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olsen</LastName>
<ForeName>G J</ForeName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="N">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>AF078607</AccessionNumber>
<AccessionNumber>AF078608</AccessionNumber>
<AccessionNumber>AF078609</AccessionNumber>
<AccessionNumber>AF078610</AccessionNumber>
<AccessionNumber>AF078611</AccessionNumber>
<AccessionNumber>AF078612</AccessionNumber>
<AccessionNumber>AF078613</AccessionNumber>
<AccessionNumber>AF078614</AccessionNumber>
<AccessionNumber>AF078615</AccessionNumber>
<AccessionNumber>AF078616</AccessionNumber>
<AccessionNumber>AF078617</AccessionNumber>
<AccessionNumber>AF078618</AccessionNumber>
<AccessionNumber>AF078619</AccessionNumber>
<AccessionNumber>AF078620</AccessionNumber>
<AccessionNumber>AF078621</AccessionNumber>
<AccessionNumber>AF078622</AccessionNumber>
<AccessionNumber>AF078623</AccessionNumber>
<AccessionNumber>AF078624</AccessionNumber>
<AccessionNumber>AF078625</AccessionNumber>
<AccessionNumber>AF078626</AccessionNumber>
<AccessionNumber>AF078627</AccessionNumber>
<AccessionNumber>AF078628</AccessionNumber>
<AccessionNumber>AF078629</AccessionNumber>
<AccessionNumber>AF078630</AccessionNumber>
<AccessionNumber>AF078631</AccessionNumber>
<AccessionNumber>AF078632</AccessionNumber>
<AccessionNumber>AF078633</AccessionNumber>
<AccessionNumber>AF078634</AccessionNumber>
<AccessionNumber>AF078635</AccessionNumber>
<AccessionNumber>AF078636</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM07283</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Bacterial Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>S</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>J Theor Biol. 1975 Mar;50(1):167-83</RefSource>
<PMID Version="1">1127956</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1975 May 15;255(5505):256-9</RefSource>
<PMID Version="1">1143325</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1992 May 1;89(9):3751-5</RefSource>
<PMID Version="1">1570293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Crit Rev Biochem Mol Biol. 1991;26(1):1-52</RefSource>
<PMID Version="1">1678690</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1991 Jul 23;30(29):7142-53</RefSource>
<PMID Version="1">1854726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1991 Jan 15;30(2):589-94</RefSource>
<PMID Version="1">1988046</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1990 Aug 7;29(31):7133-55</RefSource>
<PMID Version="1">2207096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1990 Oct 5;215(3):403-10</RefSource>
<PMID Version="1">2231712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1990 Mar 16;247(4948):1306-10</RefSource>
<PMID Version="1">2315699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1990 Mar 6;29(9):2403-8</RefSource>
<PMID Version="1">2337607</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proteins. 1989;5(1):22-37</RefSource>
<PMID Version="1">2664764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1989 Sep 5;28(18):7205-13</RefSource>
<PMID Version="1">2684274</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1989 Mar 20;206(2):397-406</RefSource>
<PMID Version="1">2716053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Protein Chem. 1988;39:191-234</RefSource>
<PMID Version="1">3072868</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1988 Feb 5;199(3):525-37</RefSource>
<PMID Version="1">3127592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1988 Dec 15;336(6200):651-6</RefSource>
<PMID Version="1">3200317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1988 Mar 5;263(7):3086-91</RefSource>
<PMID Version="1">3257756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1986 Nov;83(21):8069-72</RefSource>
<PMID Version="1">3464944</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Theor Biol. 1973 Jun;39(3):645-51</RefSource>
<PMID Version="1">4354159</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1974 Sep 6;185(4154):862-4</RefSource>
<PMID Version="1">4843792</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1979 Dec 11;18(25):5698-703</RefSource>
<PMID Version="1">518863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Theor Biol. 1968 Nov;21(2):170-201</RefSource>
<PMID Version="1">5700434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Theor Biol. 1967 Aug;16(2):187-211</RefSource>
<PMID Version="1">6048539</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1982 May 5;157(1):105-32</RefSource>
<PMID Version="1">7108955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Biochem. 1982 Nov 15;128(2-3):565-75</RefSource>
<PMID Version="1">7151796</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Biochem. 1980 Jul;108(2):581-6</RefSource>
<PMID Version="1">7408869</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biochem. 1980 Dec;88(6):1895-8</RefSource>
<PMID Version="1">7462208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Appl Environ Microbiol. 1995 Jul;61(7):2762-4</RefSource>
<PMID Version="1">7618889</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Biochem. 1995 May 1;229(3):688-95</RefSource>
<PMID Version="1">7758464</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1995 Mar 3;246(4):511-21</RefSource>
<PMID Version="1">7877172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1994 Dec 2;244(3):332-50</RefSource>
<PMID Version="1">7966343</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 1993 Mar;3(3):266-72</RefSource>
<PMID Version="1">8485583</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Bacteriol. 1996 Feb;178(3):723-7</RefSource>
<PMID Version="1">8550506</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Structure. 1995 Nov 15;3(11):1147-58</RefSource>
<PMID Version="1">8591026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 1996 Jan 1;24(1):1-5</RefSource>
<PMID Version="1">8594554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochemistry. 1996 Feb 27;35(8):2597-609</RefSource>
<PMID Version="1">8611563</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Protein Eng. 1995 Aug;8(8):779-89</RefSource>
<PMID Version="1">8637847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1996 Aug 23;273(5278):1058-73</RefSource>
<PMID Version="1">8688087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Protein Eng. 1996 Jan;9(1):27-36</RefSource>
<PMID Version="1">9053899</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proteins. 1997 May;28(1):117-30</RefSource>
<PMID Version="1">9144797</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1997 Jun 20;269(4):631-43</RefSource>
<PMID Version="1">9217266</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene. 1997 Dec 31;205(1-2):309-16</RefSource>
<PMID Version="1">9461405</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2056-60</RefSource>
<PMID Version="1">9482837</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acclimatization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bacterial Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Methanococcus</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Species Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Temperature</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC22336</OtherID>
<KeywordList Owner="NASA">
<Keyword MajorTopicYN="N">NASA Discipline Exobiology</Keyword>
<Keyword MajorTopicYN="N">Non-NASA Center</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Woese</LastName>
<ForeName>C R</ForeName>
<Initials>CR</Initials>
<Affiliation>U IL, Urbana</Affiliation>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10101342</PMID>
<DateCreated>
<Year>1999</Year>
<Month>04</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0733-8627</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>17</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Emergency medicine clinics of North America</Title>
<ISOAbbreviation>Emerg. Med. Clin. North Am.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of the patient with extremity trauma: an evidence based approach.</ArticleTitle>
<Pagination>
<MedlinePgn>77-95, viii</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This article reviews relevant literature to provide evidence based guidelines for the evaluation of patients with extremity trauma in the emergency department. The development of clinical decision rules for extremity trauma in the ankle and knee, and guidelines for obtaining postreduction radiographs of shoulder dislocations and nursemaid's elbows are discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kaufman</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<Affiliation>Division of Emergency Medicine, Northwestern University Medical School, Chicago, Illinois, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Leung</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Emerg Med Clin North Am</MedlineTA>
<NlmUniqueID>8219565</NlmUniqueID>
<ISSNLinking>0733-8627</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ankle Injuries</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Decision Support Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Emergencies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Extremities</DescriptorName>
<QualifierName MajorTopicYN="Y">injuries</QualifierName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fractures, Bone</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Knee Injuries</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Shoulder Dislocation</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">radiography</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10188493</PMID>
<DateCreated>
<Year>1999</Year>
<Month>04</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>04</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1354-5760</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>5</Volume>
<Issue>8</Issue>
<PubDate>
<MedlineDate>1998 Dec-1999 Jan</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Nursing management (Harrow, London, England : 1994)</Title>
<ISOAbbreviation>Nurs Manag (Harrow)</ISOAbbreviation>
</Journal>
<ArticleTitle>Women's health osteopathy: an alternative view.</ArticleTitle>
<Pagination>
<MedlinePgn>6-9</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hyne</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Nurs Manag (Harrow)</MedlineTA>
<NlmUniqueID>9433248</NlmUniqueID>
<ISSNLinking>1354-5760</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Great Britain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Osteopathic Medicine</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">State Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Women's Health</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10192114</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>01</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-7144</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>54</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1999</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Die Pharmazie</Title>
<ISOAbbreviation>Pharmazie</ISOAbbreviation>
</Journal>
<ArticleTitle>Antimicrobial activity of some Nepalese medicinal plants.</ArticleTitle>
<Pagination>
<MedlinePgn>232-4</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rajbhandari</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Schpke</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Pharmazie</MedlineTA>
<NlmUniqueID>9800766</NlmUniqueID>
<ISSNLinking>0031-7144</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Plant Extracts</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gram-Positive Bacteria</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Nepal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plants, Medicinal</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10192115</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>01</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-7144</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>54</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1999</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Die Pharmazie</Title>
<ISOAbbreviation>Pharmazie</ISOAbbreviation>
</Journal>
<ArticleTitle>Different kinetics of hydroquinone depletion in various medicinal plant tissue cultures producing arbutin.</ArticleTitle>
<Pagination>
<MedlinePgn>234-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jahodr</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<Affiliation>Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University, Hradec Krlov, Czech Republic.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Duskov</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Polsek</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Papugov</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Pharmazie</MedlineTA>
<NlmUniqueID>9800766</NlmUniqueID>
<ISSNLinking>0031-7144</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Hydroquinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>497-76-7</RegistryNumber>
<NameOfSubstance>Arbutin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Arbutin</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
<QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Culture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Flow Injection Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hydroquinones</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Plants, Medicinal</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10331748</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-9023</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>79</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1999</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Physical therapy</Title>
<ISOAbbreviation>Phys Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Looking for the Forrest.</ArticleTitle>
<Pagination>
<MedlinePgn>454-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rothstein</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Phys Ther</MedlineTA>
<NlmUniqueID>0022623</NlmUniqueID>
<ISSNLinking>0031-9023</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Empathy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Knowledge</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Physical Therapy Modalities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Professional-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Social Change</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Violence</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10331749</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-9023</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>79</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1999</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Physical therapy</Title>
<ISOAbbreviation>Phys Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of side lying on lung function in older individuals.</ArticleTitle>
<Pagination>
<MedlinePgn>456-66</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Body positioning exerts a strong effect on pulmonary function, but its effect on other components of the oxygen transport pathway are less well understood, especially the effects of side-lying positions. This study investigated the interrelationships between side-lying positions and indexes of lung function such as spirometry, alveolar diffusing capacity, and inhomogeneity of ventilation in older individuals.</AbstractText>
<AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">Nineteen nonsmoking subjects (mean age=62.8 years, SD=6.8, range=50-74) with no history of cardiac or pulmonary disease were tested over 2 sessions. The test positions were sitting and left side lying in one session and sitting and right side lying in the other session. In each of the positions, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), single-breath pulmonary diffusing capacity (DLCO/VA), and the slope of phase III (DN2%/L) of the single-breath nitrogen washout test to determine inhomogeneity of ventilation were measured.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with measurements obtained in the sitting position, FVC and FEV1 were decreased equally in the side-lying positions, but no change was observed in DLCO/VA or DN2%/L.</AbstractText>
<AbstractText Label="CONCLUSION AND DISCUSSION" NlmCategory="CONCLUSIONS">Side-lying positions resulted in decreases in FVC and FEV1, which is consistent with the well-documented effects of the supine position. These findings further support the need for prescriptive rather than routine body positioning of patients with risks of cardiopulmonary compromise and the need to use upright positions in which lung volumes and capacities are maximized.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Manning</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<Affiliation>Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Dean</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ross</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abboud</LastName>
<ForeName>R T</ForeName>
<Initials>RT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Phys Ther</MedlineTA>
<NlmUniqueID>0022623</NlmUniqueID>
<ISSNLinking>0031-9023</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Forced Expiratory Volume</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lung Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Posture</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pulmonary Diffusing Capacity</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spirometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vital Capacity</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10389168</PMID>
<DateCreated>
<Year>1999</Year>
<Month>07</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>07</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0869-8139</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>85</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1999</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Rossiskii fiziologicheski zhurnal imeni I.M. Sechenova / Rossiskaia akademiia nauk</Title>
<ISOAbbreviation>Ross Fiziol Zh Im I M Sechenova</ISOAbbreviation>
</Journal>
<ArticleTitle>[Ethanol modifies the ion selectivity of sodium channels in the rat sensory neurons].</ArticleTitle>
<Pagination>
<MedlinePgn>110-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Ethanol was shown to decrease the reversal potential of tetrodotoxin-resistant (TTXr) and TTX-sensitive channels in short-term culture of the dorsal root ganglion cells. The ethanol led to alterations in ionic selectivity of the TTXr channels (its shifting from the X-th Eisenmann selectivity sequence to the XI-th one). The data obtained suggest that the findings were due to selectivity filter modification because of disturbed hydrogen bounds in the channel macromolecule.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Krylov</LastName>
<ForeName>B V</ForeName>
<Initials>BV</Initials>
<Affiliation>I. P. Pavlov Institute of Physiology, Russian Acad. Sci., St. Petersburg, Russia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Vilin</LastName>
<ForeName>Iu Iu</ForeName>
<Initials>IuIu</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Katina</LastName>
<ForeName>I E</ForeName>
<Initials>IE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Podzorova</LastName>
<ForeName>S A</ForeName>
<Initials>SA</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType>English Abstract</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Etanol modifitsiruet ionnuiu izbiratel'nost' natrievykh kanalov sensornykh neronov krysy.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>RUSSIA</Country>
<MedlineTA>Ross Fiziol Zh Im I M Sechenova</MedlineTA>
<NlmUniqueID>9715665</NlmUniqueID>
<ISSNLinking>0869-8139</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cations</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Sodium Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4368-28-9</RegistryNumber>
<NameOfSubstance>Tetrodotoxin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>64-17-5</RegistryNumber>
<NameOfSubstance>Ethanol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cations</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ethanol</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ganglia, Spinal</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ion Channel Gating</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neurons, Afferent</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sodium Channels</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tetrodotoxin</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14796701</PMID>
<DateCreated>
<Year>1951</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>02</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0028-0836</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>166</Volume>
<Issue>4234</Issue>
<PubDate>
<Year>1950</Year>
<Month>Dec</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Reduction by molecular hydrogen of acetoacetate to butyrate by butyric acid bacteria.</ArticleTitle>
<Pagination>
<MedlinePgn>1077-8</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>COHEN</LastName>
<ForeName>G N</ForeName>
<Initials>GN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>COHEN-BAZIRE</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Acetoacetates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>107-92-6</RegistryNumber>
<NameOfSubstance>Butyric Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>541-50-4</RegistryNumber>
<NameOfSubstance>acetoacetic acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acetoacetates</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Bacteria</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Butyric Acid</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="CLML">5120:27591:5:76:156</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">ACETOACETIC ACID</Keyword>
<Keyword MajorTopicYN="Y">BACTERIA</Keyword>
<Keyword MajorTopicYN="Y">BUTYRIC ACID</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14817685</PMID>
<DateCreated>
<Year>1951</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>02</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2010</Year>
<Month>01</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<Volume>47</Volume>
<Issue>52</Issue>
<PubDate>
<Year>1950</Year>
<Month>Dec</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>Svenska lkartidningen</Title>
<ISOAbbreviation>Sven Lakartidn</ISOAbbreviation>
</Journal>
<ArticleTitle>[The beriberi heart].</ArticleTitle>
<Pagination>
<MedlinePgn>3017-23</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>PALMBORG</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>und</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Om beriberihjrta.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Sven Lakartidn</MedlineTA>
<NlmUniqueID>0030130</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Beriberi</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Heart Diseases</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="CLML">5120:49529:96:423</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">BERIBERI</Keyword>
<Keyword MajorTopicYN="Y">HEART IN VARIOUS DISEASES</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">13072632</PMID>
<DateCreated>
<Year>1953</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>05</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<Volume>217</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1953</Year>
<Month>Jan</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Naunyn-Schmiedebergs Archiv fr experimentelle Pathologie und Pharmakologie</Title>
<ISOAbbreviation>Naunyn Schmiedebergs Arch Exp Pathol Pharmakol</ISOAbbreviation>
</Journal>
<ArticleTitle>[Pharmacology of phosphoric acid esters; diethylthiophosphoric acid ester of ethylthioglycol].</ArticleTitle>
<Pagination>
<MedlinePgn>144-52</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>WIRTH</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
</AuthorList>
<Language>und</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Zur Pharmakologie der Phosphorsureester; diathylthiophosphorsureester des Athylthioglykol Systox-Wirkstoff.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Naunyn Schmiedebergs Arch Exp Pathol Pharmakol</MedlineTA>
<NlmUniqueID>0054224</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Insecticides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Phosphates</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Insecticides</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Phosphates</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="CLML">5324:43336:331:494</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">INSECTICIDES</Keyword>
<Keyword MajorTopicYN="Y">PHOSPHATES</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">13634534</PMID>
<DateCreated>
<Year>1959</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>07</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0014-2565</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>71</Volume>
<Issue>6</Issue>
<PubDate>
<Year>1958</Year>
<Month>Dec</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Revista clnica espaola</Title>
<ISOAbbreviation>Rev Clin Esp</ISOAbbreviation>
</Journal>
<ArticleTitle>[Physiopathology of phosphorus and calcium changes and of bone lesions in glomerular nephropathies].</ArticleTitle>
<Pagination>
<MedlinePgn>365-77</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>LICHTWITZ</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>DE SEZE</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>PARLIER</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>HIOCO</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>BORDIER</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>STRAUSS</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>FERGOLA-MIRAVET</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>spa</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Fisiopatologa de las modificaciones fosfoclcicas y de las lesiones seas en las nefropatas glomerulares.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Rev Clin Esp</MedlineTA>
<NlmUniqueID>8608576</NlmUniqueID>
<ISSNLinking>0014-2565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7723-14-0</RegistryNumber>
<NameOfSubstance>Phosphorus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Glomerulonephritis</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phosphorus</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="CLML">5936:8365:92:105:226:416</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">BONE DISEASES/physiology</Keyword>
<Keyword MajorTopicYN="Y">CALCIUM/metabolism</Keyword>
<Keyword MajorTopicYN="Y">GLOMERULONEPHRITIS/physiology</Keyword>
<Keyword MajorTopicYN="Y">PHOSPHORUS/metabolism</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14177620</PMID>
<DateCreated>
<Year>1964</Year>
<Month>11</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>12</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0016-5662</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>68</Volume>
<PubDate>
<Year>1963</Year>
<Month>Dec</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Gazzetta internazionale di medicina e chirurgia</Title>
<ISOAbbreviation>Gazz Int Med Chir</ISOAbbreviation>
</Journal>
<ArticleTitle>[JEJUNAL BIOPSY AND LIPEMIA TOLERANCE TEST IN CIRRHOTIC PATIENTS].</ArticleTitle>
<Pagination>
<MedlinePgn>SUPPL:4309-22</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>CESAREBASILE</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>GABBRIELLI</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>COLAVOLPE</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>RULLI</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
</AuthorList>
<Language>ita</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>BIOPSIA DIGIUNALE E LIPEMIA DA CARICO DEL CIRROTICO.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>ITALY</Country>
<MedlineTA>Gazz Int Med Chir</MedlineTA>
<NlmUniqueID>0373000</NlmUniqueID>
<ISSNLinking>0016-5662</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Chylomicrons</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Lipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Lipoproteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Ascites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Chylomicrons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Diabetes Mellitus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gastric Acidity Determination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gastritis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Hepatitis A</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Jaundice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Jejunum</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Lipid Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lipids</DescriptorName>
<QualifierName MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Lipoproteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Liver Cirrhosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Malaria</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Pathology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Pleurisy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Protein Deficiency</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">ASCITES</Keyword>
<Keyword MajorTopicYN="Y">BLOOD LIPIDS</Keyword>
<Keyword MajorTopicYN="Y">CHYLOMICRONS</Keyword>
<Keyword MajorTopicYN="Y">DIABETES MELLITUS</Keyword>
<Keyword MajorTopicYN="Y">GASTRIC ACIDITY DETERMINATION</Keyword>
<Keyword MajorTopicYN="Y">GASTRITIS</Keyword>
<Keyword MajorTopicYN="Y">HEPATITIS, INFECTIOUS</Keyword>
<Keyword MajorTopicYN="Y">JAUNDICE</Keyword>
<Keyword MajorTopicYN="Y">JEJUNUM</Keyword>
<Keyword MajorTopicYN="Y">LIPID METABOLISM</Keyword>
<Keyword MajorTopicYN="Y">LIPOPROTEINS</Keyword>
<Keyword MajorTopicYN="Y">LIVER CIRRHOSIS</Keyword>
<Keyword MajorTopicYN="Y">MALARIA</Keyword>
<Keyword MajorTopicYN="Y">PATHOLOGY</Keyword>
<Keyword MajorTopicYN="Y">PLEURISY</Keyword>
<Keyword MajorTopicYN="Y">PROTEIN DEFICIENCY</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14316043</PMID>
<DateCreated>
<Year>1965</Year>
<Month>10</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>12</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2010</Year>
<Month>05</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0042-0255</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>59</Volume>
<PubDate>
<MedlineDate>1965 Dec-1966 Jan</MedlineDate>
</PubDate>
</JournalIssue>
<Title>University of Toronto undergraduate dental journal</Title>
<ISOAbbreviation>Univ Toronto Undergrad Dent J</ISOAbbreviation>
</Journal>
<ArticleTitle>THE RESPONSIBILITY OF THE DENTIST AND THE DENTAL PROFESSION WITH RESPECT TO JAW FRACTURES.</ArticleTitle>
<Pagination>
<MedlinePgn>5-11</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>PHILLIPS</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>CANADA</Country>
<MedlineTA>Univ Toronto Undergrad Dent J</MedlineTA>
<NlmUniqueID>7905911</NlmUniqueID>
<ISSNLinking>0042-0255</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>D</CitationSubset>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Dentists</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fracture Fixation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fractures, Bone</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Interprofessional Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Jaw</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mandibular Injuries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Maxillofacial Injuries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Practice Management, Dental</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">DENTISTS</Keyword>
<Keyword MajorTopicYN="Y">FRACTURE FIXATION</Keyword>
<Keyword MajorTopicYN="Y">FRACTURES</Keyword>
<Keyword MajorTopicYN="Y">INTERPROFESSIONAL RELATIONS</Keyword>
<Keyword MajorTopicYN="Y">JAW</Keyword>
<Keyword MajorTopicYN="Y">MANDIBULAR INJURIES</Keyword>
<Keyword MajorTopicYN="Y">MAXILLOFACIAL INJURIES</Keyword>
<Keyword MajorTopicYN="Y">PRACTICE MANAGEMENT, DENTAL</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="OLDMEDLINE">
<PMID Version="1">14337379</PMID>
<DateCreated>
<Year>1965</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>12</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0002-9378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>93</Volume>
<PubDate>
<Year>1965</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>American journal of obstetrics and gynecology</Title>
<ISOAbbreviation>Am. J. Obstet. Gynecol.</ISOAbbreviation>
</Journal>
<ArticleTitle>SEROTONIN CONTENT OF HUMAN PLACENTA AND FETUS DURING PREGNANCY.</ArticleTitle>
<Pagination>
<MedlinePgn>411-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>KOREN</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>PFEIFER</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>SULMAN</LastName>
<ForeName>F G</ForeName>
<Initials>FG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Am J Obstet Gynecol</MedlineTA>
<NlmUniqueID>0370476</NlmUniqueID>
<ISSNLinking>0002-9378</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>50-67-9</RegistryNumber>
<NameOfSubstance>Serotonin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cesarean Section</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fetus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Histocytochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Placenta</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Serotonin</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">ABORTION</Keyword>
<Keyword MajorTopicYN="Y">CESAREAN SECTION</Keyword>
<Keyword MajorTopicYN="Y">FETUS</Keyword>
<Keyword MajorTopicYN="Y">HISTOCYTOCHEMISTRY</Keyword>
<Keyword MajorTopicYN="Y">METABOLISM</Keyword>
<Keyword MajorTopicYN="Y">PLACENTA</Keyword>
<Keyword MajorTopicYN="Y">PREGNANCY</Keyword>
<Keyword MajorTopicYN="Y">SEROTONIN</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15611660</PMID>
<DateCreated>
<Year>2005</Year>
<Month>03</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2006</Year>
<Month>03</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1551-4005</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>4</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2005</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Cell cycle (Georgetown, Tex.)</Title>
<ISOAbbreviation>Cell Cycle</ISOAbbreviation>
</Journal>
<ArticleTitle>Altered epigenetic patterning leading to replicative senescence and reduced longevity. A role of a novel SNF2 factor, PASG.</ArticleTitle>
<Pagination>
<MedlinePgn>3-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Understanding the biological mechanisms underlying aging and cancer predisposition remains a fundamentally important goal in biomedicine. The generation of a PASG hypomorphic mutant mouse model shows that PASG, an SNF2 family member, is essential for properly maintaining normal DNA methylation and gene expression patterns. Disruption of PASG leads to decreased incorporation of BrdU, accumulation of senescence-associated tumor suppressor genes, and increased senescence-associated beta-galactosidase as well as age-related phenotypes. These observations demonstrate that PASG plays a critical role in maintenance of tissue homeostasis, normal growth and longevity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Lin-Quan</ForeName>
<Initials>LQ</Initials>
<Affiliation>Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Arceci</LastName>
<ForeName>Robert J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2005</Year>
<Month>01</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell Cycle</MedlineTA>
<NlmUniqueID>101137841</NlmUniqueID>
<ISSNLinking>1551-4005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>59-14-3</RegistryNumber>
<NameOfSubstance>Bromodeoxyuridine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance>DNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.-</RegistryNumber>
<NameOfSubstance>Methyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.2.1.23</RegistryNumber>
<NameOfSubstance>beta-Galactosidase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance>DNA Helicases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.99.-</RegistryNumber>
<NameOfSubstance>Hells protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bromodeoxyuridine</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Aging</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Homeostasis</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Longevity</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Methyltransferases</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice, Mutant Strains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">beta-Galactosidase</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15611661</PMID>
<DateCreated>
<Year>2005</Year>
<Month>03</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2006</Year>
<Month>03</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1551-4005</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>4</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2005</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Cell cycle (Georgetown, Tex.)</Title>
<ISOAbbreviation>Cell Cycle</ISOAbbreviation>
</Journal>
<ArticleTitle>TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance.</ArticleTitle>
<Pagination>
<MedlinePgn>8-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Nerve growth factor receptor TrkA is critical for development and maturation of central and peripheral nervous systems, regulating proliferation, differentiation and apoptosis. In cancer, TrkA frequently exhibits suppressor activity in nonmutated form and oncogenic activity upon mutation. Our identification of a novel hypoxia-regulated alternative TrkAIII splice variant, expressed by neural crest-derived neuroblastic tumors, that exhibits neuroblastoma tumor promoting activity, adds significantly to our understanding of potential TrkA involvement in cancer. Our observation that hypoxia, which characterizes the tumor micro-environment, stimulates alternative TrkAIII splicing, provides a way by which TrkA tumor suppressing signals may convert to tumor promoting signals during progression and is consistent with conservation and pathological subversion by neural crest-derived neuroblastic tumors of a mechanism of potential physiological importance to normal neural stem/neural crest progenitors.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tacconelli</LastName>
<ForeName>Antonella</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Farina</LastName>
<ForeName>Antonietta R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cappabianca</LastName>
<ForeName>Lucia</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gulino</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mackay</LastName>
<ForeName>Andrew R</ForeName>
<Initials>AR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2005</Year>
<Month>01</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell Cycle</MedlineTA>
<NlmUniqueID>101137841</NlmUniqueID>
<ISSNLinking>1551-4005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance>Receptor, trkA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Alternative Splicing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Hypoxia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Genetic Variation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neural Crest</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptor, trkA</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15611667</PMID>
<DateCreated>
<Year>2005</Year>
<Month>03</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2006</Year>
<Month>03</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1551-4005</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>4</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2005</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Cell cycle (Georgetown, Tex.)</Title>
<ISOAbbreviation>Cell Cycle</ISOAbbreviation>
</Journal>
<ArticleTitle>Replication timing of human chromosome 6.</ArticleTitle>
<Pagination>
<MedlinePgn>172-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Genomic microarrays have been used to assess DNA replication timing in a variety of eukaryotic organisms. A replication timing map of the human genome has already been published at a 1Mb resolution. Here we describe how the same method can be used to assess the replication timing of chromosome 6 with a greater resolution using an array of overlapping tile path clones. We report the replication timing map of the whole of chromosome 6 in general, and the MHC region in particular. Positive correlations are observed between replication timing and a number of genomic features including GC content, repeat content and transcriptional activity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Woodfine</LastName>
<ForeName>Kathryn</ForeName>
<Initials>K</Initials>
<Affiliation>Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Beare</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ichimura</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Debernardi</LastName>
<ForeName>Silvana</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mungall</LastName>
<ForeName>Andrew J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fiegler</LastName>
<ForeName>Heike</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Collins</LastName>
<ForeName>V Peter</ForeName>
<Initials>VP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carter</LastName>
<ForeName>Nigel P</ForeName>
<Initials>NP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dunham</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2005</Year>
<Month>01</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell Cycle</MedlineTA>
<NlmUniqueID>101137841</NlmUniqueID>
<ISSNLinking>1551-4005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>71-30-7</RegistryNumber>
<NameOfSubstance>Cytosine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>73-40-5</RegistryNumber>
<NameOfSubstance>Guanine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance>DNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromosome Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromosomes, Human, Pair 6</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cytosine</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Repeat Expansion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">DNA Replication Timing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">G1 Phase</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Guanine</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Major Histocompatibility Complex</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">S Phase</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15739502</PMID>
<DateCreated>
<Year>2005</Year>
<Month>03</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2010</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1000-8713</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1997</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Se pu = Chinese journal of chromatography / Zhongguo hua xue hui</Title>
<ISOAbbreviation>Se Pu</ISOAbbreviation>
</Journal>
<ArticleTitle>[The determination of olaquindox in feeds by HPLC].</ArticleTitle>
<Pagination>
<MedlinePgn>440-1</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A liquid chromatographic procedure for the determination of olaquindox in feeds is described. Chromatography was performed on a PC8-10/S2504 (4.0 mm i.d. x 250 mm, 10 microm, Shimadzu Co.) column at 30 degrees C by using a mobile phase of methanol:water (20:80, V/V ) with a flow rate of 0.8 mL/min and UV detection at 260 nm. Acetanilide was used as internal standard. Olaquindox was extracted with dimethylformamide (DMF) from the feeds. The average recoveries of olaquindox were 98.58%-101.63% and the relative standard deviations were 2.67%-4.25%. The method is simple, rapid, reliable and inexpensive.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<Affiliation>Institute of Applied Chemistry, Nanchang University, Nanchang, 330047.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Qiu</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType>English Abstract</PublicationType>
<PublicationType>Evaluation Studies</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Se Pu</MedlineTA>
<NlmUniqueID>9424804</NlmUniqueID>
<ISSNLinking>1000-8713</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Food Additives</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Quinoxalines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>23696-28-8</RegistryNumber>
<NameOfSubstance>olaquindox</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animal Feed</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Food Additives</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Quinoxalines</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">15810377</PMID>
<DateCreated>
<Year>2005</Year>
<Month>04</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2010</Year>
<Month>05</Month>
<Day>21</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1000-0593</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>17</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1997</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Guang pu xue yu guang pu fen xi = Guang pu</Title>
<ISOAbbreviation>Guang Pu Xue Yu Guang Pu Fen Xi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Study on cleavage mechanisms of dimer (t-Bu)2NO in several solvent phases].</ArticleTitle>
<Pagination>
<MedlinePgn>124-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>In this paper, we studied the cleavage products of dimer t-BuNO in aqueous and organic solutions using method of 1HNMR and UV-Vis, analyzed the reactive kinetics, put forward that dimer (t-Bu)2NO homolytically cleavaged in nonpolar organic solution, and that dimer (t-Bu)2NO homolytically and heterolyticall cleavaged in a competitive manner in polar aqueous solution.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<Affiliation>Cancer Research Institute, Hunan Medical University, Changsha.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType>English Abstract</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Guang Pu Xue Yu Guang Pu Fen Xi</MedlineTA>
<NlmUniqueID>9424805</NlmUniqueID>
<ISSNLinking>1000-0593</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15968009</PMID>
<DateCreated>
<Year>2005</Year>
<Month>06</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2005</Year>
<Month>06</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1539-3704</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>142</Volume>
<Issue>12 Pt 1</Issue>
<PubDate>
<Year>2005</Year>
<Month>Jun</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>Annals of internal medicine</Title>
<ISOAbbreviation>Ann. Intern. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.</ArticleTitle>
<Pagination>
<MedlinePgn>953-62</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE).</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effect of hormone replacement therapy (HRT) on disease activity in postmenopausal women with SLE.</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized, double-blind, placebo-controlled noninferiority trial conducted from March 1996 to June 2002.</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">16 university-affiliated rheumatology clinics or practices in 11 U.S. states.</AbstractText>
<AbstractText Label="PATIENTS" NlmCategory="METHODS">351 menopausal patients (mean age, 50 years) with inactive (81.5%) or stable-active (18.5%) SLE. Interventions: 12 months of treatment with active drug (0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month) or placebo. The 12-month follow-up rate was 82% for the HRT group and 87% for the placebo group.</AbstractText>
<AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">The primary end point was occurrence of a severe flare as defined by Safety of Estrogens in Lupus Erythematosus, National Assessment-Systemic Lupus Erythematosus Disease Activity Index composite.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Severe flare was rare in both treatment groups: The 12-month severe flare rate was 0.081 for the HRT group and 0.049 for the placebo group, yielding an estimated difference of 0.033 (P = 0.23). The upper limit of the 1-sided 95% CI for the treatment difference was 0.078, within the prespecified margin of 9% for noninferiority. Mild to moderate flares were significantly increased in the HRT group: 1.14 flares/person-year for HRT and 0.86 flare/person-year for placebo (relative risk, 1.34; P = 0.01). The probability of any type of flare by 12 months was 0.64 for the HRT group and 0.51 for the placebo group (P = 0.01). In the HRT group, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an arteriovenous graft; in the placebo group, 1 patient developed deep venous thrombosis.</AbstractText>
<AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Findings are not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adding a short course of HRT is associated with a small risk for increasing the natural flare rate of lupus. Most of these flares are mild to moderate. The benefits of HRT can be balanced against the risk for flare because HRT did not significantly increase the risk for severe flare compared with placebo.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Buyon</LastName>
<ForeName>Jill P</ForeName>
<Initials>JP</Initials>
<Affiliation>Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA. jill.buyon@nyumc.org</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Petri</LastName>
<ForeName>Michelle A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Mimi Y</ForeName>
<Initials>MY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kalunian</LastName>
<ForeName>Kenneth C</ForeName>
<Initials>KC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grossman</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hahn</LastName>
<ForeName>Bevra H</ForeName>
<Initials>BH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Merrill</LastName>
<ForeName>Joan T</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sammaritano</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lockshin</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alarcn</LastName>
<ForeName>Graciela S</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Manzi</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Belmont</LastName>
<ForeName>H Michael</ForeName>
<Initials>HM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Askanase</LastName>
<ForeName>Anca D</ForeName>
<Initials>AD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sigler</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dooley</LastName>
<ForeName>Mary Anne</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Von Feldt</LastName>
<ForeName>Joan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McCune</LastName>
<ForeName>W Joseph</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Friedman</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wachs</LastName>
<ForeName>Jane</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cronin</LastName>
<ForeName>Mary</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hearth-Holmes</LastName>
<ForeName>Michelene</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Licciardi</LastName>
<ForeName>Frederick</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00000419</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AR 43727</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01 RR00052</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>M01 RR00096</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 AR42540</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Multicenter Study</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Ann Intern Med</MedlineTA>
<NlmUniqueID>0372351</NlmUniqueID>
<ISSNLinking>0003-4819</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Estrogens, Conjugated (USP)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>520-85-4</RegistryNumber>
<NameOfSubstance>Medroxyprogesterone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Ann Intern Med. 2005 Jun 21;142(12 Pt 1):1014-5</RefSource>
<PMID Version="1">15968016</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="SummaryForPatientsIn">
<RefSource>Ann Intern Med. 2005 Jun 21;142(12 Pt 1):I22</RefSource>
<PMID Version="1">15968006</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Estrogen Replacement Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Estrogens, Conjugated (USP)</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
<QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Medroxyprogesterone</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Postmenopause</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16779244</PMID>
<DateCreated>
<Year>2006</Year>
<Month>06</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>02</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>03</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1942-597X</ISSN>
<JournalIssue CitedMedium="Internet">
<PubDate>
<Year>2005</Year>
</PubDate>
</JournalIssue>
<Title>AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium</Title>
<ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation>
</Journal>
<ArticleTitle>MeSH Speller + askMEDLINE: auto-completes MeSH terms then searches MEDLINE/PubMed via free-text, natural language queries.</ArticleTitle>
<Pagination>
<MedlinePgn>957</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Medical terminology is challenging even for healthcare personnel. Spelling errors can make searching MEDLINE/PubMed ineffective. We developed a utility that provides MeSH term and Specialist Lexicon Vocabulary suggestions as it is typed on a search page. The correctly spelled term can be incorporated into a free-text, natural language search or used as a clinical queries search.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fontelo</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<Affiliation>Office of High Performance Computing and Communications, National Library of Medicine, 8600 Rockville Pike, Bethesda, Maryland 20894, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Fang</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ackerman</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>Z99 LM999999</GrantID>
<Acronym>LM</Acronym>
<Agency>NLM NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>AMIA Annu Symp Proc</MedlineTA>
<NlmUniqueID>101209213</NlmUniqueID>
<ISSNLinking>1559-4076</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>J Med Internet Res. 2003 Dec 11;5(4):e31</RefSource>
<PMID Version="1">14713659</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 1998 Oct 21;280(15):1336-8</RefSource>
<PMID Version="1">9794314</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Information Storage and Retrieval</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Medical Subject Headings</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Natural Language Processing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">PubMed</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC1513542</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16776646</PMID>
<DateCreated>
<Year>2006</Year>
<Month>06</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2006</Year>
<Month>08</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0248-4900</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>98</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2006</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Biology of the cell / under the auspices of the European Cell Biology Organization</Title>
<ISOAbbreviation>Biol. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Books for free? How can this be? - A PubMed resource you may be overlooking.</ArticleTitle>
<Pagination>
<MedlinePgn>439-43</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The NCBI (National Center for Biotechnology Information) at the National Institutes of Health collects a wide range of molecular biological data, and develops tools and databases to analyse and disseminate this information. Many life scientists are familiar with the website maintained by the NCBI (http://www.ncbi.nlm.nih.gov), because they use it to search GenBank for homologues of their genes of interest or to search the PubMed database for scientific literature of interest. There is also a database called the Bookshelf that includes searchable popular life science textbooks, medical and research reference books and NCBI reference materials. The Bookshelf can be useful for researchers and educators to find basic biological information. This article includes a representative list of the resources currently available on the Bookshelf, as well as instructions on how to access the information in these resources.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Corsi</LastName>
<ForeName>Ann K</ForeName>
<Initials>AK</Initials>
<Affiliation>Department of Biology, The Catholic University of America, Washington, DC 20064, USA. corsi@cua.edu</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biol Cell</MedlineTA>
<NlmUniqueID>8108529</NlmUniqueID>
<ISSNLinking>0248-4900</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Biological Science Disciplines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Books</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Internet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">National Library of Medicine (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">PubMed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Reference Books</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Reference Books, Medical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Textbooks as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16888359</PMID>
<DateCreated>
<Year>2006</Year>
<Month>08</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2006</Year>
<Month>09</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>06</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1064-3745</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>338</Volume>
<PubDate>
<Year>2006</Year>
</PubDate>
</JournalIssue>
<Title>Methods in molecular biology (Clifton, N.J.)</Title>
<ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mining microarray data at NCBI's Gene Expression Omnibus (GEO)*.</ArticleTitle>
<Pagination>
<MedlinePgn>175-90</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) has emerged as the leading fully public repository for gene expression data. This chapter describes how to use Web-based interfaces, applications, and graphics to effectively explore, visualize, and interpret the hundreds of microarray studies and millions of gene expression patterns stored in GEO. Data can be examined from both experiment-centric and gene-centric perspectives using user-friendly tools that do not require specialized expertise in microarray analysis or time-consuming download of massive data sets. The GEO database is publicly accessible through the World Wide Web at http://www.ncbi.nlm.nih.gov/geo.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barrett</LastName>
<ForeName>Tanya</ForeName>
<Initials>T</Initials>
<Affiliation>National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Edgar</LastName>
<ForeName>Ron</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Methods Mol Biol</MedlineTA>
<NlmUniqueID>9214969</NlmUniqueID>
<ISSNLinking>1064-3745</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2003 Jun 13;300(5626):1749-51</RefSource>
<PMID Version="1">12805549</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W213-6</RefSource>
<PMID Version="1">15215383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13618-23</RefSource>
<PMID Version="1">15353598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2002 Jan 1;30(1):207-10</RefSource>
<PMID Version="1">11752295</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Physiol Genomics. 2004 Sep 16;19(1):131-42</RefSource>
<PMID Version="1">15238619</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2005 Jan 1;33(Database issue):D562-6</RefSource>
<PMID Version="1">15608262</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods Enzymol. 1996;266:141-62</RefSource>
<PMID Version="1">8743683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1990 Oct 5;215(3):403-10</RefSource>
<PMID Version="1">2231712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Biol. 2004 Dec;2(12):e427</RefSource>
<PMID Version="1">15562319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2005 Jan 1;33(Database issue):D39-45</RefSource>
<PMID Version="1">15608222</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Databases, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
<QualifierName MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Information Storage and Retrieval</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Internet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">National Library of Medicine (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
<QualifierName MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Software</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS12705</OtherID>
<OtherID Source="NLM">PMC1619899</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16923641</PMID>
<DateCreated>
<Year>2006</Year>
<Month>08</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>01</Month>
<Day>25</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0803-9488</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>60</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2006</Year>
</PubDate>
</JournalIssue>
<Title>Nordic journal of psychiatry</Title>
<ISOAbbreviation>Nord J Psychiatry</ISOAbbreviation>
</Journal>
<ArticleTitle>The use of PubMed/Medline in psychiatry. 3: Searching PubMed.</ArticleTitle>
<Pagination>
<MedlinePgn>310-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This paper is the third in a series of three, intended as a tutorial in the use of PubMed/Medline for an inexperienced user. The papers have the following contents: I--a description of NLM, Medline, PubMed and the system of Medical Subject Headings (MeSH), which form the basis for the indexing of scientific articles, books and other items at NLM. II--A description and a tutorial of the PubMed search window. III--The present article deals mainly with the searching for references in PubMed. Ways of restricting and concentrating the search are presented, and exercises are proposed. A reader may also find guidance for a search for medical books in the NLM Catalog, and in the use of tools like Related Articles, Bookshelf, and Index. With eating disorders as an example, more information is presented on the use of MeSH terms.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Theander</LastName>
<ForeName>Sten S</ForeName>
<Initials>SS</Initials>
<Affiliation>Division of Psychiatry, Department of Clinical Neuroscience, Lund University, Sweden. sten.theander@med.lu.se</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Norway</Country>
<MedlineTA>Nord J Psychiatry</MedlineTA>
<NlmUniqueID>100927567</NlmUniqueID>
<ISSNLinking>0803-9488</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">MEDLINE</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Medical Subject Headings</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Psychiatry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">PubMed</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16949478</PMID>
<DateCreated>
<Year>2006</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2006</Year>
<Month>09</Month>
<Day>21</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1558-3597</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>48</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2006</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Journal of the American College of Cardiology</Title>
<ISOAbbreviation>J. Am. Coll. Cardiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death).</ArticleTitle>
<Pagination>
<MedlinePgn>e247-346</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<CollectiveName>European Heart Rhythm Association</CollectiveName>
</Author>
<Author ValidYN="Y">
<CollectiveName>Heart Rhythm Society</CollectiveName>
</Author>
<Author ValidYN="Y">
<LastName>Zipes</LastName>
<ForeName>Douglas P</ForeName>
<Initials>DP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Camm</LastName>
<ForeName>A John</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Borggrefe</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buxton</LastName>
<ForeName>Alfred E</ForeName>
<Initials>AE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chaitman</LastName>
<ForeName>Bernard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fromer</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gregoratos</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klein</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moss</LastName>
<ForeName>Arthur J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Myerburg</LastName>
<ForeName>Robert J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Priori</LastName>
<ForeName>Silvia G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Quinones</LastName>
<ForeName>Miguel A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roden</LastName>
<ForeName>Dan M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Silka</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tracy</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Sidney C</ForeName>
<Initials>SC</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author ValidYN="Y">
<LastName>Jacobs</LastName>
<ForeName>Alice K</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adams</LastName>
<ForeName>Cynthia D</ForeName>
<Initials>CD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Antman</LastName>
<ForeName>Elliott M</ForeName>
<Initials>EM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anderson</LastName>
<ForeName>Jeffrey L</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hunt</LastName>
<ForeName>Sharon A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Halperin</LastName>
<ForeName>Jonathan L</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishimura</LastName>
<ForeName>Rick</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ornato</LastName>
<ForeName>Joseph P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Page</LastName>
<ForeName>Richard L</ForeName>
<Initials>RL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Riegel</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Priori</LastName>
<ForeName>Silvia G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blanc</LastName>
<ForeName>Jean-Jacques</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Budaj</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Camm</LastName>
<ForeName>A John</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dean</LastName>
<ForeName>Veronica</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deckers</LastName>
<ForeName>Jaap W</ForeName>
<Initials>JW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Despres</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dickstein</LastName>
<ForeName>Kenneth</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lekakis</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McGregor</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Metra</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morais</LastName>
<ForeName>Joao</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Osterspey</LastName>
<ForeName>Ady</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tamargo</LastName>
<ForeName>Juan Luis</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zamorano</LastName>
<ForeName>Jos Luis</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>American College of Cardiology</CollectiveName>
</Author>
<Author ValidYN="Y">
<CollectiveName>American Heart Association Task Force</CollectiveName>
</Author>
<Author ValidYN="Y">
<CollectiveName>European Society of Cardiology Committee for Practice Guidelines</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Practice Guideline</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Am Coll Cardiol</MedlineTA>
<NlmUniqueID>8301365</NlmUniqueID>
<ISSNLinking>0735-1097</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-Arrhythmia Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiac Output, Low</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiomyopathies</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Catheter Ablation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Death, Sudden, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Defibrillators, Implantable</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electrocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Arrest</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Function Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tachycardia, Ventricular</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ventricular Fibrillation</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17059514</PMID>
<DateCreated>
<Year>2006</Year>
<Month>10</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>05</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0269-2813</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>24</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2006</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Alimentary pharmacology &amp; therapeutics</Title>
<ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>1333-40</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although thiopurines have a proven role in maintenance therapy for Crohn's disease, an alternative therapy is needed for patients intolerant or resistant to thiopurines.</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the effectiveness of home enteral nutrition as a maintenance therapy regimen in which half of the daily calorie requirement is provided by an elemental diet and the remaining half by a free diet. We refer to this home enteral nutrition therapy as 'half elemental diet'.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Between 2002 and 2005, 51 patients in remission from two hospitals were randomly assigned to a half elemental diet group (n = 26) or a free diet group (n = 25). The primary outcome measure of this study was the occurrence of relapse over the 2-year period.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The relapse rate in the half elemental diet group was significantly lower [34.6% vs. 64.0%; multivariate hazard ratio 0.40 (95% CI: 0.16-0.98)] than that in the free diet group after a mean follow-up of 11.9 months. Compliance was similar in the two groups. No adverse event occurred in any of the patients throughout the study.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This randomized-controlled trial shows the effectiveness of an half elemental diet, which is a promising maintenance therapy for Crohn's disease patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Takagi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<Affiliation>Division of Gastroenterology, Department of Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. stakagi@int3.med.tohoku.ac.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Utsunomiya</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuriyama</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yokoyama</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iwabuchi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kinouchi</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hiwatashi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Funayama</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sasaki</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tsuji</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shimosegawa</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Aliment Pharmacol Ther</MedlineTA>
<NlmUniqueID>8707234</NlmUniqueID>
<ISSNLinking>0269-2813</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Crohn Disease</DescriptorName>
<QualifierName MajorTopicYN="Y">diet therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Enteral Nutrition</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Food, Formulated</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Parenteral Nutrition</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17712873</PMID>
<DateCreated>
<Year>2007</Year>
<Month>08</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>08</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>10</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1432-2218</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>21</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2007</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Surgical endoscopy</Title>
<ISOAbbreviation>Surg Endosc</ISOAbbreviation>
</Journal>
<ArticleTitle>Crura ultrastructural alterations in patients with hiatal hernia: a pilot study.</ArticleTitle>
<Pagination>
<MedlinePgn>907-11</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fei</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<Affiliation>Unit of Surgical Digestive Physiopathology, Second University of Naples, via Pansini 5, I-80131 Naples, Italy. landino.fei@tin.it</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>del Genio</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brusciano</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Esposito</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cuttitta</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pizza</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rossetti</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trapani</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Filippone</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moccia</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="N">
<LastName>Francesco</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>del Genio</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Surg Endosc</MedlineTA>
<NlmUniqueID>8806653</NlmUniqueID>
<ISSNLinking>0930-2794</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Surg Endosc. 2007 Aug;21(8):1473</RefSource>
<Note>Francesco, M [removed]; Moccia, F [added]</Note>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Connective Tissue</DescriptorName>
<QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diaphragm</DescriptorName>
<QualifierName MajorTopicYN="N">abnormalities</QualifierName>
<QualifierName MajorTopicYN="Y">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastroesophageal Reflux</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hernia, Hiatal</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17713168</PMID>
<DateCreated>
<Year>2007</Year>
<Month>08</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>10</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1359-6535</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2007</Year>
</PubDate>
</JournalIssue>
<Title>Antiviral therapy</Title>
<ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation>
</Journal>
<ArticleTitle>Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.</ArticleTitle>
<Pagination>
<MedlinePgn>835-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">A major barrier to successful viral suppression in HIV type 1 (HIV-1)-infected individuals is the emergence of virus resistant to antiretroviral drugs. We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Prevalence of major International AIDS Society-USA HIV-1 drug resistance mutations was measured over calendar years in a population with treatment failure and undergoing resistance testing. Predictors of the presence of resistance mutations were analysed by logistic regression.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant reductions of the prevalence of resistance to all three drug classes examined were observed. This was accompanied by a reduction in the proportion of treatment-failing patients. Independent predictors of drug resistance were the earlier calendar year, prior use of suboptimal nucleoside analogue therapy, male sex and higher CD4 levels at testing.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In a single clinical cohort, we observed a decrease in the prevalence of resistance to all three examined antiretroviral drug classes over time. If this finding is confirmed in multicentre cohorts it may translate into reduced transmission of drug-resistant virus from treated patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Di Giambenedetto</LastName>
<ForeName>Simona</ForeName>
<Initials>S</Initials>
<Affiliation>Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy. simona.digiambenedetto@rm.unicatt.it</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bracciale</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Colafigli</LastName>
<ForeName>Manuela</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="N">
<LastName>Colatigli</LastName>
<ForeName>Manuela</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cattani</LastName>
<ForeName>Paola</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pinnetti</LastName>
<ForeName>Carmen</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="N">
<LastName>Pannetti</LastName>
<ForeName>Carmen</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bacarelli</LastName>
<ForeName>Alessandro</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Prosperi</LastName>
<ForeName>Mattia</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fadda</LastName>
<ForeName>Giovanni</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cauda</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Luca</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Antivir Ther</MedlineTA>
<NlmUniqueID>9815705</NlmUniqueID>
<ISSNLinking>1359-6535</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Antivir Ther. 2007;12(7):1145</RefSource>
<Note>Colatigli, Manuela [corrected to Colafigli, Manuela; Cattani, Paola [added]; Pannetti, Carmen [corrected to Pinnetti, Carmen]</Note>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Population Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">RNA, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Treatment Failure</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17823161</PMID>
<DateCreated>
<Year>2007</Year>
<Month>09</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>09</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>03</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1756-1833</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>335</Volume>
<Issue>7618</Issue>
<PubDate>
<Year>2007</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>BMJ (Clinical research ed.)</Title>
<ISOAbbreviation>BMJ</ISOAbbreviation>
</Journal>
<ArticleTitle>Agency warns about dosing error for amphotericin after patients with cancer die.</ArticleTitle>
<Pagination>
<MedlinePgn>467</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hawkes</LastName>
<ForeName>Nigel</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>News</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMJ</MedlineTA>
<NlmUniqueID>8900488</NlmUniqueID>
<ISSNLinking>0959-535X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antifungal Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1397-89-3</RegistryNumber>
<NameOfSubstance>Amphotericin B</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>BMJ. 2008 Jan 12;336(7635). doi: 10.1136/bmj.39454.454676.AD</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Amphotericin B</DescriptorName>
<QualifierName MajorTopicYN="Y">poisoning</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antifungal Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">poisoning</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">England</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Medication Errors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mycoses</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC1971151</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="OLDMEDLINE">
<PMID Version="1">18122624</PMID>
<DateCreated>
<Year>1949</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>12</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0891-3633</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>59 (1 vol.)</Volume>
<PubDate>
<MedlineDate>1947-1948</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Transactions of the Southern Surgical Association. Southern Surgical Association (U.S.)</Title>
<ISOAbbreviation>Trans South Surg Assoc</ISOAbbreviation>
</Journal>
<ArticleTitle>Mesenteric vascular occlusion.</ArticleTitle>
<Pagination>
<MedlinePgn>136-55</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>RIVES</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>STRUG</LastName>
<ForeName>L H</ForeName>
<Initials>LH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>ESSRIG</LastName>
<ForeName>I M</ForeName>
<Initials>IM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Trans South Surg Assoc</MedlineTA>
<NlmUniqueID>20930080R</NlmUniqueID>
<ISSNLinking>0891-3633</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>OM</CitationSubset>
<OtherID Source="CLML">4916:397a1</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">MESENTERY/occlusion</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">18243949</PMID>
<DateCreated>
<Year>2008</Year>
<Month>02</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2012</Year>
<Month>10</Month>
<Day>02</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0278-0062</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1985</Year>
</PubDate>
</JournalIssue>
<Title>IEEE transactions on medical imaging</Title>
<ISOAbbreviation>IEEE Trans Med Imaging</ISOAbbreviation>
</Journal>
<ArticleTitle>Electrophoretic recording of electronically stored radiographs.</ArticleTitle>
<Pagination>
<MedlinePgn>39-43</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Continuous tone hard copies of electronically stored radiographs are recorded on transparent film with a silverless conductive coating by electrophoretic deposition of toner particles. A stationary experimental print head with a row of 320 electrodes (eight electrodes per mm) was employed. The performance of the recording process with regard to the most important parameters, i.e., toner concentration, width of the gap between recording medium and electrodes, recording voltage, and speed will be described. The process exhibits continuous tone characteristics, because the optical density can be varied continuously by the recording voltage. The image resolution which can be achieved is characterized by a modulation transfer function.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hinz</LastName>
<ForeName>H D</ForeName>
<Initials>HD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lobl</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>IEEE Trans Med Imaging</MedlineTA>
<NlmUniqueID>8310780</NlmUniqueID>
<ISSNLinking>0278-0062</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Data-Review">
<PMID Version="1">18311089</PMID>
<DateCreated>
<Year>2008</Year>
<Month>03</Month>
<Day>03</Day>
</DateCreated>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1091-0220</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2008</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Mayo Clinic women's healthsource</Title>
<ISOAbbreviation>Mayo Clin Womens Healthsource</ISOAbbreviation>
</Journal>
<ArticleTitle>Cancer death rates have fallen faster since 2002.</ArticleTitle>
<Pagination>
<MedlinePgn>3</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mayo Clin Womens Healthsource</MedlineTA>
<NlmUniqueID>9891120</NlmUniqueID>
<ISSNLinking>1091-0220</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>K</CitationSubset>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17926191</PMID>
<DateCreated>
<Year>2008</Year>
<Month>03</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2008</Year>
<Month>04</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1042-8194</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>48</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2007</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia &amp; lymphoma</Title>
<ISOAbbreviation>Leuk. Lymphoma</ISOAbbreviation>
</Journal>
<ArticleTitle>Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.</ArticleTitle>
<Pagination>
<MedlinePgn>2145-51</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>AML with inv(3)/t(3;3) are generally considered of having a poor prognosis. For further insight in this rare entity the outcome of 65 inv(3)/t(3;3) positive AML cases were examined with special emphasis o n patient a nd disease related factors at diagnosis. Survival data were available from 35 patients. A hematological CR was achieved in 16/35 patients (46%). Eight patients (50%) relapsed. The median duration of remission was 177 days. Probability of OS was 23% at 2 years. Advanced age and high initial WBC count were associated with shorter OS (p = 0.021 and p = 0.005, respectively). Loss of chromosome 7 was the most frequent additional aberration (n = 34; 52%), followed complex aberrant aberrations (n = 5). Cases with monosomy 7 or the presence of FLT3-length mutations (FLT3-LM)--detected in 13% of cases--were not associated with an even more inferior outcome. Allogeneic stem cell translplantation, performed in 12 cases, resulted in a probability of OS of 62% at 2 years. Our data (1) confirm that inv(3)/t(3;3) AML has a poor prognosis (2) show that age and initial WBC are risk factors for prognosis; (3) suggest that this group may benefit from allogeneic stem cell transplantation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Weisser</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<Affiliation>Medical Department III, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany. martin.weisser@gmx.de</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Haferlach</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haferlach</LastName>
<ForeName>Torsten</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schnittger</LastName>
<ForeName>Susanne</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Evaluation Studies</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leuk Lymphoma</MedlineTA>
<NlmUniqueID>9007422</NlmUniqueID>
<ISSNLinking>1026-8022</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>10540-29-1</RegistryNumber>
<NameOfSubstance>Tamoxifen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>125-84-8</RegistryNumber>
<NameOfSubstance>Aminoglutethimide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147-94-4</RegistryNumber>
<NameOfSubstance>Cytarabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>17230-88-5</RegistryNumber>
<NameOfSubstance>Danazol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>65271-80-9</RegistryNumber>
<NameOfSubstance>Mitoxantrone</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Protocol">MAC chemotherapy protocol</SupplMeshName>
<SupplMeshName Type="Protocol">TAD protocol</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Leuk Lymphoma. 2007 Nov;48(11):2096-7</RefSource>
<PMID Version="1">17990175</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aminoglutethimide</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Chromosome Inversion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Chromosomes, Human, Pair 3</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cytarabine</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Danazol</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Karyotyping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="N">mortality</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Leukocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mitoxantrone</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tamoxifen</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Translocation, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">18719013</PMID>
<DateCreated>
<Year>2008</Year>
<Month>08</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2008</Year>
<Month>09</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1756-1833</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>337</Volume>
<PubDate>
<Year>2008</Year>
</PubDate>
</JournalIssue>
<Title>BMJ (Clinical research ed.)</Title>
<ISOAbbreviation>BMJ</ISOAbbreviation>
</Journal>
<ArticleTitle>Health related quality of life after combined hormone replacement therapy: randomised controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>a1190</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.a1190</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">337/aug21_2/a1190</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life.</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">Randomised placebo controlled double blind trial.</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">General practices in United Kingdom (384), Australia (94), and New Zealand (24).</AbstractText>
<AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively.</AbstractText>
<AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year.</AbstractText>
<AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Health related quality of life and psychological wellbeing as measured by the women's health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiological Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">After one year small but significant improvements were observed in three of nine components of the women's health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P&lt;0.001), sexual functioning (P&lt;0.001), and sleep problems (P&lt;0.001). Significantly fewer women in the combined HRT group reported hot flushes (P&lt;0.001), night sweats (P&lt;0.001), aching joints and muscles (P=0.001), insomnia (P&lt;0.001), and vaginal dryness (P&lt;0.001) than in the placebo group, but greater proportions reported breast tenderness (P&lt;0.001) or vaginal discharge (P&lt;0.001). Hot flushes were experienced in the combined HRT and placebo groups by 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Combined HRT started many years after the menopause can improve health related quality of life.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ISRCTN 63718836.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Welton</LastName>
<ForeName>Amanda J</ForeName>
<Initials>AJ</Initials>
<Affiliation>MRC General Practice Research Framework, Stephenson House, London NW1 2ND.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Vickers</LastName>
<ForeName>Madge R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ford</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lawton</LastName>
<ForeName>Beverley A</ForeName>
<Initials>BA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacLennan</LastName>
<ForeName>Alastair H</ForeName>
<Initials>AH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meredith</LastName>
<ForeName>Sarah K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martin</LastName>
<ForeName>Jeannett</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meade</LastName>
<ForeName>Tom W</ForeName>
<Initials>TW</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>WISDOM team</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ISRCTN</DataBankName>
<AccessionNumberList>
<AccessionNumber>ISRCTN63718836</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<Agency>British Heart Foundation</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Department of Health</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Multicenter Study</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2008</Year>
<Month>08</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMJ</MedlineTA>
<NlmUniqueID>8900488</NlmUniqueID>
<ISSNLinking>0959-535X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Estrogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Progestins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Obstet Gynecol. 1994 Feb;170(2):618-24</RefSource>
<PMID Version="1">7509570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Public Health. 1994;15:535-59</RefSource>
<PMID Version="1">8054098</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Soc Sci Med. 1994 Dec;39(11):1537-44</RefSource>
<PMID Version="1">7817218</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Support Care Cancer. 1995 Jan;3(1):11-22</RefSource>
<PMID Version="1">7697298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Horm Behav. 1996 Sep;30(3):244-50</RefSource>
<PMID Version="1">8918680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Qual Life Res. 1996 Oct;5(5):469-80</RefSource>
<PMID Version="1">8973126</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Obstet Gynaecol. 1997 Oct;104(10):1191-5</RefSource>
<PMID Version="1">9332999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stroke. 1997 Oct;28(10):1876-82</RefSource>
<PMID Version="1">9341688</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Med Care. 1997 Nov;35(11):1109-18</RefSource>
<PMID Version="1">9366890</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stroke. 1998 Jan;29(1):63-8</RefSource>
<PMID Version="1">9445330</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Allergy Clin Immunol. 1998 Jul;102(1):16-7</RefSource>
<PMID Version="1">9679842</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Fertil Steril. 2005 Mar;83(3):558-66</RefSource>
<PMID Version="1">15749481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Climacteric. 2005 Mar;8(1):49-55</RefSource>
<PMID Version="1">15804731</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Intern Med. 2005 Apr 25;165(8):863-7</RefSource>
<PMID Version="1">15851636</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2005 Jul 13;294(2):183-93</RefSource>
<PMID Version="1">16014592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Intern Med. 2005 Sep 26;165(17):1976-86</RefSource>
<PMID Version="1">16186467</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neurobiol Aging. 2006 Jan;27(1):141-9</RefSource>
<PMID Version="1">16298249</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Horm Behav. 2006 Apr;49(4):441-9</RefSource>
<PMID Version="1">16257405</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2006 Apr 6;354(14):1497-506</RefSource>
<PMID Version="1">16598046</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hypertension. 2006 May;47(5):833-9</RefSource>
<PMID Version="1">16585410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Gen Intern Med. 2006 Apr;21(4):363-6</RefSource>
<PMID Version="1">16686814</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Climacteric. 2007 Jun;10(3):181-94</RefSource>
<PMID Version="1">17487645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMJ. 2007 Aug 4;335(7613):239</RefSource>
<PMID Version="1">17626056</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neurology. 2007 Sep 25;69(13):1322-30</RefSource>
<PMID Version="1">17893293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Decubitus. 1993 Sep;6(5):56-8</RefSource>
<PMID Version="1">8286021</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMJ. 1993 Oct 2;307(6908):836-40</RefSource>
<PMID Version="1">8401125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Psychiatry. 1983 Jan;140(1):41-6</RefSource>
<PMID Version="1">6847983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Menopause. 2004 Sep-Oct;11(5):508-18</RefSource>
<PMID Version="1">15356403</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Gen Intern Med. 2004 Jul;19(7):791-804</RefSource>
<PMID Version="1">15209595</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Health Qual Life Outcomes. 2003;1:24</RefSource>
<PMID Version="1">12848895</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMJ. 2004 Feb 14;328(7436):371</RefSource>
<PMID Version="1">14962874</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biol Psychiatry. 2004 Feb 15;55(4):406-12</RefSource>
<PMID Version="1">14960294</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2004 Feb 5;350(6):622</RefSource>
<PMID Version="1">14762196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2003 May 8;348(19):1839-54</RefSource>
<PMID Version="1">12642637</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Climacteric. 2002 Dec;5(4):317-25</RefSource>
<PMID Version="1">12626209</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Intern Med. 2003 Jan 27;163(2):205-9</RefSource>
<PMID Version="1">12546611</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Menopause. 2003 Jan-Feb;10(1):4-5</RefSource>
<PMID Version="1">12544670</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2002 Jul 17;288(3):321-33</RefSource>
<PMID Version="1">12117397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2002 Feb 6;287(5):591-7</RefSource>
<PMID Version="1">11829697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Gen Psychiatry. 2001 Jun;58(6):529-34</RefSource>
<PMID Version="1">11386980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Fertil Steril. 2001 Jun;75(6):1080-7</RefSource>
<PMID Version="1">11384630</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Obstet Gynecol. 2000 Aug;183(2):414-20</RefSource>
<PMID Version="1">10942479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Qual Life Res. 2004 Mar;13(2):311-20</RefSource>
<PMID Version="1">15085903</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>BMJ. 2008;337:a1494</RefSource>
<PMID Version="1">18768558</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>BMJ. 2009;338:a2597</RefSource>
<PMID Version="1">19139137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):136-7</RefSource>
<PMID Version="1">19229231</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Estrogens</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hormone Replacement Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Postmenopause</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Progestins</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Women's Health</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC2518695</OtherID>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Abdalla</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>DeStavola</LastName>
<ForeName>B L</ForeName>
<Initials>BL</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Allen</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Allen</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Bastick</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Foulger</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Fox</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Glynn</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Hall</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Hand</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Hill</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Leathem</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Mackinnon</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Marshall</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Collins N</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>O'Conner</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Darbyshire</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Ghali</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Furness</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Islam</LastName>
<ForeName>M Z</ForeName>
<Initials>MZ</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Harrild</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Knott</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Taylor</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Walgrove</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Wilkes</LastName>
<ForeName>H C</ForeName>
<Initials>HC</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>C-Q</ForeName>
<Initials>CQ</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Zuhrie</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Griffith</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Ryan</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Komesaroff</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Marley</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Paine</LastName>
<ForeName>B J</ForeName>
<Initials>BJ</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Stocks</LastName>
<ForeName>N P</ForeName>
<Initials>NP</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Dowell</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Rose</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="In-Process">
<PMID Version="1">18941263</PMID>
<DateCreated>
<Year>2008</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1833-3575</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>37</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2008</Year>
</PubDate>
</JournalIssue>
<Title>The HIM journal</Title>
<ISOAbbreviation>HIM J</ISOAbbreviation>
</Journal>
<ArticleTitle>Issues in the measurement of social determinants of health.</ArticleTitle>
<Pagination>
<MedlinePgn>26-32</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This article focuses on the measurement of the social determinants of health, and specifically on issues relating to two key variables relevant to the analysis of public health information: poverty and inequality. Although the paper has been written from the perspective of economics, the discipline of the two authors, it is also of relevance to researchers in other disciplines. It is argued that there is a need to ensure that, when considering measurement in this largely neglected area of research, sufficient thought is given to the relationships that are being examined or assessed. We argue further that any attempt at measurement in this area must take into account the historical backdrop and the complex nature of the relationships between these key variables.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mooney</LastName>
<ForeName>Gavin</ForeName>
<Initials>G</Initials>
<Affiliation>Curtin University of Technology, Perth, Western Australia. g.mooney@curtin.edu.au</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Fohtung</LastName>
<ForeName>Nubong G</ForeName>
<Initials>NG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Australia</Country>
<MedlineTA>HIM J</MedlineTA>
<NlmUniqueID>101122643</NlmUniqueID>
<ISSNLinking>1833-3583</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>H</CitationSubset>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">18964660</PMID>
<DateCreated>
<Year>2008</Year>
<Month>10</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2012</Year>
<Month>10</Month>
<Day>02</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0039-9140</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>35</Volume>
<Issue>12</Issue>
<PubDate>
<Year>1988</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Talanta</Title>
<ISOAbbreviation>Talanta</ISOAbbreviation>
</Journal>
<ArticleTitle>Multiparametric curve fitting-XIII Reliability of formation constants determined by analysis of potentiometric titration data.</ArticleTitle>
<Pagination>
<MedlinePgn>981-91</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The formation (protonation) constants log K(i), of the acid H(j)L are determined by regression analysis of potentiometric titration data when common parameters (log K(i), i = 1,..., j) and group parameters (E(0)', L(0), H(T)) are refined. The influence of three kinds of error on the protonation constants has been investigated: error from the strategy of minimization, random error, and error from uncertain estimates of group parameters. An analysis of variance of the log K(i), matrix was made for 7 identical titrations and 8 computational strategies, or of 7 identical titrations and 8 different options of group parameters to be refined. The influence of the standard potential E(0) of the glass-electrode cell on the systematic error in log K is greater than that of the acid concentration (L(0)) or the concentration of titrant used (H(T)). The ill-conditioned group parameters should be refined together with the common parameters (K(i)), otherwise the estimates of log K(i), are not accurate enough. Two ways of calibrating the glass electrode cell were compared. Internal calibration (performed during titration) was more accurate than external calibration done separately. Of the programs tested ESAB and ACBA are the most powerful because they permit refinement of group parameters and internal calibration. Citric acid was chosen as model substance.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Meloun</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Analytical Chemistry, College of Chemical Technology, CS-532 10 Pardubice, Czechoslovakia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bartos</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hgfeldt</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Talanta</MedlineTA>
<NlmUniqueID>2984816R</NlmUniqueID>
<ISSNLinking>0039-9140</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">19771122</PMID>
<DateCreated>
<Year>2009</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2009</Year>
<Month>12</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0146-9592</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>24</Issue>
<PubDate>
<Year>1990</Year>
<Month>Dec</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Optics letters</Title>
<ISOAbbreviation>Opt Lett</ISOAbbreviation>
</Journal>
<ArticleTitle>Ultrashort-laser-pulse amplification in a XeF[C --&gt; A] excimer amplifier.</ArticleTitle>
<Pagination>
<MedlinePgn>1461-3</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Tunable blue-green subpicosecond laser pulses have been amplified in an electron-beam-pumped XeF(C --&gt; A) excimer amplifier. Small-signal gains of 3.5% cm(-1) were measured using a 50-cm active gain length. At output energy densities as high as 170 mJ/cm(2), only a small degree of saturation occurred, resulting in a gain of 2.5% cm(-1).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sharp</LastName>
<ForeName>T E</ForeName>
<Initials>TE</Initials>
<Affiliation>Department of Electrical and Computer Engineering, Rice University, P.O. Box 1892, Houston, Texas 77251, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hofmann</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dane</LastName>
<ForeName>C B</ForeName>
<Initials>CB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>W L</ForeName>
<Initials>WL</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author ValidYN="Y">
<LastName>Tittel</LastName>
<ForeName>F K</ForeName>
<Initials>FK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wisoff</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Szab</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Opt Lett</MedlineTA>
<NlmUniqueID>7708433</NlmUniqueID>
<ISSNLinking>0146-9592</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">20405411</PMID>
<DateCreated>
<Year>2010</Year>
<Month>04</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2011</Year>
<Month>05</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1828-1427</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>44</Volume>
<Issue>1</Issue>
<PubDate>
<MedlineDate>2008 Jan-Mar</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Veterinaria italiana</Title>
<ISOAbbreviation>Vet. Ital.</ISOAbbreviation>
</Journal>
<ArticleTitle>Long distance animal transport: the way forward.</ArticleTitle>
<Pagination>
<MedlinePgn>43-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Too often, the issue of animal welfare during transport is the subject of emotional debates. For farmers within the International Federation of Agricultural Producers, it is important that the economic, scientific and practical aspects be taken into account when setting international rules for animal welfare. Farmers also stress the need to combine scientific data with their practical experience. Raising awareness, adopting a risk-based approach, education, labelling, slaughterhouse capacity and animal health, as well as standards and rules, are issues of importance for developing a long distance transportation infrastructure respectful of animal welfare around the world.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Osinga</LastName>
<ForeName>Klaas Johan</ForeName>
<Initials>KJ</Initials>
<Affiliation>International Federation of Agricultural Producers/LTO Netherland, Drachten, The Netherlands. klaasjohan@yahoo.com</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Italy</Country>
<MedlineTA>Vet Ital</MedlineTA>
<NlmUniqueID>0201543</NlmUniqueID>
<ISSNLinking>0505-401X</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="OLDMEDLINE">
<PMID Version="1">21002435</PMID>
<DateCreated>
<Year>1946</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2010</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>04</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0002-9955</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>132</Volume>
<Issue>12</Issue>
<PubDate>
<Year>1946</Year>
<Month>Nov</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Journal of the American Medical Association</Title>
<ISOAbbreviation>J Am Med Assoc</ISOAbbreviation>
</Journal>
<ArticleTitle>BRUTALITIES of Nazi physicians.</ArticleTitle>
<Pagination>
<MedlinePgn>714</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>J Am Med Assoc</MedlineTA>
<NlmUniqueID>7507176</NlmUniqueID>
<ISSNLinking>0002-9955</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">War Crimes</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="CLML">4611:956w</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">RESEARCH, MEDICAL/human experimentation</Keyword>
<Keyword MajorTopicYN="Y">WAR/crimes</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21007460</PMID>
<DateCreated>
<Year>1946</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2010</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>04</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<PubDate>
<MedlineDate>1944-1945</MedlineDate>
</PubDate>
</JournalIssue>
<Title>The Proceedings of the Cardiff Medical Society</Title>
<ISOAbbreviation>Proc Cardiff Med Soc</ISOAbbreviation>
</Journal>
<ArticleTitle>Social psychiatry in the post-war world.</ArticleTitle>
<Pagination>
<MedlinePgn>55-9</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>REES</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Proc Cardiff Med Soc</MedlineTA>
<NlmUniqueID>7505858</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>OM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Community Psychiatry</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="CLML">4610:216i1</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">PSYCHIATRY/social</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="OLDMEDLINE">
<PMID Version="1">21024418</PMID>
<DateCreated>
<Year>1946</Year>
<Month>12</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2010</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<JournalIssue CitedMedium="Print">
<Volume>64</Volume>
<PubDate>
<MedlineDate>1944-1945</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Transactions. Ophthalmological Society of the United Kingdom</Title>
<ISOAbbreviation>Trans Opthal Soc U K</ISOAbbreviation>
</Journal>
<ArticleTitle>Preventable blindness in war.</ArticleTitle>
<Pagination>
<MedlinePgn>165-78</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>CRUISE</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Not Available</Country>
<MedlineTA>Trans Opthal Soc U K</MedlineTA>
<NlmUniqueID>0201270</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>OM</CitationSubset>
<OtherID Source="CLML">4610:1030s</OtherID>
<KeywordList Owner="NLM">
<Keyword MajorTopicYN="Y">BLINDNESS/in war</Keyword>
<Keyword MajorTopicYN="Y">MILITARY MEDICINE/ophthalmology</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23326248</PMID>
<DateCreated>
<Year>2013</Year>
<Month>01</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>06</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1612-3174</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>German medical science : GMS e-journal</Title>
<ISOAbbreviation>Ger Med Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Transcatheter Amplatzer vascular plug-embolization of a giant postnephrectomy arteriovenous fistula combined with an aneurysm of the renal pedicle by through-and-through, arteriovenous access.</ArticleTitle>
<Pagination>
<MedlinePgn>Doc01</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3205/000169</ELocationID>
<Abstract>
<AbstractText>Although endovascular transcatheter embolization of arteriovenous fistulas is minimally invasive, the torrential flow prevailing within a fistula implies the risk of migration of the deployed embolization devices into the downstream venous and pulmonary circulation. We present the endovascular treatment of a giant postnephrectomy arteriovenous fistula between the right renal pedicle and the residual renal vein in a 63-year-old man. The purpose of this case report is to demonstrate that the Amplatzer vascular plug (AVP) can be safely positioned to embolize even relatively large arteriovenous fistulas (AVFs). Secondly, we illustrate that this occluder can even be introduced to the fistula via a transvenous catheter in cases where it is initially not possible to advance the deployment-catheter through a tortuous feeder artery. Migration of the vascular plug was ruled out at follow-up 4 months subsequently to the intervention. Thus, the Amplatzer vascular plug and the arteriovenous through-and-through guide wire access with subsequent transvenous deployment should be considered in similar cases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kayser</LastName>
<ForeName>Ole</ForeName>
<Initials>O</Initials>
<Affiliation>Department of Radiology, University Hospital Schleswig-Holstein, Kiel, Germany. o.kayser@rad.uni-kiel.de</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Schfer</LastName>
<ForeName>Philipp</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>01</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Ger Med Sci</MedlineTA>
<NlmUniqueID>101227686</NlmUniqueID>
<ISSNLinking>1612-3174</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Vasc Endovascular Surg. 2003 Jan-Feb;37(1):47-57</RefSource>
<PMID Version="1">12577139</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Vasc Pharmacol. 2003 Oct;1(3):347-54</RefSource>
<PMID Version="1">15320481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Chir (Paris). 1978 Oct;115(10):541-4</RefSource>
<PMID Version="1">739047</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Urology. 1985 Jan;25(1):13-6</RefSource>
<PMID Version="1">3966275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surgery. 1986 Jan;99(1):114-8</RefSource>
<PMID Version="1">3941996</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surgery. 1989 Jan;105(1):1-12</RefSource>
<PMID Version="1">2643193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Vasc Surg. 1992 Jul;6(4):378-80</RefSource>
<PMID Version="1">1390028</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cardiovasc Surg (Torino). 1998 Aug;39(4):433-6</RefSource>
<PMID Version="1">9788787</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Med. 1964 Oct;37:499-513</RefSource>
<PMID Version="1">14215839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):363-7</RefSource>
<PMID Version="1">16517784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Emerg Radiol. 2008 Mar;15(2):119-22</RefSource>
<PMID Version="1">17593408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cardiovasc Intervent Radiol. 2008 Jul;31 Suppl 2:S92-5</RefSource>
<PMID Version="1">18049835</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Vascular. 2009 Jan-Feb;17(1):40-3</RefSource>
<PMID Version="1">19344582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cardiovasc Intervent Radiol. 2009 May;32(3):543-7</RefSource>
<PMID Version="1">18574625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Urol. 2009 Jul;16(7):648-9</RefSource>
<PMID Version="1">19659804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Heart Vessels. 2010 Jul;25(4):356-8</RefSource>
<PMID Version="1">20676847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Urology. 2011 Oct;78(4):820-6</RefSource>
<PMID Version="1">21813164</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Endovasc Ther. 2011 Dec;18(6):811-8</RefSource>
<PMID Version="1">22149231</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aneurysm</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aortography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Arteriovenous Fistula</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Early Diagnosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embolization, Therapeutic</DescriptorName>
<QualifierName MajorTopicYN="Y">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kidney</DescriptorName>
<QualifierName MajorTopicYN="N">injuries</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nephrectomy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Postoperative Complications</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Renal Artery</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Septal Occluder Device</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ultrasonography, Doppler, Duplex</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Vena Cava, Inferior</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3546418</OtherID>
<OtherAbstract Type="Publisher" Language="ger">
<AbstractText>Abstract available from the publisher.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AV-fistula</Keyword>
<Keyword MajorTopicYN="N">Amplatzer vascular plug</Keyword>
<Keyword MajorTopicYN="N">arteriovenous access</Keyword>
<Keyword MajorTopicYN="N">arteriovenous fistula</Keyword>
<Keyword MajorTopicYN="N">embolisation</Keyword>
<Keyword MajorTopicYN="N">endovascular treatment</Keyword>
<Keyword MajorTopicYN="N">nephrectomy</Keyword>
<Keyword MajorTopicYN="N">through-and-through</Keyword>
<Keyword MajorTopicYN="N">transvenous access</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23674598</PMID>
<DateCreated>
<Year>2013</Year>
<Month>05</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>07</Month>
<Day>16</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>The neural crest.</ArticleTitle>
<Pagination>
<MedlinePgn>2247-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.091751</ELocationID>
<Abstract>
<AbstractText>The neural crest (NC) is a highly migratory multipotent cell population that forms at the interface between the neuroepithelium and the prospective epidermis of a developing embryo. Following extensive migration throughout the embryo, NC cells eventually settle to differentiate into multiple cell types, ranging from neurons and glial cells of the peripheral nervous system to pigment cells, fibroblasts to smooth muscle cells, and odontoblasts to adipocytes. NC cells migrate in large numbers and their migration is regulated by multiple mechanisms, including chemotaxis, contact-inhibition of locomotion and cell sorting. Here, we provide an overview of NC formation, differentiation and migration, highlighting the molecular mechanisms governing NC migration.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mayor</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
<Affiliation>Department of Cell and Developmental Biology, University College London, Gower Street, London WC1E 6BT, UK. r.mayor@ucl.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Theveneau</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chemotaxis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chick Embryo</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryonic Development</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neural Crest</DescriptorName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Xenopus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">Cell migration</Keyword>
<Keyword MajorTopicYN="N">Chemotaxis</Keyword>
<Keyword MajorTopicYN="N">Contact-inhibition of locomotion</Keyword>
<Keyword MajorTopicYN="N">Epithelium-to-mesenchyme transition</Keyword>
<Keyword MajorTopicYN="N">Neural crest cells</Keyword>
<Keyword MajorTopicYN="N">Neurocristopathies</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23685357</PMID>
<DateCreated>
<Year>2013</Year>
<Month>06</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1460-2075</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jun</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>The EMBO journal</Title>
<ISOAbbreviation>EMBO J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activity.</ArticleTitle>
<Pagination>
<MedlinePgn>1730-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2013.107</ELocationID>
<Abstract>
<AbstractText>Actin-based remodelling underlies spine structural changes occurring during synaptic plasticity, the process that constantly reshapes the circuitry of the adult brain in response to external stimuli, leading to learning and memory formation. A positive correlation exists between spine shape and synaptic strength and, consistently, abnormalities in spine number and morphology have been described in a number of neurological disorders. In the present study, we demonstrate that the actin-regulating protein, Eps8, is recruited to the spine head during chemically induced long-term potentiation in culture and that inhibition of its actin-capping activity impairs spine enlargement and plasticity. Accordingly, mice lacking Eps8 display immature spines, which are unable to undergo potentiation, and are impaired in cognitive functions. Additionally, we found that reduction in the levels of Eps8 occurs in brains of patients affected by autism compared to controls. Our data reveal the key role of Eps8 actin-capping activity in spine morphogenesis and plasticity and indicate that reductions in actin-capping proteins may characterize forms of intellectual disabilities associated with spine defects.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Menna</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<Affiliation>CNR Institute of Neuroscience, Milano, Italy. e.menna@in.cnr.it</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Zambetti</LastName>
<ForeName>Stefania</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morini</LastName>
<ForeName>Raffaella</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Donzelli</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Disanza</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Calvigioni</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Braida</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nicolini</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Orlando</LastName>
<ForeName>Marta</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fossati</LastName>
<ForeName>Giuliana</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cristina Regondi</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pattini</LastName>
<ForeName>Linda</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frassoni</LastName>
<ForeName>Carolina</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Francolini</LastName>
<ForeName>Maura</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scita</LastName>
<ForeName>Giorgio</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000000179841889</Identifier>
</Author>
<Author ValidYN="Y">
<LastName>Sala</LastName>
<ForeName>Mariaelvina</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fahnestock</LastName>
<ForeName>Margaret</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matteoli</LastName>
<ForeName>Michela</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>05</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>EMBO J</MedlineTA>
<NlmUniqueID>8208664</NlmUniqueID>
<ISSNLinking>0261-4189</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Eps8 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Actins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Autistic Disorder</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Brain</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cognition</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dendritic Spines</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Long-Term Potentiation</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Synapses</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3680733 [Available on 06/12/14]</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23807877</PMID>
<DateCreated>
<Year>2013</Year>
<Month>06</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>07</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Print">1662-4548</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>7</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Frontiers in neuroscience</Title>
<ISOAbbreviation>Front Neurosci</ISOAbbreviation>
</Journal>
<ArticleTitle>Improved blood velocity measurements with a hybrid image filtering and iterative Radon transform algorithm.</ArticleTitle>
<Pagination>
<MedlinePgn>106</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3389/fnins.2013.00106</ELocationID>
<Abstract>
<AbstractText>Neural activity leads to hemodynamic changes which can be detected by functional magnetic resonance imaging (fMRI). The determination of blood flow changes in individual vessels is an important aspect of understanding these hemodynamic signals. Blood flow can be calculated from the measurements of vessel diameter and blood velocity. When using line-scan imaging, the movement of blood in the vessel leads to streaks in space-time images, where streak angle is a function of the blood velocity. A variety of methods have been proposed to determine blood velocity from such space-time image sequences. Of these, the Radon transform is relatively easy to implement and has fast data processing. However, the precision of the velocity measurements is dependent on the number of Radon transforms performed, which creates a trade-off between the processing speed and measurement precision. In addition, factors like image contrast, imaging depth, image acquisition speed, and movement artifacts especially in large mammals, can potentially lead to data acquisition that results in erroneous velocity measurements. Here we show that pre-processing the data with a Sobel filter and iterative application of Radon transforms address these issues and provide more accurate blood velocity measurements. Improved signal quality of the image as a result of Sobel filtering increases the accuracy and the iterative Radon transform offers both increased precision and an order of magnitude faster implementation of velocity measurements. This algorithm does not use a priori knowledge of angle information and therefore is sensitive to sudden changes in blood flow. It can be applied on any set of space-time images with red blood cell (RBC) streaks, commonly acquired through line-scan imaging or reconstructed from full-frame, time-lapse images of the vasculature. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chhatbar</LastName>
<ForeName>Pratik Y</ForeName>
<Initials>PY</Initials>
<Affiliation>Department of Neurosciences, Medical University of South Carolina Charleston, SC, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kara</LastName>
<ForeName>Prakash</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 EY017925</GrantID>
<Acronym>EY</Acronym>
<Agency>NEI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Front Neurosci</MedlineTA>
<NlmUniqueID>101478481</NlmUniqueID>
<ISSNLinking>1662-453X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3684769</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Sobel filtering</Keyword>
<Keyword MajorTopicYN="N">blood flow</Keyword>
<Keyword MajorTopicYN="N">line-scan</Keyword>
<Keyword MajorTopicYN="N">space-time images</Keyword>
<Keyword MajorTopicYN="N">two-photon imaging</Keyword>
<Keyword MajorTopicYN="N">velocity</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23925621</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-3598</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>310</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Aug</Month>
<Day>7</Day>
</PubDate>
</JournalIssue>
<Title>JAMA : the journal of the American Medical Association</Title>
<ISOAbbreviation>JAMA</ISOAbbreviation>
</Journal>
<ArticleTitle>Mental health response to community disasters: a systematic review.</ArticleTitle>
<Pagination>
<MedlinePgn>507-18</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2013.107799</ELocationID>
<Abstract>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Exposure to a disaster is common, and one-third or more of individuals severely exposed may develop posttraumatic stress disorder or other disorders. A systematic approach to the delivery of timely and appropriate disaster mental health services may facilitate their integration into the emergency medical response.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review and summarize the evidence for how best to identify individuals in need of disaster mental health services and triage them to appropriate care.</AbstractText>
<AbstractText Label="EVIDENCE REVIEW" NlmCategory="METHODS">Search of the peer-reviewed English-language literature on disaster mental health response in PsycINFO, PubMed, Cochrane Database of Systematic Reviews, Academic Search Complete, and Google Scholar (inception to September 2012) and PILOTS (inception to February 2013), using a combination of subject headings and text words (Disasters, Natural Disasters, Mental Health, Mental Health Programs, Public Health Services, Mental Disorders, Mental Health Services, Community Mental Health Services, Emergency Services Psychiatric, Emotional Trauma, Triage, and Response).</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">Unlike physical injuries, adverse mental health outcomes of disasters may not be apparent, and therefore a systematic approach to case identification and triage to appropriate interventions is required. Symptomatic individuals in postdisaster settings may experience new-onset disaster-related psychiatric disorders, exacerbations of preexisting psychopathology, and/or psychological distress. Descriptive disaster mental health studies have found that many (11%-38%) distressed individuals presenting for evaluation at shelters and family assistance centers have stress-related and adjustment disorders; bereavement, major depression, and substance use disorders were also observed, and up to 40% of distressed individuals had preexisting disorders. Individuals with more intense reactions to disaster stress were more likely to accept referral to mental health services than those with less intense reactions. Evidence-based treatments are available for patients with active psychiatric disorders, but psychosocial interventions such as psychological first aid, psychological debriefing, crisis counseling, and psychoeducation for individuals with distress have not been sufficiently evaluated to establish their benefit or harm in disaster settings.</AbstractText>
<AbstractText Label="CONCLUSION AND RELEVANCE" NlmCategory="UNASSIGNED">In postdisaster settings, a systematic framework of case identification, triage, and mental health interventions should be integrated into emergency medicine and trauma care responses.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>North</LastName>
<ForeName>Carol S</ForeName>
<Initials>CS</Initials>
<Affiliation>VA North Texas Health Care System, Dallas, USA. carol.north@utsouthwestern.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pfefferbaum</LastName>
<ForeName>Betty</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1 U79 SM57278</GrantID>
<Acronym>SM</Acronym>
<Agency>CMHS SAMHSA HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>JAMA</MedlineTA>
<NlmUniqueID>7501160</NlmUniqueID>
<ISSNLinking>0098-7484</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Disasters</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Emergency Medical Services</DescriptorName>
<QualifierName MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mental Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mental Health Services</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Triage</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<DeleteCitation>
<PMID Version="1">23203860</PMID>
<PMID Version="1">23203861</PMID>
<PMID Version="1">23203892</PMID>
<PMID Version="1">23203893</PMID>
<PMID Version="1">23203894</PMID>
<PMID Version="1">23203895</PMID>
<PMID Version="1">23203896</PMID> 
</DeleteCitation>
</MedlineCitationSet>